PT J
AU Hostmark, AT
   Tomten, SE
AF Hostmark, Arne T.
   Tomten, Sissel E.
TI The Oslo Health Study: Cheese Intake Was Negatively Associated with the Metabolic Syndrome
SO JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION
LA English
DT Article
DE metabolic syndrome; cheese intake; men; women; cross-sectional study
ID ischemic-heart-disease; high-fiber diet; blood-lipids; dairy consumption; fatty-acids; milk-fat; risk; cholesterol; serum; butter
AB Objective: We previously reported that the frequency of cheese intake (FCI) was negatively associated with serum triglycerides and positively associated with high-density lipoprotein cholesterol (HDL), both components of the metabolic syndrome (MetS). We therefore wanted to study whether FCI is associated with MetS. Methods: The Oslo Health Study (18,770 subjects), obtained data from 7815 men and 9685 women on cheese intake and risk factors for MetS, except for fasting glucose. MetS requires central obesity and at least 2 of the following: increased triglycerides, low HDL cholesterol, increased systolic or diastolic blood pressure, and elevated fasting blood glucose. We calculated the index SumRisk, providing the number of MetS factors present, and MetSRisk to reflect the combined levels of many MetS factors. The association between FCI and MetSRisk (SumRisk) was studied using regression analyses. Results: In young (30 years), middle-aged (40 and 45 years), seniors (59-60), and old (75-76 years) subjects, there was an inverse association between FCI and MetSRisk (p <= 0.005, except in old men). Using regression, we found a consistent negative association (p < 0.001) between FCI and MetSRisk, SumRisk, single MetS components, and the complete MetS, prevailing after controlling for sex, age, time since last meal, intake of fruit/berries, fruit juice, fatty fish, coffee, alcohol, smoking, leisure time physical activity, years at school, and birthplace. FCI was also negatively associated with body mass index (p < 0.02), except in old women. Conclusion: Cheese intake can be negatively and independently associated with (1) an index including the level of many risk factors for MetS, (2) the number of MetS requirements present, (3) single MetS components, and (4) the complete MetS.
C1 [Hostmark, Arne T.] Univ Oslo, Sect Prevent Med & Epidemiol, N-0318 Oslo, Norway.
   [Tomten, Sissel E.] Norwegian Sch Sport Sci, Oslo, Norway.
C3 University of Oslo; Norwegian School of Sport Sciences
RP Hostmark, AT (corresponding author), Univ Oslo, Sect Prevent Med & Epidemiol, 1130 Blindern, N-0318 Oslo, Norway.
EM a.t.hostmark@medisin.uio.no
CR Andersen LF, 2002, EUR J PUBLIC HEALTH, V12, P208, DOI 10.1093/eurpub/12.3.208
   Unknown -, 2005, DIET GUID AM 2005, V0, P0
   Azadbakht L, 2005, AM J CLIN NUTR, V82, P523, DOI 10.1093/ajcn/82.3.523
   Beydoun MA, 2008, AM J CLIN NUTR, V87, P1914, DOI 10.1093/ajcn/87.6.1914
   Biong AS, 2004, BRIT J NUTR, V92, P791, DOI 10.1079/BJN20041257
   Biong AS, 2007, THESIS U OSLO OSLO, V0, P0
   Chi D, 2004, CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH, V12, P84
   COLQUHOUN DM, 2003, ASIA PAC J CLIN NU S, V12, P0
   EICHHOLZER M, 1993, INT J VITAM NUTR RES, V63, P159
   El-Salam MHA, 2009, DAIRY SCI TECHNOL, V89, P437, DOI 10.1051/dst/2009022
   Elwood PC, 2004, EUR J CLIN NUTR, V58, P718, DOI 10.1038/sj.ejcn.1601869
   Elwood PC, 2007, J EPIDEMIOL COMMUN H, V61, P695, DOI 10.1136/jech.2006.053157
   Engberink MF, 2009, AM J CLIN NUTR, V89, P1877, DOI 10.3945/ajcn.2008.27064
   FEHILY AM, 1993, BRIT J NUTR, V69, P303, DOI 10.1079/BJN19930035
   Gulseth HL, 2010, BRIT J NUTR, V104, P160, DOI 10.1017/S0007114510000565
   HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281
   Higurashi S, 2007, INT DAIRY J, V17, P1224, DOI 10.1016/j.idairyj.2007.03.012
   Hostmark AT, 2009, J FOOD LIPIDS, V16, P89, DOI 10.1111/j.1745-4522.2009.01134.x
   Insel Paul, 2004, NUTRITION, V0, P0
   *INT DIAB FED, 2009, IDF CONS WORLDW DEF, V0, P0
   Katan MB, 2010, AM J CLIN NUTR, V92, P459, DOI 10.3945/ajcn.2010.29692
   Lamarche B, 1999, DIABETES METAB, V25, P199
   MARCKMANN P, 1994, AM J CLIN NUTR, V59, P935, DOI 10.1093/ajcn/59.4.935
   Moebus S, 2007, CARDIOVASC DIABETOL, V6, P0, DOI 10.1186/1475-2840-6-22
   Ness AR, 2001, J EPIDEMIOL COMMUN H, V55, P379, DOI 10.1136/jech.55.6.379
   Nestel PJ, 2005, EUR J CLIN NUTR, V59, P1059, DOI 10.1038/sj.ejcn.1602211
   OCallaghan D, 1996, J CARDIOVASC RISK, V3, P441
   PICARD S, 1995, DIABETES METAB, V21, P89
   SANDSTROM B, 1992, EUR J CLIN NUTR, V46, P95
   SCHLIERF G, 1979, EUR J CLIN INVEST, V9, P319, DOI 10.1111/j.1365-2362.1979.tb00891.x
   Schuster G S, 1980, PHARMACOL THER DENT, V5, P25
   Seidel C, 2005, ANN NUTR METAB, V49, P42, DOI 10.1159/000084176
   Sjogren P, 2004, J NUTR, V134, P1729, DOI 10.1093/jn/134.7.1729
   Smedman AEM, 1999, AM J CLIN NUTR, V69, P22
   Sogaard Anne Johanne, 2004, INT J EQUITY HEALTH, V3, P3
   St-Pierre AC, 2005, ARTERIOSCL THROM VAS, V25, P553, DOI 10.1161/01.ATV.0000154144.73236.f4
   STAHELIN HB, 1992, BIBL NUTR DIET, V49, P24
   Tholstrup T, 2004, J AM COLL NUTR, V23, P169, DOI 10.1080/07315724.2004.10719358
   Tonstad S, 2003, J CARDIOVASC RISK, V10, P129, DOI 10.1097/00043798-200304000-00008
   van Hees AMJ, 2008, J NUTR, V138, P2399, DOI 10.3945/jn.108.094516
   Warensjö E, 2004, BRIT J NUTR, V91, P635, DOI 10.1079/BJN20041080
   WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P
NR 43
TC 18
Z9 18
U1 0
U2 9
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0731-5724
EI 1541-1087
J9 J AM COLL NUTR
JI J. Am. Coll. Nutr.
PD JUN 15
PY 2011
VL 30
IS 3
BP 182
EP 190
DI 10.1080/07315724.2011.10719959
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA V28MQ
UT WOS:000208685300004
PM 21896876
DA 2025-04-28
ER

PT J
AU Lecour, S
   Lamont, KT
AF Lecour, S.
   Lamont, K. T.
TI Natural Polyphenols and Cardioprotection
SO MINI-REVIEWS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Cardioprotection; cocoa; natural polyphenols; prosurvival signaling pathways; tea-wine
ID red wine polyphenols; nitric-oxide synthase; grape seed proanthocyanidin; inhibit platelet-function; low-density-lipoprotein; green tea; reperfusion injury; blood-pressure; tnf-alpha; black tea
AB With more than 8000 polyphenols found in food (mainly, wine, tea, coffee, cocoa, vegetables and cereals), many epidemiological studies suggest that the intake of polyphenol-rich foods has a beneficial effect on a large number of cardiovascular risk factors, such as high blood pressure, high blood cholesterol, obesity, diabetes and smoking. The mechanisms involved in the cardioprotective effects of polyphenols are numerous and include antioxidant, vasodilator, anti-inflammatory, anti-fibrotic, antiapoptotic and metabolic. Most importantly, recent experimental data demonstrate that polyphenols can exert its cardioprotective effect via the activation of several powerful prosurvival cellular pathways that involve metabolic intermediates, microRNAs, sirtuins and mediators of the recently described reperfusion injury salvage kinases (RISK) and survivor activating factor enhancement (SAFE) pathways.
C1 [Lecour, S.; Lamont, K. T.] Univ Cape Town, Fac Hlth Sci, Dept Med, Hatter Cardiovasc Res Inst, ZA-7925 Observatory, South Africa.
C3 University of Cape Town
RP Lecour, S (corresponding author), Univ Cape Town, Fac Hlth Sci, Dept Med, Hatter Cardiovasc Res Inst, Chris Barnard Bldg,Anzio Rd, ZA-7925 Observatory, South Africa.
EM Sandrine.lecour@uct.ac.za
FU Medical Research Council of South Africa; National Research Foundation; University of Cape Town
CR Agrawal M, 2011, EUR J PHARMACOL, V666, P5, DOI 10.1016/j.ejphar.2011.05.015
   Akhlaghi M, 2009, J MOL CELL CARDIOL, V46, P309, DOI 10.1016/j.yjmcc.2008.12.003
   Al-Awwadi NA, 2005, J AGR FOOD CHEM, V53, P151, DOI 10.1021/jf048919f
   Albini A, 2010, JNCI-J NATL CANCER I, V102, P14, DOI 10.1093/jnci/djp440
   Aviram M, 1998, ARTERIOSCL THROM VAS, V18, P1617, DOI 10.1161/01.ATV.18.10.1617
   Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649
   Aviram M, 2000, AM J CLIN NUTR, V71, P1062
   Bagchi DB, 2003, MUTAT RES-FUND MOL M, V523, P87, DOI 10.1016/S0027-5107(02)00324-X
   Baron-Menguy C, 2007, FASEB J, V21, P3511, DOI 10.1096/fj.06-7782com
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Bhat KPL, 2001, ANTIOXID REDOX SIGN, V3, P1041, DOI 10.1089/152308601317203567
   Bhatt SR, 2011, EUR J PHARMACOL, V667, P258, DOI 10.1016/j.ejphar.2011.05.026
   Boengler K, 2010, BASIC RES CARDIOL, V105, P771, DOI 10.1007/s00395-010-0124-1
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Cassidy A, 2011, AM J CLIN NUTR, V93, P338, DOI 10.3945/ajcn.110.006783
   Conklin Kenneth A, 2005, INTEGR CANCER THER, V4, P110, DOI 10.1177/1534735405276191
   Cruz MN, 2006, AM J PHYSIOL-HEART C, V290, PH1969, DOI 10.1152/ajpheart.01065.2005
   Csiszar A, 2008, AM J PHYSIOL-HEART C, V294, PH2721, DOI 10.1152/ajpheart.00235.2008
   Dal-Ros S, 2011, BIOCHEM BIOPH RES CO, V404, P743, DOI 10.1016/j.bbrc.2010.12.060
   Dao TMA, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0020700
   Das DK, 2006, MOL INTERV, V6, P36, DOI 10.1124/mi.6.1.7
   Davies MJ, 2003, J NUTR, V133, P3298S, DOI 10.1093/jn/133.10.3298S
   DellAgli M, 2008, BRIT J NUTR, V99, P945, DOI 10.1017/S0007114507837470
   DEMROW HS, 1995, CIRCULATION, V91, P1182, DOI 10.1161/01.CIR.91.4.1182
   Deuchar GA, 2007, LIFE SCI, V80, P1686, DOI 10.1016/j.lfs.2007.01.040
   Di Santo A, 2003, J THROMB HAEMOST, V1, P1089, DOI 10.1046/j.1538-7836.2003.00217.x
   Dohadwala MM, 2011, AM J CLIN NUTR, V93, P934, DOI 10.3945/ajcn.110.004242
   DRESDALE AR, 1982, AM J CLIN ONCOL-CANC, V5, P657, DOI 10.1097/00000421-198212000-00015
   Eaton S, 1997, EVOLUTION DIET HLTH, V0, P0
   Estruch R, 2004, ATHEROSCLEROSIS, V175, P117, DOI 10.1016/j.atherosclerosis.2004.03.006
   Falchi M, 2006, J AGR FOOD CHEM, V54, P6613, DOI 10.1021/jf061048k
   Faller ALK, 2010, J FOOD COMPOS ANAL, V23, P561, DOI 10.1016/j.jfca.2010.01.003
   Fernandez MT, 2002, J INORG BIOCHEM, V92, P105, DOI 10.1016/S0162-0134(02)00511-1
   Fischer UM, 2003, EUR J CARDIO-THORAC, V23, P984, DOI 10.1016/S1010-7940(03)00113-1
   Freedman JE, 2001, CIRCULATION, V103, P2792, DOI 10.1161/01.CIR.103.23.2792
   Fuglesteg BN, 2008, BASIC RES CARDIOL, V103, P444, DOI 10.1007/s00395-008-0728-x
   Fuhrman B, 2005, J NUTR, V135, P722, DOI 10.1093/jn/135.4.722
   Gurusamy N, 2010, J CELL MOL MED, V14, P2235, DOI 10.1111/j.1582-4934.2010.01140.x
   Gurusamy N, 2010, CARDIOVASC RES, V86, P103, DOI 10.1093/cvr/cvp384
   HANASAKI Y, 1994, FREE RADICAL BIO MED, V16, P845, DOI 10.1016/0891-5849(94)90202-X
   Hattori R, 2002, AM J PHYSIOL-HEART C, V282, PH1988, DOI 10.1152/ajpheart.01012.2001
   Hausenloy DJ, 2011, ANTIOXID REDOX SIGN, V14, P893, DOI 10.1089/ars.2010.3360
   Hirata K, 2004, AM J CARDIOL, V93, P1384, DOI 10.1016/j.amjcard.2004.02.035
   Hodgson JM, 2006, CLIN EXP PHARMACOL P, V33, P838, DOI 10.1111/j.1440-1681.2006.04450.x
   Hodgson JM, 2001, EUR J CLIN NUTR, V55, P881, DOI 10.1038/sj.ejcn.1601231
   Hodgson JM, 1999, J HYPERTENS, V17, P457, DOI 10.1097/00004872-199917040-00002
   Hollenberg NK, 2006, J CARDIOVASC PHARM, V47, PS119, DOI 10.1097/00005344-200606001-00005
   Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200
   Huang Y, 1998, LIFE SCI, V63, P275, DOI 10.1016/S0024-3205(98)00273-2
   Hwang JT, 2009, NEW BIOTECHNOL, V26, P17, DOI 10.1016/j.nbt.2009.03.005
   Imamura G, 2002, AM J PHYSIOL-HEART C, V282, PH1996, DOI 10.1152/ajpheart.01013.2001
   Kelly RF, 2010, BASIC RES CARDIOL, V105, P763, DOI 10.1007/s00395-010-0125-0
   Khan N, 2011, NUTR METAB CARDIOVAS, V0, P0
   Kim Jeong-A, 2008, ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, V8, P82, DOI 10.2174/187153008784534349
   Kimura Y, 2010, FOOD CHEM TOXICOL, V48, P429, DOI 10.1016/j.fct.2009.10.041
   Kostyuk VA, 2003, FEBS LETT, V537, P146, DOI 10.1016/S0014-5793(03)00113-3
   Lacerda L, 2010, CARDIOVASC RES, V87, P0
   Lacerda L, 2009, CARDIOVASC RES, V84, P201, DOI 10.1093/cvr/cvp274
   Lamont KT, 2011, J PINEAL RES, V50, P374, DOI 10.1111/j.1600-079X.2010.00853.x
   Lazzè MC, 2006, MOL NUTR FOOD RES, V50, P44, DOI 10.1002/mnfr.200500134
   Lecour S, 2005, CIRCULATION, V112, P3911, DOI 10.1161/CIRCULATIONAHA.105.581058
   Lecour S, 2005, CARDIOVASC RES, V65, P239, DOI 10.1016/j.cardiores.2004.10.003
   Lecour S, 2002, J MOL CELL CARDIOL, V34, P509, DOI 10.1006/jmcc.2002.1533
   Lecour S, 2009, J MOL CELL CARDIOL, V47, P32, DOI 10.1016/j.yjmcc.2009.03.019
   Leikert JF, 2002, CIRCULATION, V106, P1614, DOI 10.1161/01.CIR.0000034445.31543.43
   Lekli I, 2010, J CELL MOL MED, V14, P2506, DOI 10.1111/j.1582-4934.2009.00921.x
   Leonard SS, 2003, BIOCHEM BIOPH RES CO, V309, P1017, DOI 10.1016/j.bbrc.2003.08.105
   Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705
   Löest HB, 2002, J NUTR, V132, P1282, DOI 10.1093/jn/132.6.1282
   Loke WM, 2008, AM J CLIN NUTR, V88, P1018, DOI 10.1093/ajcn/88.4.1018
   Loke WM, 2008, BIOCHEM PHARMACOL, V75, P1045, DOI 10.1016/j.bcp.2007.11.002
   Lorenz M, 2004, J BIOL CHEM, V279, P6190, DOI 10.1074/jbc.M309114200
   Maher D, 2010, B WORLD HEALTH ORGAN, V88, P943, DOI 10.2471/BLT.10.077891
   Matsuyama T, 2008, OBESITY, V16, P1338, DOI 10.1038/oby.2008.60
   McCullough ML, 2006, J CARDIOVASC PHARM, V47, PS103, DOI 10.1097/00005344-200606001-00003
   Monagas M, 2009, AM J CLIN NUTR, V90, P1144, DOI 10.3945/ajcn.2009.27716
   Mosca L, 2000, J AGR FOOD CHEM, V48, P297, DOI 10.1021/jf990556+
   Mukamal KJ, 2002, CIRCULATION, V105, P2476, DOI 10.1161/01.CIR.0000017201.88994.F7
   Mukhopadhyay P, 2011, ANN NY ACAD SCI, V1215, P109, DOI 10.1111/j.1749-6632.2010.05866.x
   Mukhopadhyay P, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0015705
   Murase T, 1999, ARTERIOSCL THROM VAS, V19, P1412, DOI 10.1161/01.ATV.19.6.1412
   Mursu J, 2008, BRIT J NUTR, V100, P890, DOI 10.1017/S0007114508945694
   Nijveldt RJ, 2001, AM J CLIN NUTR, V74, P418
   Nishizuka T, 2011, P JPN ACAD B-PHYS, V87, P104, DOI 10.2183/pjab.87.104
   Oak MH, 2004, CIRCULATION, V110, P1861, DOI 10.1161/01.CIR.0000142617.52881.F4
   Olson ER, 2005, AM J PHYSIOL-HEART C, V288, PH1131, DOI 10.1152/ajpheart.00763.2004
   Opie LH, 2007, EUR HEART J, V28, P1683, DOI 10.1093/eurheartj/ehm149
   Osakabe N, 2002, EXP BIOL MED, V227, P51, DOI 10.1177/153537020222700109
   Panneerselvam M, 2010, AM J PHYSIOL-HEART C, V299, PH1604, DOI 10.1152/ajpheart.00073.2010
   Pataki T, 2002, AM J CLIN NUTR, V75, P894, DOI 10.1093/ajcn/75.5.894
   Pellegatta F, 2003, AM J CLIN NUTR, V77, P1220, DOI 10.1093/ajcn/77.5.1220
   Rein D, 2000, J NUTR, V130, P2109S, DOI 10.1093/jn/130.8.2109S
   Relja B, 2011, EUR J NUTR IN PRESS, V0, P0
   RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F
   Robich MP, 2010, CIRCULATION, V122, PS142, DOI 10.1161/CIRCULATIONAHA.109.920132
   Santos Marta R, 2004, FREE RADIC RES, V38, P1011, DOI 10.1080/10715760400003384
   Sarr M, 2006, CARDIOVASC RES, V71, P794, DOI 10.1016/j.cardiores.2006.05.022
   Sato M, 1999, J MOL CELL CARDIOL, V31, P1289, DOI 10.1006/jmcc.1999.0961
   Sato M, 2002, ANN NY ACAD SCI, V957, P122, DOI 10.1111/j.1749-6632.2002.tb02911.x
   Scalbert A, 2000, J NUTR, V130, P2073S, DOI 10.1093/jn/130.8.2073S
   Shinmura K, 2011, CIRC RES, V109, P396, DOI 10.1161/CIRCRESAHA.111.243097
   Soares PR, 2011, ARQ BRAS CARDIOL, V96, P277, DOI 10.1590/S0066-782X2011005000020
   Song DK, 2010, J KOREAN MED SCI, V25, P380, DOI 10.3346/jkms.2010.25.3.380
   Soucek P, 2011, ANTI-CANCER DRUG, V22, P176, DOI 10.1097/CAD.0b013e328341a17b
   Stein JH, 1999, CIRCULATION, V100, P1050, DOI 10.1161/01.CIR.100.10.1050
   Szkudelski T, 2011, ANN NY ACAD SCI, V1215, P34, DOI 10.1111/j.1749-6632.2010.05844.x
   Thielecke F, 2009, PHYTOCHEMISTRY, V70, P11, DOI 10.1016/j.phytochem.2008.11.011
   Thirunavukkarasu M, 2008, J AGR FOOD CHEM, V56, P6733, DOI 10.1021/jf801473v
   Vang O, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0019881
   Visioli F, 1998, NUTR REV, V56, P142
   Vitseva O, 2005, J CARDIOVASC PHARM, V46, P445, DOI 10.1097/01.fjc.0000176727.67066.1c
   Wallerath T, 2002, CIRCULATION, V106, P1652, DOI 10.1161/01.CIR.0000029925.18593.5C
   Widlansky ME, 2003, J AM COLL CARDIOL, V42, P1149, DOI 10.1016/S0735-1097(03)00994-X
   Wollgast J, 2001, J CHROMATOGR A, V926, P211, DOI 10.1016/S0021-9673(01)00994-3
   Wu JN, 2009, INT J CARDIOL, V137, P216, DOI 10.1016/j.ijcard.2008.06.051
   Xi JK, 2009, EUR J PHARMACOL, V604, P111, DOI 10.1016/j.ejphar.2008.12.024
   Xiong SQ, 2011, J BIOL CHEM, V286, P5289, DOI 10.1074/jbc.M110.163667
   Yamazaki KG, 2010, J AM COLL CARDIOL, V55, P2869, DOI 10.1016/j.jacc.2010.01.055
   Yasuda A, 2011, J AGR FOOD CHEM, V59, P1470, DOI 10.1021/jf103820b
   Yeh ETH, 2004, CIRCULATION, V109, P3122, DOI 10.1161/01.CIR.0000133187.74800.B9
   Yung LM, 2008, INFLAMMOPHARMACOLOGY, V16, P230, DOI 10.1007/s10787-008-8022-y
   Zern TL, 2003, J NUTR, V133, P2268, DOI 10.1093/jn/133.7.2268
   Zhou HB, 2005, WORLD J GASTROENTERO, V11, P280, DOI 10.3748/wjg.v11.i2.280
   Zykova TA, 2008, MOL CARCINOGEN, V47, P797, DOI 10.1002/mc.20437
NR 124
TC 79
Z9 84
U1 2
U2 81
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES
SN 1389-5575
EI 1875-5607
J9 MINI-REV MED CHEM
JI Mini-Rev. Med. Chem.
PD DEC 15
PY 2011
VL 11
IS 14
BP 1191
EP 1199
DI 
PG 9
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 869YH
UT WOS:000298635800003
PM 22070680
DA 2025-04-28
ER

PT J
AU Peng, CH
   Liu, LK
   Chuang, CM
   Chyau, CC
   Huang, CN
   Wang, CJ
AF Peng, Chiung-Huei
   Liu, Li-Kaung
   Chuang, Chao-Ming
   Chyau, Charng-Cherng
   Huang, Chieng-Ning
   Wang, Chau-Jong
TI Mulberry Water Extracts Possess an Anti-obesity Effect and Ability To Inhibit Hepatic Lipogenesis and Promote Lipolysis
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE Mulberry water extracts; anti-obese; hypolipidemic; lipogenesis; lipolysis
ID free fatty-acid; insulin-resistance; phenolic-compounds; adipose-tissue; obesity; anthocyanins; polyphenol; metabolism; liver; diet
AB Obesity plays a critical role in dyslipidemia and related disorders. Mulberry water extracts (MWEs) contain polyphenols, including gallic acid, chlorogenic acid, rutin, and anthocyanins. In this study, using 6-week-old male hamsters, we investigated the anti-obese effect of MWEs. After 12 weeks of treatment, MWEs lowered high-fat diet (HED)-induced body weight and visceral fat, accompanied with hypolipidemic effects by reducing serum triacylglycerol, cholesterol, free fatty acid, and the low-density lipoprotein (LDL)/high-density lipoprotein (HDL) ratio (n = 8 for each group). MWEs decreased hepatic lipids, thus protected livers from impairment. The hepatic peroxisome proliferator-activated receptor alpha and carnitine palmitoyltransferase-1 were elevated, while fatty acid synthase and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase were reduced by MWEs, indicating that MWEs regulated lipogenesis and lipolysis, which exerted the anti-obese and hypolipidemic effects. Noticeably, MWEs showed both efficacy and safety in vivo. In concluson, MWEs can be used to reduce body weight, serum, and liver lipids.
C1 [Liu, Li-Kaung; Wang, Chau-Jong] Chung Shan Med Univ, Inst Biochem & Biotechnol, Taichung 402, Taiwan.
   [Peng, Chiung-Huei; Chuang, Chao-Ming] Hungkuang Univ, Div Basic Med Sci, Taichung 433, Shalu County, Taiwan.
   [Chyau, Charng-Cherng] Hungkuang Univ, Inst Biotechnol, Taichung 433, Shalu County, Taiwan.
   [Huang, Chieng-Ning] Chung Shan Med Univ Hosp, Dept Internal Med, Taichung 402, Taiwan.
   [Wang, Chau-Jong] Chung Shan Med Univ Hosp, Dept Med Res, Taichung 402, Taiwan.
C3 Chung Shan Medical University; Hungkuang University; Hungkuang University; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital
RP Wang, CJ (corresponding author), Chung Shan Med Univ, Inst Biochem & Biotechnol, 110 Sect 1,Chien Kuo N Rd, Taichung 402, Taiwan.
EM wcj@csmu.edu.tw
FU National Science Council (NSC), Taiwan [NSC 99-2321-B-040-001]
CR Agouni A, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0005557
   Bose M, 2008, J NUTR, V138, P1677, DOI 10.1093/jn/138.9.1677
   Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501
   Carr MC, 2001, J CLIN ENDOCR METAB, V86, P2831, DOI 10.1210/jc.86.6.2831
   Cho AS, 2010, FOOD CHEM TOXICOL, V48, P937, DOI 10.1016/j.fct.2010.01.003
   de Jongh RT, 2004, DIABETES, V53, P2873, DOI 10.2337/diabetes.53.11.2873
   Després JP, 2006, ANN MED, V38, P52, DOI 10.1080/07853890500383895
   Finck BN, 2002, J MOL CELL CARDIOL, V34, P1249, DOI 10.1006/jmcc.2002.2061
   Fruchart JC, 2006, DRUGS TODAY, V42, P39, DOI 10.1358/dot.2006.42.1.963528
   Gouni-Berthold I, 2005, CURRENT DRUG TARGETS - CARDIOVASCULAR & HAEMATOLOGICAL DISORDERS, V5, P513, DOI 10.2174/156800605774962022
   Hsu CL, 2009, J AGR FOOD CHEM, V57, P425, DOI 10.1021/jf802715t
   Huang HP, 2008, J AGR FOOD CHEM, V56, P9286, DOI 10.1021/jf8013102
   Jang A, 2008, CHEM-BIOL INTERACT, V174, P109, DOI 10.1016/j.cbi.2008.05.018
   Kang TH, 2006, NEUROSCI LETT, V391, P122, DOI 10.1016/j.neulet.2005.08.053
   Kim YW, 1999, J KOREAN MED SCI, V14, P539, DOI 10.3346/jkms.1999.14.5.539
   Koutsari C, 2006, J LIPID RES, V47, P1643, DOI 10.1194/jlr.R600011-JLR200
   La Torre GL, 2006, FOOD CHEM, V94, P640, DOI 10.1016/j.foodchem.2005.02.007
   Liu LK, 2008, J FOOD SCI, V73, PH113, DOI 10.1111/j.1750-3841.2008.00801.x
   Liu LK, 2009, J AGR FOOD CHEM, V57, P7605, DOI 10.1021/jf9014697
   MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305
   Mittendorfer B, 2009, OBESITY, V17, P1872, DOI 10.1038/oby.2009.224
   Porter SA, 2009, DIABETES CARE, V32, P1068, DOI 10.2337/dc08-2280
   Poudyal H, 2010, J NUTR, V140, P946, DOI 10.3945/jn.109.117812
   Prior RL, 2009, MOL NUTR FOOD RES, V53, P1406, DOI 10.1002/mnfr.200900026
   Shadid S, 2007, DIABETES, V56, P1369, DOI 10.2337/db06-1680
   Wolfram S, 2005, ANN NUTR METAB, V49, P54, DOI 10.1159/000084178
   Yang DJ, 2010, J AGR FOOD CHEM, V58, P2020, DOI 10.1021/jf903355q
   Yang MY, 2010, J AGR FOOD CHEM, V58, P850, DOI 10.1021/jf903209w
   Ye Jianping, 2007, ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, V7, P65
   Zadernowski R, 2005, J AGR FOOD CHEM, V53, P2118, DOI 10.1021/jf040411p
NR 30
TC 163
Z9 174
U1 2
U2 48
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD MAR 23
PY 2011
VL 59
IS 6
BP 2663
EP 2671
DI 10.1021/jf1043508
PG 9
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science & Technology
SC Agriculture; Chemistry; Food Science & Technology
GA 735GQ
UT WOS:000288401800067
PM 21361295
DA 2025-04-28
ER

PT J
AU Kotyczka, C
   Boettler, U
   Lang, R
   Stiebitz, H
   Bytof, G
   Lantz, I
   Hofmann, T
   Marko, D
   Somoza, V
AF Kotyczka, Christine
   Boettler, Ute
   Lang, Roman
   Stiebitz, Herbert
   Bytof, Gerhard
   Lantz, Ingo
   Hofmann, Thomas
   Marko, Doris
   Somoza, Veronika
TI Dark roast coffee is more effective than light roast coffee in reducing body weight, and in restoring red blood cell vitamin E and glutathione concentrations in healthy volunteers
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Article
DE Antioxidant activity; Body weight loss; Coffee; Superoxide dismutase; Vitamin E
ID antioxidant property; oxidative stress; chlorogenic acid; in-vitro; consumption; cancer; risk
AB Recent results from prospective cohort studies have shown that moderate coffee consumption is associated with a reduced risk for diabetes mellitus type II or Alzheimer's disease. Since reactive oxygen species (ROS) are believed to be involved in the pathogenesis of these diseases, antioxidants in coffee might contribute to this risk reduction. We aimed at elucidating whether a dark roast coffee beverage (CB) rich in N-methylpyridinium ions (NMP: 785 mu mol/L) and low in chlorogenic acids (CGA: 523 mu mol/L) has stronger antioxidant effects on human erythrocytes than a CB prepared from a light roast with opposite proportions (CGA: 4538 mu mol/L; NMP: 56 mu mol/L). Following a 2-wk wash out period, 500 mL of the respective CB was administered to 30 subjects daily for 4-wk. Blood and spot urine samples were collected at the beginning and at the end of each intervention. Intake of the dark roast CB most effectively improved the antioxidant status of erythrocytes: superoxide dismutase and glutathione peroxidase activity decreased by 5.8 and 15%, respectively, whereas tocopherol and total glutathione concentrations increased by 41 and 14%, respectively. Furthermore, administration of the NMP-rich CB led to a significant body weight reduction in pre-obese subjects, whereas the CGA-rich CB did not.
C1 [Somoza, Veronika] Univ Vienna, Dept Nutr & Physiol Chem, A-1090 Vienna, Austria.
   [Kotyczka, Christine] Deutsch Forsch Anstalt Lebensmittelchem, Freising Weihenstephan, Germany.
   [Boettler, Ute; Hofmann, Thomas] Univ Vienna, Dept Food Chem & Toxicol, A-1090 Vienna, Austria.
   [Lang, Roman; Marko, Doris] Tech Univ, Lehrstuhl Lebensmittelchem & Mol Sensorik, Freising Weihenstephan, Germany.
   [Stiebitz, Herbert; Bytof, Gerhard; Lantz, Ingo] Tchibo GmbH, Hamburg, Germany.
C3 University of Vienna; Leibniz Association; Leibniz-Institute for Food Systems Biology at the Technical University of Munich; University of Vienna
RP Somoza, V (corresponding author), Univ Vienna, Dept Nutr & Physiol Chem, Althanstr 14, A-1090 Vienna, Austria.
EM veronika.somoza@univie.ac.at
FU Federal Ministry of Education and Research (BMBF) [0313843]; Tchibo GmbH, Germany
CR Boettler U, 2011, MOL NUTR FOOD RES, V55, P798, DOI 10.1002/mnfr.201100115
   Boettler U, 2011, J NUTR BIOCHEM, V22, P426, DOI 10.1016/j.jnutbio.2010.03.011
   Daglia M, 2004, J AGR FOOD CHEM, V52, P1700, DOI 10.1021/jf030298n
   Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753
   ESPOSITO F, 2003, BIOORGAN MED CHEM, V11, P4797
   Greenberg JA, 2006, AM J CLIN NUTR, V84, P682, DOI 10.1093/ajcn/84.4.682
   Grubben MJAL, 2000, ALIMENT PHARM THER, V14, P1181, DOI 10.1046/j.1365-2036.2000.00826.x
   Hassan HA, 2009, FOOD CHEM TOXICOL, V47, P2332, DOI 10.1016/j.fct.2009.06.023
   Jenner P, 2003, ANN NEUROL, V53, PS26, DOI 10.1002/ana.10483
   Mena S, 2009, MUTAT RES-GEN TOX EN, V674, P36, DOI 10.1016/j.mrgentox.2008.09.017
   Moreira DP, 2005, J AGR FOOD CHEM, V53, P1399, DOI 10.1021/jf0485436
   Mursu J, 2005, FREE RADICAL BIO MED, V38, P527, DOI 10.1016/j.freeradbiomed.2004.11.025
   Natella F, 2002, J AGR FOOD CHEM, V50, P6211, DOI 10.1021/jf025768c
   Nicoli MC, 1997, FOOD SCI TECHNOL-LEB, V30, P292, DOI 10.1006/fstl.1996.0181
   OHNISHI M, 1994, PHYTOCHEMISTRY, V36, P579, DOI 10.1016/S0031-9422(00)89778-2
   Ranheim T, 2005, MOL NUTR FOOD RES, V49, P274, DOI 10.1002/mnfr.200400109
   Somoza V, 2003, J AGR FOOD CHEM, V51, P6861, DOI 10.1021/jf034750e
   Stalmach A, 2010, ARCH BIOCHEM BIOPHYS, V501, P98, DOI 10.1016/j.abb.2010.03.005
   Tavani A, 2000, EUR J CANCER PREV, V9, P241, DOI 10.1097/00008469-200008000-00004
   Thom E, 2007, J INT MED RES, V35, P900, DOI 10.1177/147323000703500620
NR 20
TC 52
Z9 53
U1 0
U2 44
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
EI 1613-4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD OCT 15
PY 2011
VL 55
IS 10
BP 1582
EP 1586
DI 10.1002/mnfr.201100248
PG 5
WC Food Science & Technology
SC Food Science & Technology
GA 841XE
UT WOS:000296547700016
PM 21809439
DA 2025-04-28
ER

PT J
AU Seifert, JG
   Nelson, A
   Devonish, J
   Burke, ER
   Stohs, SJ
AF Seifert, John G.
   Nelson, Aaron
   Devonish, Julia
   Burke, Edmund R.
   Stohs, Sidney J.
TI Effect of Acute Administration of an Herbal Preparation on Blood Pressure and Heart Rate in Humans
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Citrus aurantium; p-synephrine; blood pressure; heart rate; bitter orange; caffeine; green tea
ID citrus-aurantium; dietary-supplement; bitter-orange; weight-loss; synephrine; extract; obesity
AB Confusion and controversy exist regarding the cardiovascular effects of dietary supplements containing caffeine and Citrus aurantium (bitter orange) extract. The primary protoalkaloidal ingredient in bitter orange extract is p-synephrine which has some structural similarities to ephedrine and nor-epinehrine, but exhibits markedly different pharmacokinetic and receptor binding properties. The goal of this study was to investigate the cardiovascular effects of a product containing caffeine, bitter orange extract (p-synephrine) and green tea extract in mildly overweight individuals. Fourteen female and nine male subjects (age 24.7 +/- 7.4 yrs, BMI: 26.6 +/- 3.8) volunteered in this randomized, placebo-controlled, crossover, double-blind designed study. On day one, subjects entered the laboratory following an overnight fast. Heart rate and blood pressure were recorded at 60 min. Expired air was analyzed for the next 10 min of the session. At each of three meals, subjects ingested one capsule that was either a non-caloric placebo or a dietary supplement that contained 13 mg p-synephrine and 176 mg caffeine. On the following day, the subjects returned and repeated the protocol for data collection beginning 60 min after consuming one capsule of the placebo or the dietary supplement. No effects of the dietary supplement on heart rate, systolic and diastolic blood pressure or mean arterial pressure were observed. No between or within group differences were observed when data were analyzed for gender and caffeine usage. A small but significant decrease in resting respiratory exchange ratio was observed for the low caffeine user group in response to the product containing caffeine and p-synephrine. The results of this study indicate that ingestion of a product containing bitter orange extract, caffeine and green tea extract does not lead to increased cardiovascular stress and that fat oxidation may increase in certain populations.
C1 [Seifert, John G.] Montana State Univ, Movement Sci Human Performance Lab, Bozeman, MT 59717 USA.
   [Nelson, Aaron; Devonish, Julia] St Cloud State Univ, Human Performance Lab, St Cloud, MN 56301 USA.
   [Burke, Edmund R.] Univ Colorado, Dept Biol, Colorado Springs, CO 80907 USA.
   [Stohs, Sidney J.] Creighton Univ, Med Ctr, Sch Pharm & Hlth Profess, Omaha, NE USA.
C3 Montana State University System; Montana State University Bozeman; Minnesota State Colleges & Universities; Saint Cloud State University; University of Colorado System; University of Colorado at Colorado Springs; Creighton University
RP Seifert, JG (corresponding author), Montana State Univ, Movement Sci Human Performance Lab, Bozeman, MT 59717 USA.
EM john.seifert@montana.edu
FU Enforma Natural Products
CR Arch JRS, 2002, EUR J PHARMACOL, V440, P99, DOI 10.1016/S0014-2999(02)01421-8
   Barkin SL, 2010, J BUS PSYCHOL, V25, P239, DOI 10.1007/s10869-010-9166-5
   Bent S, 2004, AM J CARDIOL, V94, P1359, DOI 10.1016/j.amjcard.2004.07.137
   Bui LT, 2006, ANN PHARMACOTHER, V40, P53, DOI 10.1345/aph.1G488
   Cai LM, 2010, MED CARE, V48, P510, DOI 10.1097/MLR.0b013e3181dbdb20
   Carpéné C, 1999, N-S ARCH PHARMACOL, V359, P310, DOI 10.1007/PL00005357
   Colker CM, 1999, CURR THER RES CLIN E, V60, P145, DOI 10.1016/S0011-393X(00)88523-9
   Dews PB, 2002, FOOD CHEM TOXICOL, V40, P1257, DOI 10.1016/S0278-6915(02)00095-9
   DEWS PB, 1982, ANNU REV NUTR, V2, P323, DOI 10.1146/annurev.nu.02.070182.001543
   Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014
   Fugh-Berman A, 2004, EXP BIOL MED, V229, P698, DOI 10.1177/153537020422900802
   Gougeon R, 2005, OBES RES, V13, P1187, DOI 10.1038/oby.2005.141
   Gray S, 2005, J ADOLESCENT HEALTH, V37, P415, DOI 10.1016/j.jadohealth.2004.12.011
   Haller CA, 2005, AM J MED, V118, P998, DOI 10.1016/j.amjmed.2005.02.034
   Haller CA, 2008, BRIT J CLIN PHARMACO, V65, P833, DOI 10.1111/j.1365-2125.2008.03144.x
   Inchiosa MA, 2011, J OBES, V2011, P0, DOI 10.1155/2011/764584
   Min B, 2005, PHARMACOTHERAPY, V25, P1719, DOI 10.1592/phco.2005.25.12.1719
   Penzak SR, 2001, J CLIN PHARMACOL, V41, P1059, DOI 10.1177/00912700122012652
   Preuss Harry G, 2002, JOURNAL OF MEDICINE (WESTBURY), V33, P247
   Sale C, 2006, INT J OBESITY, V30, P764, DOI 10.1038/sj.ijo.0803209
   Sander LC, 2008, ANAL BIOANAL CHEM, V391, P2023, DOI 10.1007/s00216-008-2074-0
   Stephensen TA, 2009, MIL MED, V174, P1313, DOI 10.7205/MILMED-D-01-5009
   STEWART A, 2010, ANESTH ANALG, V0, P0
   Stmedema JP, 2008, SAMJ S AFR MED J, V98, P372
   Thomas JE, 2009, TEX HEART I J, V36, P586
   Tsujita T, 2007, J NUTR SCI VITAMINOL, V53, P547, DOI 10.3177/jnsv.53.547
   Zenk JL, 2005, NUTRITION, V21, P179, DOI 10.1016/j.nut.2004.05.025
NR 29
TC 28
Z9 32
U1 0
U2 15
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-1907
EI 
J9 INT J MED SCI
JI Int. J. Med. Sci.
PD JUN 15
PY 2011
VL 8
IS 3
BP 192
EP 197
DI 10.7150/ijms.8.192
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 747YB
UT WOS:000289356100002
PM 21448304
DA 2025-04-28
ER

PT J
AU Rains, TM
   Agarwal, S
   Maki, KC
AF Rains, Tia M.
   Agarwal, Sanjiv
   Maki, Kevin C.
TI Antiobesity effects of green tea catechins: a mechanistic review
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Review
DE Green tea catechins; Obesity; Energy expenditure; Fat oxidation
ID fatty-acid oxidation; diet-induced obesity; reduces body-fat; intestinal-absorption; energy-expenditure; double-blind; food-intake; epigallocatechin gallate; weight maintenance; o-methyltransferase
AB Green tea catechins (GTC) are polyphenolic compounds present in the unfermented dried leaves of the plant, Camellia sinensis. Results from a number of randomized, controlled intervention trials have shown that consumption of GTC (270 mg to 1200 mg/day) may reduce body weight and fat. There are several proposed mechanisms whereby GTC may influence body weight and composition. The predominating hypothesis is that GTC influences sympathetic nervous system (SNS) activity, increasing energy expenditure and promoting the oxidation of fat. Caffeine, naturally present in green tea, also influences SNS activity, and may act synergistically with GTC to increase energy expenditure and fat oxidation. Other potential mechanisms include modifications in appetite, up-regulation of enzymes involved in hepatic fat oxidation, and decreased nutrient absorption. This article reviews the evidence for each of these purported mechanisms, with particular reference to studies in humans. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Rains, Tia M.; Maki, Kevin C.] Provident Clin Res, Glen Ellyn, IL 60137 USA.
RP Maki, KC (corresponding author), Provident Clin Res, Glen Ellyn, IL 60137 USA.
EM kmaki@providentcrc.com
CR Ashida H, 2004, BIOFACTORS, V22, P135, DOI 10.1002/biof.5520220126
   ASTRUP A, 1992, INT J OBESITY, V16, P269
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   Auvichayapat P, 2008, PHYSIOL BEHAV, V93, P486, DOI 10.1016/j.physbeh.2007.10.009
   Belza A, 2007, INT J OBESITY, V31, P121, DOI 10.1038/sj.ijo.0803351
   Belza A, 2009, EUR J CLIN NUTR, V63, P57, DOI 10.1038/sj.ejcn.1602901
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   BORCHARDT RT, 1975, J MED CHEM, V18, P120, DOI 10.1021/jm00235a030
   Boschmann M, 2007, J AM COLL NUTR, V26, P389S, DOI 10.1080/07315724.2007.10719627
   Bray GA, 2008, J CLIN ENDOCR METAB, V93, PS81, DOI 10.1210/jc.2008-1294
   Brown WJ, 2005, OBES RES, V13, P1431, DOI 10.1038/oby.2005.173
   Cabrera C, 2006, J AM COLL NUTR, V25, P79, DOI 10.1080/07315724.2006.10719518
   Chan CCW, 2006, J SOC GYNECOL INVEST, V13, P63, DOI 10.1016/j.jsgi.2005.10.006
   Chan PT, 1999, J NUTR, V129, P1094, DOI 10.1093/jn/129.6.1094
   Chantre P, 2002, PHYTOMEDICINE, V9, P3, DOI 10.1078/0944-7113-00078
   Choo JJ, 2003, J NUTR BIOCHEM, V14, P671, DOI 10.1016/j.jnutbio.2003.08.005
   Chow HHS, 2005, CLIN CANCER RES, V11, P4627, DOI 10.1158/1078-0432.CCR-04-2549
   Cooper R, 2005, J ALTERN COMPLEM MED, V11, P521, DOI 10.1089/acm.2005.11.521
   Diepvens K, 2006, PHYSIOL BEHAV, V87, P185, DOI 10.1016/j.physbeh.2005.09.013
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   Friedman MI, 2007, DRUG NEWS PERSPECT, V20, P573, DOI 10.1358/dnp.2007.20.9.1162243
   Fukino Y, 2005, J NUTR SCI VITAMINOL, V51, P335, DOI 10.3177/jnsv.51.335
   Gregersen NT, 2009, BRIT J NUTR, V102, P1187, DOI 10.1017/S0007114509371779
   Hasegawa N, 2003, PHYTOTHER RES, V17, P477, DOI 10.1002/ptr.1177
   Hill AM, 2007, J AM COLL NUTR, V26, P396S, DOI 10.1080/07315724.2007.10719628
   Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857
   Hodgson JM, 2006, BRIT J NUTR, V95, P14, DOI 10.1079/BJN20051621
   Hsu CH, 2008, CLIN NUTR, V27, P363, DOI 10.1016/j.clnu.2008.03.007
   Hsu TF, 2006, EUR J CLIN NUTR, V60, P1330, DOI 10.1038/sj.ejcn.1602464
   Hursel R, 2009, INT J OBESITY, V33, P956, DOI 10.1038/ijo.2009.135
   IKEDA I, 1992, BIOCHIM BIOPHYS ACTA, V1127, P141, DOI 10.1016/0005-2760(92)90269-2
   Ikeda I, 2003, J AGR FOOD CHEM, V51, P7303, DOI 10.1021/jf034728l
   Johnston K, 2005, FEBS LETT, V579, P1653, DOI 10.1016/j.febslet.2004.12.099
   Juhel C, 2000, J NUTR BIOCHEM, V11, P45, DOI 10.1016/S0955-2863(99)00070-4
   Kahler A, 1999, NUTRITION, V15, P819, DOI 10.1016/S0899-9007(99)00212-9
   Kamphuis MMJW, 2003, AM J CLIN NUTR, V77, P1133, DOI 10.1093/ajcn/77.5.1133
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Khan N, 2007, LIFE SCI, V81, P519, DOI 10.1016/j.lfs.2007.06.011
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Kobayashi Y, 2000, J AGR FOOD CHEM, V48, P5618, DOI 10.1021/jf0006832
   Komatsu Tatsushi, 2003, JOURNAL OF MEDICAL INVESTIGATION, V50, P170
   Koo SI, 2007, J NUTR BIOCHEM, V18, P179, DOI 10.1016/j.jnutbio.2006.12.005
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   Krul C, 2001, MUTAT RES-FUND MOL M, V474, P71, DOI 10.1016/S0027-5107(00)00158-5
   Lin YS, 2003, J AGR FOOD CHEM, V51, P1864, DOI 10.1021/jf021066b
   Maki KC, 2009, NUTRITION, V25, P627, DOI 10.1016/j.nut.2008.11.028
   Maki KC, 2009, J NUTR, V139, P264, DOI 10.3945/jn.108.098293
   Matsui T, 1996, BIOSCI BIOTECH BIOCH, V60, P2019, DOI 10.1271/bbb.60.2019
   MATSUMOTO N, 1993, BIOSCI BIOTECH BIOCH, V57, P525, DOI 10.1271/bbb.57.525
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Nagao T, 2007, OBESITY, V15, P1473, DOI 10.1038/oby.2007.176
   Nagao T, 2009, OBESITY, V17, P310, DOI 10.1038/oby.2008.505
   Nagle DG, 2006, PHYTOCHEMISTRY, V67, P1849, DOI 10.1016/j.phytochem.2006.06.020
   Ota N, 2005, J HEALTH SCI, V51, P233, DOI 10.1248/jhs.51.233
   Palmatier MA, 1999, BIOL PSYCHIAT, V46, P557, DOI 10.1016/S0006-3223(99)00098-0
   Park JH, 2009, J PHYSIOL PHARMACOL, V60, P101
   Phung OJ, 2010, AM J CLIN NUTR, V91, P73, DOI 10.3945/ajcn.2009.28157
   Popkin BM, 2010, AM J CLIN NUTR, V91, P284S, DOI 10.3945/ajcn.2009.28473C
   Raederstorff DG, 2003, J NUTR BIOCHEM, V14, P326, DOI 10.1016/S0955-2863(03)00054-8
   Rudelle S, 2007, OBESITY, V15, P349, DOI 10.1038/oby.2007.529
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   Sabu MC, 2002, J ETHNOPHARMACOL, V83, P109
   SCHARRER E, 1986, AM J PHYSIOL, V250, P1003, DOI 10.1152/ajpregu.1986.250.6.R1003
   Scharrer E, 1999, NUTRITION, V15, P704, DOI 10.1016/S0899-9007(99)00125-2
   Secher A, 2009, INT CLIN PSYCHOPHARM, V24, P199, DOI 10.1097/YIC.0b013e32832d6be2
   Shishikura Y, 2006, J AGR FOOD CHEM, V54, P1906, DOI 10.1021/jf051988p
   St-Onge MP, 2002, J NUTR, V132, P329
   Takeshita M, 2008, JPN PHARMACOL THER, V36, P767
   Tentolouris N, 2006, ANN NY ACAD SCI, V1083, P129, DOI 10.1196/annals.1367.010
   Tsuneki Hiroshi, 2004, BMC PHARMACOLOGY, V4, P18, DOI 10.1186/1471-2210-4-18
   Unno T, 2009, J NUTR SCI VITAMINOL, V55, P447, DOI 10.3177/jnsv.55.447
   Van Amelsvoort JMM, 2001, XENOBIOTICA, V31, P891, DOI 10.1080/00498250110079149
   Venables MC, 2008, AM J CLIN NUTR, V87, P778, DOI 10.1093/ajcn/87.3.778
   Wang HQ, 2010, OBESITY, V18, P773, DOI 10.1038/oby.2009.256
   Wang S, 2006, J NUTR, V136, P2791, DOI 10.1093/jn/136.11.2791
   Wang S, 2006, J NUTR BIOCHEM, V17, P492, DOI 10.1016/j.jnutbio.2006.03.004
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   Wu CH, 2003, OBES RES, V11, P1088, DOI 10.1038/oby.2003.149
   Zhong LT, 2006, AM J CLIN NUTR, V84, P551, DOI 10.1093/ajcn/84.3.551
NR 85
TC 311
Z9 343
U1 1
U2 145
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0955-2863
EI 1873-4847
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD JAN 15
PY 2011
VL 22
IS 1
BP 1
EP 7
DI 10.1016/j.jnutbio.2010.06.006
PG 7
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA 701XO
UT WOS:000285858700001
PM 21115335
DA 2025-04-28
ER

PT J
AU Bracesco, N
   Sanchez, AG
   Contreras, V
   Menini, T
   Gugliucci, A
AF Bracesco, N.
   Sanchez, A. G.
   Contreras, V.
   Menini, T.
   Gugliucci, A.
TI Recent advances on Ilex paraguariensis research: Minireview
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Review
DE Ilex paraguariensis; Obesity; Inflammation; Oxidative stress; Hypercholesterolemia; Antimutagenesis
ID density-lipoprotein; chlorogenic acids; esophageal cancer; mate consumption; aqueous extract; black tobacco; tea; leaves; expression; inhibitors
AB Ilex paraguariensis dried and minced leaves are made into a brewed tea, prepared in a sui generis manner by large populations in South America, having evolved from a tea drunk by the Guarani ethnic group to a beverage that has a social and almost ritualistic role in some South American modern societies. It is used both as a source of caffeine, in lieu or in parallel with tea and coffee, but also as a therapeutic agent for its alleged pharmacological properties. Although with some exceptions, research on biomedical properties of this herb has had a late start and strongly lags behind the impressive amount of literature on green tea and coffee. However, in the past 15 years, there was a several-fold increase in the literature studying Ilex paraguariensis properties showing effects such as antioxidant properties in chemical models and ex vivo lipoprotein studies, vaso-dilating and lipid reduction properties, antimutagenic effects, controversial association with oropharyngeal cancer, anti-glycation effects and weight reduction properties. Lately, promising results from human intervention studies have surfaced and the literature offers several developments on this area. The aim of this review is to provide a concise summary of the research published in the past three years, with an emphasis on translational studies, inflammation and lipid metabolism. Ilex paraguariensis reduces LDL-cholesterol levels in humans with Ilex paraguariensis dyslipoproteinemia and the effect is synergic with that of statins. Plasma antioxidant capacity as well as expression of antioxidant enzymes is positively modulated by intervention with Ilex paraguariensis in human cohorts. A review on the evidence implicating Ilex paraguariensis heavy consumption with some neoplasias show data that are inconclusive but indicate that contamination with alkylating agents during the drying process of the leaves should be avoided. On the other hand, several new studies confirm the antimutagenic effects of Ilex paraguariensis in different models, from DNA double breaks in cell culture models to mice studies. Novel interesting work has emerged showing significant effect on weight reduction both in mice and in rat models. Some mechanisms involved are inhibition of pancreatic lipase, activation of AMPK and uncoupling of electron transport. Intervention studies in animals have provided strong evidence of anti-inflammatory effects of Ilex paraguariensis, notably protecting cigarette-induced lung inflammation acting on macrophage migration and inactivating matrix-metalloproteinase. Research on the effects of Ilex paraguariensis in health and disease has confirmed its antioxidant, anti-inflammatory, antimutagenic and lipid-lowering activities. Although we are still waiting for the double-blind, randomized prospective clinical trial, the evidence seems to provide support for beneficial effects of mate drinking on chronic diseases with inflammatory component and lipid metabolism disorders. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Menini, T.; Gugliucci, A.] Touro Univ Calif, Glycat Oxidat & Dis Lab, Vallejo, CA 94592 USA.
   [Bracesco, N.; Sanchez, A. G.; Contreras, V.] Univ Republica, Fac Med & Ciencias, Lab Radiobiol Dpt Biofis, Montevideo, Uruguay.
C3 Touro University California; Universidad de la Republica, Uruguay
RP Gugliucci, A (corresponding author), Touro Univ Calif, Glycat Oxidat & Dis Lab, 1310 Johnson Lane, Vallejo, CA 94592 USA.
EM alejandro.gugliucci@tu.edu
FU ANII (Agencia Nacional Para la Investigacion y la Innovacion -Uruguay)
CR Actis-Goretta L, 2002, ANN NY ACAD SCI, V957, P279, DOI 10.1111/j.1749-6632.2002.tb02925.x
   Andersen T, 2001, J HUM NUTR DIET, V14, P243, DOI 10.1046/j.1365-277X.2001.00290.x
   Arçari DP, 2009, OBESITY, V17, P2127, DOI 10.1038/oby.2009.158
   Bastos DHM, 2007, MED AROMAT PLANT SCI BIOTECHNOL, V1, P37
   Bracesco N, 2003, J ALTERN COMPLEM MED, V9, P379, DOI 10.1089/107555303765551606
   Bracesco N, 2003, THESIS FM CIENCIAS, V0, P0
   Clifford MN, 2004, PLANTA MED, V70, P1103, DOI 10.1055/s-2004-835835
   Clifford MN, 1999, J SCI FOOD AGR, V79, P362, DOI 10.1002/(SICI)1097-0010(19990301)79:3<362::AID-JSFA256>3.0.CO;2-D
   de Morais EC, 2009, J AGR FOOD CHEM, V57, P8316, DOI 10.1021/jf901660g
   DESTEFANI E, 1991, CANCER-AM CANCER SOC, V67, P536, DOI 10.1002/1097-0142(19910115)67:2<536::AID-CNCR2820670236>3.0.CO;2-8
   DESTEFANI E, 1988, REV EPIDEMIOL SANTE, V36, P389
   Dickel ML, 2007, J ETHNOPHARMACOL, V109, P60, DOI 10.1016/j.jep.2006.07.003
   Filip R, 2010, RECENT ADV PHYTOCHEM, V1, P113
   Filip R, 2010, PHYTOTHER RES, V24, P715, DOI 10.1002/ptr.3004
   Garcia RV, 1997, ARCH LATINOAM NUTR, V47, P77
   Gnoatto SCB, 2008, BIOORGAN MED CHEM, V16, P771, DOI 10.1016/j.bmc.2007.10.031
   GUGLIUCCI A, 1995, BIOCHEM MOL BIOL INT, V35, P47
   Gugliucci A, 1996, BIOCHEM BIOPH RES CO, V224, P338, DOI 10.1006/bbrc.1996.1030
   Gugliucci A, 2002, LIFE SCI, V71, P693, DOI 10.1016/S0024-3205(02)01734-4
   Gugliucci A, 2009, FITOTERAPIA, V80, P339, DOI 10.1016/j.fitote.2009.04.007
   Gugliucci A, 2009, FITOTERAPIA, V80, P138, DOI 10.1016/j.fitote.2009.01.001
   Heck CI, 2007, J FOOD SCI, V72, PR138, DOI 10.1111/j.1750-3841.2007.00535.x
   Heck CI, 2008, J AGR FOOD CHEM, V56, P8394, DOI 10.1021/jf801748s
   HSU CK, 1995, ARCH INTERN MED, V155, P2245, DOI 10.1001/archinte.155.20.2245
   Jacques RA, 2007, J AGR FOOD CHEM, V55, P10081, DOI 10.1021/jf071544o
   Jaiswal R, 2010, J AGR FOOD CHEM, V58, P5471, DOI 10.1021/jf904537z
   Kamangar F, 2008, CANCER EPIDEM BIOMAR, V17, P1262, DOI 10.1158/1055-9965.EPI-08-0025
   Lanzetti M, 2008, NUTRITION, V24, P375, DOI 10.1016/j.nut.2008.01.002
   Lee Richard, 2007, HARV HEART LETT, V18, P8
   LEITAO AC, 1994, BRAZ J MED BIOL RES, V27, P1517
   Loria D, 2009, REV PANAM SALUD PUBL, V25, P530, DOI 10.1590/S1020-49892009000600010
   Martinet A, 1999, PHYTOMEDICINE, V6, P231, DOI 10.1016/S0944-7113(99)80014-2
   Martinet A, 2001, PHYTOCHEM ANALYSIS, V12, P48, DOI 10.1002/1099-1565(200101/02)12:1<48::AID-PCA560>3.0.CO;2-#
   Martins F, 2010, OBESITY, V18, P42, DOI 10.1038/oby.2009.189
   Martins F, 2009, BRIT J NUTR, V101, P527, DOI 10.1017/S000711450802504X
   Matsumoto RLT, 2009, J AGR FOOD CHEM, V57, P1775, DOI 10.1021/jf803096g
   Menini T, 2007, PLANTA MED, V73, P1141, DOI 10.1055/s-2007-981585
   Miranda DDC, 2008, MUTAGENESIS, V23, P261, DOI 10.1093/mutage/gen011
   Mosimann ALP, 2006, BIOFACTORS, V26, P59, DOI 10.1002/biof.5520260106
   Oliveira DM, 2008, J AGR FOOD CHEM, V56, P10527, DOI 10.1021/jf8021404
   Olthof MR, 2001, J NUTR, V131, P66, DOI 10.1093/jn/131.1.66
   Pang J, 2008, ARCH BIOCHEM BIOPHYS, V476, P178, DOI 10.1016/j.abb.2008.02.019
   PINTOS J, 1994, EPIDEMIOLOGY, V5, P583, DOI 10.1097/00001648-199411000-00005
   Pittler MH, 2005, OBES REV, V6, P93, DOI 10.1111/j.1467-789X.2005.00169.x
   Puangpraphant S, 2009, J AGR FOOD CHEM, V57, P8873, DOI 10.1021/jf902255h
   Ramirez-Mares MV, 2004, MUTAT RES-FUND MOL M, V554, P53, DOI 10.1016/j.mrfmmm.2004.03.002
   SANZ MDT, 1991, ARCH LATINOAM NUTR, V41, P441
   Schinella G, 2005, CLIN NUTR, V24, P360, DOI 10.1016/j.clnu.2004.11.013
   Schubert A, 2007, PHARMAZIE, V62, P876, DOI 10.1691/ph.2007.11.7052
   Sewram V, 2003, CANCER EPIDEM BIOMAR, V12, P508
   Stein FLP, 2005, BIOL RES NURS, V7, P146, DOI 10.1177/1099800405280521
   Strassmann BB, 2008, J AGR FOOD CHEM, V56, P8348, DOI 10.1021/jf801041f
   Sugimoto S, 2009, CHEM PHARM BULL, V57, P257, DOI 10.1248/cpb.57.257
   Taketa ATC, 2004, J NAT PROD, V67, P1697, DOI 10.1021/np040059+
   Alves RJV, 2008, TOXICOL IN VITRO, V22, P695, DOI 10.1016/j.tiv.2007.11.005
   VASSALLO A, 1985, JNCI-J NATL CANCER I, V75, P1005
   Vieira MA, 2008, J AGR FOOD CHEM, V56, P4637, DOI 10.1021/jf8011085
   Warnakulasuriya S, 2009, BRIT DENT J, V207, P471, DOI 10.1038/sj.bdj.2009.1009
   Wnuk M, 2009, MUTAT RES-GEN TOX EN, V679, P18, DOI 10.1016/j.mrgentox.2009.07.017
   Wróbel K, 2000, BIOL TRACE ELEM RES, V78, P271, DOI 10.1385/BTER:78:1-3:271
   Xu GH, 2009, ARCH PHARM RES, V32, P1215, DOI 10.1007/s12272-009-1905-7
   Zanoelo EF, 2009, J AGR FOOD CHEM, V57, P11564, DOI 10.1021/jf903388a
   Zuin WG, 2005, J CHROMATOGR A, V1091, P2, DOI 10.1016/j.chroma.2005.07.057
NR 63
TC 312
Z9 334
U1 3
U2 116
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0378-8741
EI 1872-7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JUL 14
PY 2011
VL 136
IS 3
BP 378
EP 384
DI 10.1016/j.jep.2010.06.032
PG 7
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine
GA 802AR
UT WOS:000293482200002
PM 20599603
DA 2025-04-28
ER

PT J
AU Hussein, GME
   Matsuda, H
   Nakamura, S
   Akiyama, T
   Tamura, K
   Yoshikawa, M
AF Hussein, Ghazi M. E.
   Matsuda, Hisashi
   Nakamura, Seikou
   Akiyama, Toshihito
   Tamura, Kouhei
   Yoshikawa, Masayuki
TI Protective and ameliorative effects of mate (Ilex paraguariensis) on metabolic syndrome in TSOD mice
SO PHYTOMEDICINE
LA English
DT Article
DE Mate; Ilex paraguariensis; Metabolic syndrome; Insulin resistance; Adiponectin
ID assessing insulin sensitivity; chlorogenic acid; plasma-glucose; caffeic acid; green tea; model; resistance; mouse; identification; homeostasis
AB Yerba mate (mate) tea, a herbal tea prepared from the leaves of hex paraguariensis, is widely consumed in southern Latin America, and is gaining popularity worldwide. We investigated effects of an aqueous extract of mate on metabolic syndrome features in a metabolic syndrome model Tsumura Suzuki obese diabetic (TSOD) mouse. Oral administration of mate (100 mg/kg) for 7 weeks induced significant decreases in body weight, body mass index, and food intake in TSOD. It significantly decreased the hyperglycemia by reducing fasting blood glucose level, and increasing glucose uptake in glucose tolerance test. It also showed significant improvement in insulin sensitivity by increasing glucose uptake in insulin tolerance test, increasing quantitative insulin sensitivity check index, and decreasing homeostasis model assessment of insulin resistance index. The results also showed significant effects of mate on hyperlipidemia by decreasing blood levels of triglycerides, non-esterified fatty acids, and total cholesterol. Moreover, mate significantly improved adiponectin (AD) level, and exhibited significant reduction in white adipose tissue weight, and adiposity index in TSOD. It also showed significant ameliorative effects on TSOD histopathology, by reducing adipocytes proliferation, and improving hepatic steatosis. Furthermore, mate administration induced a dose-dependent delay in gastric emptying. The current data suggest that mate ameliorates metabolic syndrome by mechanisms involving increase of peripheral insulin sensitivity and cellular glucose uptake, and by modulating the level of circulating lipid metabolites and AD. These results indicate that mate can induce protective and ameliorative effects on insulin resistance, diabesity, and dyslipidemia in metabolic syndrome. (C) 2011 Elsevier GmbH. All rights reserved.
C1 [Hussein, Ghazi M. E.; Matsuda, Hisashi; Nakamura, Seikou; Yoshikawa, Masayuki] Kyoto Pharmaceut Univ, Yamashina Ku, Kyoto 6078412, Japan.
   [Hussein, Ghazi M. E.; Akiyama, Toshihito; Tamura, Kouhei] Tamura Pharmaceut Co Ltd, Gose, Nara 6392295, Japan.
C3 Kyoto Pharmaceutical University
RP Yoshikawa, M (corresponding author), Kyoto Pharmaceut Univ, Yamashina Ku, Kyoto 6078412, Japan.
EM myoshika@mb.kyoto-phu.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
CR Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8
   Banos G, 2008, CARDIOVASCULAR & HEMATOLOGICAL AGENTS IN MEDICINAL CHEMISTRY, V6, P237, DOI 10.2174/187152508785909465
   Bassoli BK, 2008, CELL BIOCHEM FUNCT, V26, P320, DOI 10.1002/cbf.1444
   Bastos DHM, 2007, MOLECULES, V12, P423, DOI 10.3390/12030423
   Battram DS, 2006, J NUTR, V136, P1276, DOI 10.1093/jn/136.5.1276
   Bixby M, 2005, LIFE SCI, V77, P345, DOI 10.1016/j.lfs.2004.11.030
   CLAUDIA A, 2005, PHYTOCHEM ANALYSIS, V16, P307
   de Sotillo DVR, 2002, J NUTR BIOCHEM, V13, P717, DOI 10.1016/S0955-2863(02)00231-0
   Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7
   Flordellis CS, 2005, TRENDS ENDOCRIN MET, V16, P254, DOI 10.1016/j.tem.2005.06.001
   Heck CI, 2007, J FOOD SCI, V72, PR138, DOI 10.1111/j.1750-3841.2007.00535.x
   Hollander JM, 2008, J AM DIET ASSOC, V108, P495, DOI 10.1016/j.jada.2007.12.007
   Hsu FL, 2000, PLANTA MED, V66, P228, DOI 10.1055/s-2000-8561
   Jung UJ, 2006, J PHARMACOL EXP THER, V318, P476, DOI 10.1124/jpet.106.105163
   Katz A, 2000, J CLIN ENDOCR METAB, V85, P2402, DOI 10.1210/jc.85.7.2402
   KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Lafay S, 2006, BRIT J NUTR, V96, P39, DOI 10.1079/BJN20061714
   Lee JI, 2007, J CHROMATOGR B, V852, P195, DOI 10.1016/j.jchromb.2007.01.013
   Matfin G, 2008, CURR DIABETES REP, V8, P31, DOI 10.1007/s11892-008-0007-0
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Minich DM, 2008, NUTR REV, V66, P429, DOI 10.1111/j.1753-4887.2008.00075.x
   Muniyappa R, 2008, AM J PHYSIOL-ENDOC M, V294, PE15, DOI 10.1152/ajpendo.00645.2007
   Nakatani N, 2000, J AGR FOOD CHEM, V48, P5512, DOI 10.1021/jf000422s
   Nugent AP, 2004, NUTRITION BULLETIN, V29, P36, DOI 10.1111/j.1467-3010.2004.00403.x
   Potenza MA, 2006, DIABETES, V55, P3594, DOI 10.2337/db06-0667
   Ren J, 2007, PHARMAZIE, V62, P689, DOI 10.1691/ph.2007.9.6213
   Scott CL, 2003, AM J CARDIOL, V92, P35I, DOI 10.1016/S0002-9149(03)00507-1
   Shearer J, 2007, CAN J PHYSIOL PHARM, V85, P823, DOI 10.1139/Y07-070
   SINGLETON VL, 1965, AMER J ENOL VITICULT, V16, P144
   Sugimoto S, 2009, CHEM PHARM BULL, V57, P257, DOI 10.1248/cpb.57.257
   Suzuki W, 1999, EXP ANIM TOKYO, V48, P181, DOI 10.1538/expanim.48.181
   TACHE Y, 1987, AM J PHYSIOL, V253, PG241, DOI 10.1152/ajpgi.1987.253.2.G241
   Takahashi A, 2006, METABOLISM, V55, P1664, DOI 10.1016/j.metabol.2006.08.007
   Taylor BA, 1996, GENOMICS, V34, P389, DOI 10.1006/geno.1996.0302
   Tolonen A, 2002, PHYTOCHEM ANALYSIS, V13, P316, DOI 10.1002/pca.663
   Wittemer SM, 2005, PHYTOMEDICINE, V12, P28, DOI 10.1016/j.phymed.2003.11.002
   Yamada T, 2008, PHARMACOL THERAPEUT, V117, P188, DOI 10.1016/j.pharmthera.2007.09.006
NR 38
TC 35
Z9 37
U1 1
U2 24
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944-7113
EI 1618-095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD DEC 15
PY 2011
VL 19
IS 1
BP 88
EP 97
DI 10.1016/j.phymed.2011.06.036
PG 10
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine
GA 881CA
UT WOS:000299456900014
PM 22018902
DA 2025-04-28
ER

PT J
AU Imada, S
   Tanaka, A
   Nishiumi, S
   Ashida, H
AF Imada, Sayuri
   Tanaka, Akihito
   Nishiumi, Shin
   Ashida, Hitoshi
TI Concentration of Catechins and Caffeine in Black Tea Affects Suppression of Fat Accumulation and Hyperglycemia in High-fat Diet-fed Mice
SO FOOD SCIENCE AND TECHNOLOGY RESEARCH
LA English
DT Article
DE black tea; glucose transporter 4; insulin receptor-beta; high-fat diet
ID glut4 glucose-transporter; green tea; insulin-resistance; skeletal-muscle; (-)-epigallocatechin gallate; lipid-accumulation; 3t3-l1 cells; expression; obesity; kinase
AB In this study, we investigated preventive effects of black tea on obesity and hyperglycemia in C57BL/6 mice fed a high-fat diet for 14 weeks. During the feeding period, mice were given the following black teas: BT1 containing 3,000 mg/L total catechins and 864 mg/L caffeine; and BT2 containing 1,437 mg/L total catechins and 594 mg/L caffeine. Both BT1 and BT2 suppressed high-fat diet-caused body weight gain, deposition of white adipose tissue, and increases in plasma lipids and glucose. Moreover, both BT1 and BT2 counteracted the high-fat diet-caused decrease in the expression of insulin receptor (IR)-beta and glucose transporter 4 (GLUT4), markers for insulin resistance. Of these effects, BT2 were stronger than that of BT1. In conclusion, black tea prevents hyperglycemia and insulin resistance through maintenance of IR-beta and GLUT4 expression in high-fat diet-fed mice, with an appropriate concentration of tea producing maximal effectiveness.
C1 [Imada, Sayuri; Tanaka, Akihito; Nishiumi, Shin; Ashida, Hitoshi] Kobe Univ, Grad Sch Agr Sci, Dept Agrobiosci, Nada Ku, Kobe, Hyogo 6578501, Japan.
   [Nishiumi, Shin] Kobe Univ, Grad Sch Med, Dept Internal Med, Chuo Ku, Kobe, Hyogo 6500017, Japan.
C3 Kobe University; Kobe University
RP Ashida, H (corresponding author), Kobe Univ, Grad Sch Agr Sci, Dept Agrobiosci, Nada Ku, 1-1 Rokkodai Cho, Kobe, Hyogo 6578501, Japan.
EM ashida@kobe-u.ac.jp
FU Creation of Innovation Centers for Advanced Interdisciplinary Research Areas (Innovative Bioproduction Kobe), MEXT, Japan
CR Akiba T, 2004, BIOCHEM PHARMACOL, V68, P1929, DOI 10.1016/j.bcp.2004.07.036
   Ashida H, 2004, BIOFACTORS, V22, P135, DOI 10.1002/biof.5520220126
   BARON AD, 1988, AM J PHYSIOL, V255, P768
   Bose M, 2008, J NUTR, V138, P1677, DOI 10.1093/jn/138.9.1677
   Bruno RS, 2008, J NUTR, V138, P323, DOI 10.1093/jn/138.2.323
   Choi Kangduk, 2010, KOREAN JOURNAL OF INTERNAL MEDICINE, V25, P119, DOI 10.3904/kjim.2010.25.2.119
   DeFronzo RA, 1997, DIABETES REV, V5, P177
   Dey D, 2007, BIOCHEM BIOPH RES CO, V357, P474, DOI 10.1016/j.bbrc.2007.03.183
   Dominici FP, 2005, GROWTH HORM IGF RES, V15, P324, DOI 10.1016/j.ghir.2005.07.001
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Formiguera X, 2004, BEST PRACT RES CL GA, V18, P1125, DOI 10.1016/j.bpg.2004.06.030
   Furuyashiki T, 2004, BIOSCI BIOTECH BIOCH, V68, P2353, DOI 10.1271/bbb.68.2353
   GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329
   Guo L, 2006, PHARMACOL THERAPEUT, V111, P145, DOI 10.1016/j.pharmthera.2005.10.009
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Huang SH, 2007, CELL METAB, V5, P237, DOI 10.1016/j.cmet.2007.03.006
   Johansson SM, 2007, BIOCHEM PHARMACOL, V74, P1628, DOI 10.1016/j.bcp.2007.08.006
   KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x
   Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508
   Lapidot TM, 2002, J AGR FOOD CHEM, V50, P7220, DOI 10.1021/jf020615a
   León D, 2005, NEUROSCIENCE, V131, P481, DOI 10.1016/j.neuroscience.2004.11.028
   Lin CL, 2007, J LIPID RES, V48, P2334, DOI 10.1194/jlr.M700128-JLR200
   Lin J, 2005, OBES RES, V13, P982, DOI 10.1038/oby.2005.115
   Lin JK, 2006, MOL NUTR FOOD RES, V50, P211, DOI 10.1002/mnfr.200500138
   Long LH, 2000, BIOCHEM BIOPH RES CO, V273, P50, DOI 10.1006/bbrc.2000.2895
   Moon HS, 2007, OBESITY, V15, P2571, DOI 10.1038/oby.2007.309
   Nakagawa K, 2009, BIOSCI BIOTECH BIOCH, V73, P2014, DOI 10.1271/bbb.90195
   Nishiumi S, 2007, BIOSCI BIOTECH BIOCH, V71, P2343, DOI 10.1271/bbb.70342
   Nishiumi S, 2010, J AGR FOOD CHEM, V58, P12916, DOI 10.1021/jf102840w
   Plomgaard P, 2005, DIABETES, V54, P2939, DOI 10.2337/diabetes.54.10.2939
   Robinson LE, 2004, J NUTR, V134, P2528, DOI 10.1093/jn/134.10.2528
   Ueda M, 2008, BIOCHEM BIOPH RES CO, V377, P286, DOI 10.1016/j.bbrc.2008.09.128
   VERGAUWEN L, 1994, J CLIN INVEST, V93, P974, DOI 10.1172/JCI117104
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   Wu BT, 2005, J AGR FOOD CHEM, V53, P5695, DOI 10.1021/jf050045p
   Xiao DM, 2000, J NEUROCHEM, V74, P392, DOI 10.1046/j.1471-4159.2000.0740392.x
   YOUNGS G, 1972, GUT, V13, P154, DOI 10.1136/gut.13.2.154
   Zorzano A, 2005, ACTA PHYSIOL SCAND, V183, P43, DOI 10.1111/j.1365-201X.2004.01380.x
NR 38
TC 6
Z9 6
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1344-6606
EI 
J9 FOOD SCI TECHNOL RES
JI Food Sci. Technol. Res.
PD JUL 15
PY 2011
VL 17
IS 4
BP 353
EP 359
DI 10.3136/fstr.17.353
PG 7
WC Food Science & Technology
SC Food Science & Technology
GA 817CN
UT WOS:000294648500013
DA 2025-04-28
ER

PT J
AU Andreazzi, AE
   Grassiolli, S
   Marangon, PB
   Martins, AG
   de Oliveira, JC
   Torrezan, R
   Gravena, C
   Garcia, RMG
   Mathias, PCD
AF Andreazzi, Ana Eliza
   Grassiolli, Sabrina
   Marangon, Paula Beatriz
   Martins, Adriana Gallego
   de Oliveira, Julio Cezar
   Torrezan, Rosana
   Gravena, Clarice
   Gonzalez Garcia, Raul Marcel
   de Freitas Mathias, Paulo Cezar
TI Impaired Sympathoadrenal Axis Function Contributes to Enhanced Insulin Secretion in Prediabetic Obese Rats
SO EXPERIMENTAL DIABETES RESEARCH
LA English
DT Article
ID sympathetic-nervous-system; monosodium-l-glutamate; adrenal chromaffin cells; reduced norepinephrine turnover; brown adipose-tissue; msg-treated-rats; protein-kinase-c; energy homeostasis; pancreatic-islets; beta-cell
AB The involvement of sympathoadrenal axis activity in obesity onset was investigated using the experimental model of treating neonatal rats with monosodium L-glutamate. To access general sympathetic nervous system activity, we recorded the firing rates of sympathetic superior cervical ganglion nerves in animals. Catecholamine content and secretion from isolated adrenal medulla were measured. Intravenous glucose tolerance test was performed, and isolated pancreatic islets were stimulated with glucose and adrenergic agonists. The nerve firing rate of obese rats was decreased compared to the rate for lean rats. Basal catecholamine secretion decreased whereas catecholamine secretion induced by carbachol, elevated extracellular potassium, and caffeine in the isolated adrenal medulla were all increased in obese rats compared to control. Both glucose intolerance and hyperinsulinaemia were observed in obese rats. Adrenaline strongly inhibited glucose-induced insulin secretion in obese animals. These findings suggest that low sympathoadrenal activity contributes to impaired glycaemic control in prediabetic obese rats.
C1 [Andreazzi, Ana Eliza] Univ Fed Juiz de Fora, Dept Physiol, Physiol Lab, BR-36036900 Juiz De Fora, MG, Brazil.
   [Grassiolli, Sabrina; Marangon, Paula Beatriz; Martins, Adriana Gallego; de Oliveira, Julio Cezar; Torrezan, Rosana; Gravena, Clarice; de Freitas Mathias, Paulo Cezar] Univ Estadual Maringa, Dept Cell Biol & Genet, Lab Secret Cell Biol, BR-87020900 Maringa, Parana, Brazil.
   [Gonzalez Garcia, Raul Marcel] Univ Fed Juiz de Fora, Dept Biol, Cell Biol Lab, BR-36036900 Juiz De Fora, MG, Brazil.
C3 Universidade Federal de Juiz de Fora; Universidade Estadual de Maringa; Universidade Federal de Juiz de Fora
RP Andreazzi, AE (corresponding author), Univ Fed Juiz de Fora, Dept Physiol, Physiol Lab, BR-36036900 Juiz De Fora, MG, Brazil.
EM anaeliza.andreazzi@ufjf.edu.br
FU Brazilian Science Foundation CNPq; Brazilian Science Foundation CAPES; Brazilian Science Foundation Fundacao Araucaria
CR Abizaid A, 2008, REGUL PEPTIDES, V149, P3, DOI 10.1016/j.regpep.2007.10.006
   AKAIKE A, 1993, JPN J PHARMACOL, V61, P145, DOI 10.1254/jjp.61.145
   ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P7713, DOI 10.1073/pnas.81.24.7713
   Andreazzi AE, 2009, J ENDOCRINOL, V201, P351, DOI 10.1677/JOE-08-0312
   ASTRUP A, 1995, INT J OBESITY, V19, P0
   Balbo SL, 2007, ENDOCRINE, V31, P142, DOI 10.1007/s12020-007-0021-z
   Balbo SL, 2000, RES COMMUN MOL PATH, V108, P291
   BERNARDIS LL, 1968, J ENDOCRINOL, V40, P527, DOI 10.1677/joe.0.0400527
   Berthoud HR, 2008, ANNU REV PSYCHOL, V59, P55, DOI 10.1146/annurev.psych.59.103006.093551
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BRAY GA, 1991, J NUTR, V121, P1146, DOI 10.1093/jn/121.8.1146
   Bray GA, 1989, VITAM HORM, V45, P1
   BUNYAN J, 1976, BRIT J NUTR, V35, P25, DOI 10.1079/BJN19760005
   Campbell RK, 2009, J AM PHARM ASSOC, V49, PS10, DOI 10.1331/JAPhA.2009.09076
   CAWTHORN EG, 1991, MOL CELL ENDOCRINOL, V75, P197, DOI 10.1016/0303-7207(91)90161-K
   Coll Teresa, 2009, CURR MOL PHARMACOL, V2, P46
   Cruciani-Guglielmacci C, 2005, AM J PHYSIOL-ENDOC M, V288, PE148, DOI 10.1152/ajpendo.00225.2004
   Davy KP, 2009, NEUROSCI BIOBEHAV R, V33, P116, DOI 10.1016/j.neubiorev.2008.05.024
   Davy KP, 2004, AM J PHYSIOL-REG I, V286, PR803, DOI 10.1152/ajpregu.00707.2003
   de Andrade IS, 2006, NEUROSCI LETT, V398, P6, DOI 10.1016/j.neulet.2005.12.043
   De Flines J, 2010, ACTA GASTRO-ENT BELG, V73, P261
   Díaz-Flores L, 2008, ACTA PHYSIOL, V192, P145, DOI 10.1111/j.1748-1716.2007.01811.x
   Dolnikoff M, 2001, INT J OBESITY, V25, P426, DOI 10.1038/sj.ijo.0801517
   Gao Q, 2008, FEBS LETT, V582, P132, DOI 10.1016/j.febslet.2007.11.063
   Grassiolli S, 2007, EUR J PHARMACOL, V556, P223, DOI 10.1016/j.ejphar.2006.11.022
   Grassiolli S, 2006, ENDOCRINE, V30, P191, DOI 10.1385/ENDO:30:2:191
   HERMANS MP, 1987, ENDOCRINOLOGY, V120, P1765, DOI 10.1210/endo-120-5-1765
   Hirata AE, 1997, BRAZ J MED BIOL RES, V30, P671, DOI 10.1590/S0100-879X1997000500016
   Jeanrenaud B, 1986, INT J VITAM NUTR RES SUPPL, V29, P41
   Jocken JWE, 2008, PHYSIOL BEHAV, V94, P219, DOI 10.1016/j.physbeh.2008.01.002
   Kalra SP, 2010, PROG BRAIN RES, V181, P17, DOI 10.1016/S0079-6123(08)81002-3
   KELNER KL, 1985, NEUROCHEM INT, V7, P373, DOI 10.1016/0197-0186(85)90128-7
   Kim YW, 1999, J KOREAN MED SCI, V14, P539, DOI 10.3346/jkms.1999.14.5.539
   KRSTULOVIC AM, 1982, J CHROMATOGR, V229, P1, DOI 10.1016/S0378-4347(00)86033-8
   Kumer SC, 1996, J NEUROCHEM, V67, P443
   Lee M, 2009, PITUITARY, V12, P87, DOI 10.1007/s11102-008-0096-4
   LEIGH FSM, 1992, INT J OBESITY, V16, P597
   Leon-Quinto T, 1998, ENDOCRINOLOGY, V139, P3382, DOI 10.1210/en.139.8.3382
   LEVIN BE, 1995, AM J PHYSIOL-REG I, V268, PR389, DOI 10.1152/ajpregu.1995.268.2.R389
   Macho L, 2000, PHYSIOL RES, V49, P0
   MAITER D, 1991, ENDOCRINOLOGY, V128, P1100
   Marçal AC, 2006, ENDOCRINE, V29, P445, DOI 10.1385/ENDO:29:3:445
   Martins ACP, 2004, LIFE SCI, V74, P3211, DOI 10.1016/j.lfs.2003.10.034
   Martins ACP, 2001, NEUROSCI RES COMMUN, V28, P49, DOI 10.1002/1520-6769(200101/02)28:1<49::AID-NRC6>3.0.CO;2-L
   Mitrani P, 2007, AM J PHYSIOL-ENDOC M, V292, PE1364, DOI 10.1152/ajpendo.00672.2006
   Nolan CJ, 2006, DIABETOLOGIA, V49, P2120, DOI 10.1007/s00125-006-0305-5
   Obici S, 2009, ENDOCRINOLOGY, V150, P2512, DOI 10.1210/en.2009-0409
   OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719
   Ravussin E, 1996, P NUTR SOC, V55, P793, DOI 10.1079/PNS19960079
   Reaven GM, 2005, ANNU REV NUTR, V25, P391, DOI 10.1146/annurev.nutr.24.012003.132155
   SAAD MF, 1991, AM J PHYSIOL, V261, PE789, DOI 10.1152/ajpendo.1991.261.6.E789
   Sala F, 2008, ACTA PHYSIOL, V192, P203, DOI 10.1111/j.1748-1716.2007.01804.x
   Schenk S, 2008, J CLIN INVEST, V118, P2992, DOI 10.1172/JCI34260
   Scomparin DX, 2006, LIFE SCI, V79, P2151, DOI 10.1016/j.lfs.2006.07.012
   SCOTT AM, 1981, DIABETOLOGIA, V21, P470
   Sieg A, 2004, AM J PHYSIOL-ENDOC M, V286, PE463, DOI 10.1152/ajpendo.00365.2003
   Silva JE, 2008, THYROID, V18, P157, DOI 10.1089/thy.2007.0252
   TASSAVA TM, 1992, AM J PHYSIOL, V262, PE338, DOI 10.1152/ajpendo.1992.262.3.E338
   Teff KL, 2008, JPEN-PARENTER ENTER, V32, P569, DOI 10.1177/0148607108321705
   Tentolouris N, 2008, NEUROMOL MED, V10, P169, DOI 10.1007/s12017-008-8022-5
   Thirone ACP, 2004, ENDOCRINOLOGY, V145, P281, DOI 10.1210/en.2003-0575
   Vernochet C, 2009, FEBS J, V276, P5729, DOI 10.1111/j.1742-4658.2009.07302.x
   Williams G, 2001, PHYSIOL BEHAV, V74, P683, DOI 10.1016/S0031-9384(01)00612-6
   YOSHIDA T, 1990, J NUTR SCI VITAMINOL, V36, P123, DOI 10.3177/jnsv.36.123
   YOSHIDA T, 1985, LIFE SCI, V36, P931, DOI 10.1016/0024-3205(85)90388-1
   YOSHIMATSU H, 1993, BRAIN RES, V601, P121, DOI 10.1016/0006-8993(93)91702-T
   Young JB, 2006, INT J OBESITY, V30, PS41, DOI 10.1038/sj.ijo.0803518
   YOUNG JB, 1992, INT J OBESITY, V16, P959
   Young JB, 2002, TRENDS ENDOCRIN MET, V13, P381, DOI 10.1016/S1043-2760(02)00661-6
   YOUNG JB, 1983, AM J PHYSIOL, V245, PE148, DOI 10.1152/ajpendo.1983.245.2.E148
NR 70
TC 16
Z9 17
U1 0
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-5214
EI 1687-5303
J9 EXP DIABETES RES
JI Exp. Diabetes Res.
PD JUN 15
PY 2011
VL 0
IS 
BP 
EP 
DI 10.1155/2011/947917
PG 11
WC Endocrinology & Metabolism; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 830DY
UT WOS:000295638800001
PM 21860615
DA 2025-04-28
ER

PT J
AU Sofianou, A
   Fung, TT
   Tucker, KL
AF Sofianou, Anastasia
   Fung, Teresa T.
   Tucker, Katherine L.
TI Differences in Diet Pattern Adherence by Nativity and Duration of US Residence in the Mexican-American Population
SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION
LA English
DT Article
ID food-frequency questionnaire; cardiovascular-disease risk; united-states; eating patterns; older-adults; women; association; obesity; habits; health
AB Literature on the diet of the Mexican-American population suggests that food consumption differs by nativity and duration of residence in the United States. However, no studies have used dietary pattern analysis to investigate these differences. To create dietary patterns, we used principal components analysis on food frequency questionnaire data for all adult respondents of the National Health and Nutrition Examination Survey years 2003-2006. Four dietary patterns were identified: Western, Healthy, Tomato/Tortilla, and Coffee/Sugar. Least squares means regression was used to test differences in adjusted mean dietary adherence scores among Mexico-born Mexican-American adults residing in the United States for <15 years (n=302), Mexico-born Mexican-American adults residing in the United States for a 15 years (n=234), US-born Mexican-American adults (n= 509), and US-born non-Hispanic whites (n=2,530) aged 18 to 69 years. Mean score for each diet pattern did not differ significantly by duration of US residence category in the Mexico-born Mexican-American population. However, in comparison to all Mexico-born Mexican Americans, US-born Mexican Americans had significantly lower score for the Tomato/Tortilla pattern, and significantly higher score for the Western pattern. Scores for the Healthy pattern were relatively low in all Mexican-American subgroups, indicating low adherence to the Healthy diet. However, Healthy diet scores of Mexico-born Mexican Americans among those aged :541 years appeared more similar to those of US-born non-Hispanic whites than US-born Mexican Americans. Education and policy action promoting healthy food access in Hispanic neighborhoods could help limit consumption of Western and Coffee/Sugar diet patterns and promote healthier choices in the Mexican-American population. J Am Diet Assoc. 2011;111:1563-1569.
C1 [Sofianou, Anastasia; Tucker, Katherine L.] Northeastern Univ, Dept Hlth Sci, Boston Puerto Rican Hlth Study, Boston, MA 02115 USA.
   [Fung, Teresa T.] Simmons Coll, Boston, MA 02115 USA.
   [Fung, Teresa T.] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA.
C3 Northeastern University; Simmons University; Harvard University; Harvard T.H. Chan School of Public Health
RP Tucker, KL (corresponding author), Northeastern Univ, Dept Hlth Sci, Boston Puerto Rican Hlth Study, 316 Robinson Hall,360 Huntington Aye, Boston, MA 02115 USA.
EM kl.tucker@neu.edu
CR Arsenault LN, 2009, AM J EPIDEMIOL, V170, P95, DOI 10.1093/aje/kwp089
   Bermúdez OI, 2000, J AM DIET ASSOC, V100, P665, DOI 10.1016/S0002-8223(00)00195-4
   Carrera PM, 2007, J AM DIET ASSOC, V107, P1735, DOI 10.1016/j.jada.2007.07.016
   CHAVEZ N, 1994, J NUTR EDUC, V26, P79
   Dixon LB, 2000, AM J EPIDEMIOL, V152, P548, DOI 10.1093/aje/152.6.548
   Fung TT, 2001, AM J CLIN NUTR, V73, P61
   GUENDELMAN S, 1995, AM J PUBLIC HEALTH, V85, P20, DOI 10.2105/AJPH.85.1.20
   Harley K, 2005, PAEDIATR PERINAT EP, V19, P125, DOI 10.1111/j.1365-3016.2005.00640.x
   Hu FB, 1999, AM J CLIN NUTR, V69, P243
   Hu FB, 2008, CIRCULATION, V118, P1913, DOI 10.1161/CIRCULATIONAHA.108.808493
   Jacques PF, 2001, AM J CLIN NUTR, V73, P1, DOI 10.1093/ajcn/73.1.1
   Johansson L, 1999, BRIT J NUTR, V81, P211, DOI 10.1017/S0007114599000409
   Kaiser L, 2009, J AM DIET ASSOC, V109, P1997, DOI 10.1016/j.jada.2009.09.007
   Kant AK, 2004, J AM DIET ASSOC, V104, P615, DOI 10.1016/j.jada.2004.01.010
   Kerver JM, 2003, AM J CLIN NUTR, V78, P1103, DOI 10.1093/ajcn/78.6.1103
   Lallukka T, 2007, EUR J CLIN NUTR, V61, P701, DOI 10.1038/sj.ejcn.1602583
   Montez JK, 2008, J AM DIET ASSOC, V108, P473, DOI 10.1016/j.jada.2007.12.008
   Morland KB, 2009, HEALTH PLACE, V15, P491, DOI 10.1016/j.healthplace.2008.09.004
   Murtaugh MA, 2007, J AM DIET ASSOC, V107, P1311, DOI 10.1016/j.jada.2007.05.008
   Newby PK, 2006, J NUTR, V136, P2580, DOI 10.1093/jn/136.10.2580
   Newby PK, 2004, NUTR REV, V62, P177, DOI 10.1301/rn.2004.may.177-203
   Newby PK, 2004, AM J CLIN NUTR, V80, P504, DOI 10.1093/ajcn/80.2.504
   Powell LM, 2007, PREV MED, V44, P189, DOI 10.1016/j.ypmed.2006.08.008
   Schulze MB, 2006, OBESITY, V14, P1444, DOI 10.1038/oby.2006.164
   Slattery ML, 2008, AM J CLIN NUTR, V88, P14, DOI 10.1093/ajcn/88.1.14
   Slattery ML, 1998, AM J EPIDEMIOL, V148, P4, DOI 10.1093/aje/148.1.4-a
   Tucker KL, 2002, AM J CLIN NUTR, V76, P245, DOI 10.1093/ajcn/76.1.245
   Vlismas Konstantinos, 2009, CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH, V17, P55
   Willett W, 1990, NUTR EPIDEMIOLOGY, V0, P396
NR 31
TC 42
Z9 56
U1 0
U2 3
PU AMER DIETETIC ASSOC
PI CHICAGO
PA 120 S RIVERSIDE PLZ, STE 2000, CHICAGO, IL 60606-6995 USA
SN 0002-8223
EI 
J9 J AM DIET ASSOC
JI J. Am. Diet. Assoc.
PD OCT 15
PY 2011
VL 111
IS 10
BP 1563
EP 1569
DI 10.1016/j.jada.2011.07.005
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 833TF
UT WOS:000295907100020
PM 21963024
DA 2025-04-28
ER

PT J
AU Wedick, NM
   Brennan, AM
   Sun, Q
   Hu, FB
   Mantzoros, CS
   van Dam, RM
AF Wedick, Nicole M.
   Brennan, Aoife M.
   Sun, Qi
   Hu, Frank B.
   Mantzoros, Christos S.
   van Dam, Rob M.
TI Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial
SO NUTRITION JOURNAL
LA English
DT Article
ID insulin-resistance; chlorogenic acid; glucose-tolerance; fetuin-a; consumption; metaanalysis; sensitivity; mellitus; healthy; plasma
AB Background: Coffee consumption has been associated with a lower risk of type 2 diabetes in prospective cohort studies, but the underlying mechanisms remain unclear. The aim of this study was to evaluate the effects of regular and decaffeinated coffee on biological risk factors for type 2 diabetes. Methods: Randomized parallel-arm intervention conducted in 45 healthy overweight volunteers who were nonsmokers and regular coffee consumers. Participants were assigned to consumption of 5 cups (177 mL each) per day of instant caffeinated coffee, decaffeinated coffee, or no coffee (i.e., water) for 8 weeks. Results: Average age was 40 years and body mass index was 29.5 kg/m(2). Compared with consuming no coffee, consumption of caffeinated coffee increased adiponectin (difference in change from baseline 1.4 mu g/mL; 95% CI: 0.2, 2.7) and interleukin-6 (difference: 60%; 95% CI: 8, 138) concentrations and consumption of decaffeinated coffee decreased fetuin-A concentrations (difference: -20%; 95% CI: -35, -1). For measures of glucose tolerance, insulin sensitivity, and insulin secretion, no significant differences were found between treatment groups. Conclusions: Although no changes in glycemia and/or insulin sensitivity were observed after 8 weeks of coffee consumption, improvements in adipocyte and liver function as indicated by changes in adiponectin and fetuin-A concentrations may contribute to beneficial metabolic effects of long-term coffee consumption.
C1 [Wedick, Nicole M.; Sun, Qi; Hu, Frank B.; van Dam, Rob M.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   [Brennan, Aoife M.; Mantzoros, Christos S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA.
   [Hu, Frank B.; van Dam, Rob M.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Sun, Qi; Hu, Frank B.; van Dam, Rob M.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
   [Mantzoros, Christos S.] Harvard Univ, Sch Med, Endocrinol Sect, Boston VA Healthcare Syst, Boston, MA 02115 USA.
   [Mantzoros, Christos S.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University Medical Affiliates; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Harvard University; Harvard University Medical Affiliates; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health
RP Wedick, NM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
EM nwedick@hsph.harvard.edu
FU Boston Obesity Nutrition Research Center [2005-P-000377/2]; National Center for Research Resources [UL1RR025758]
CR Battram DS, 2006, J NUTR, V136, P1276, DOI 10.1093/jn/136.5.1276
   BERGMAN RN, 1985, ENDOCR REV, V6, P45, DOI 10.1210/edrv-6-1-45
   de Sotillo DVR, 2002, J NUTR BIOCHEM, V13, P717, DOI 10.1016/S0955-2863(02)00231-0
   Fève B, 2009, NAT REV ENDOCRINOL, V5, P305, DOI 10.1038/nrendo.2009.62
   Homan DJ, 2006, NUTR REV, V64, P43, DOI 10.1301/nr.2006.jan.43-46
   Huxley R, 2009, ARCH INTERN MED, V169, P2053, DOI 10.1001/archinternmed.2009.439
   Ix JH, 2008, JAMA-J AM MED ASSOC, V300, P182, DOI 10.1001/jama.300.2.182
   Jee SH, 2001, AM J EPIDEMIOL, V153, P353, DOI 10.1093/aje/153.4.353
   Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364
   KEMPF K, 1900, V91, V0, P950
   Kotani K, 2008, CLIN CHEM LAB MED, V46, P1434, DOI 10.1515/CCLM.2008.286
   LEVER M, 1992, ANAL BIOCHEM, V205, P14, DOI 10.1016/0003-2697(92)90572-O
   Li SS, 2009, JAMA-J AM MED ASSOC, V302, P179, DOI 10.1001/jama.2009.976
   Lopez-Garcia E, 2006, AM J CLIN NUTR, V84, P888, DOI 10.1093/ajcn/84.4.888
   Mathews ST, 2000, MOL CELL ENDOCRINOL, V164, P87, DOI 10.1016/S0303-7207(00)00237-9
   Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Mori K, 2006, DIABETES CARE, V29, P468, DOI 10.2337/diacare.29.02.06.dc05-1484
   Noordzij M, 2005, J HYPERTENS, V23, P921, DOI 10.1097/01.hjh.0000166828.94699.1d
   Shearer J, 2007, CAN J PHYSIOL PHARM, V85, P823, DOI 10.1139/Y07-070
   Thong FSL, 2002, DIABETES, V51, P583, DOI 10.2337/diabetes.51.3.583
   TRUGO LC, 1984, ANALYST, V109, P263, DOI 10.1039/an9840900263
   Tunnicliffe JM, 2008, APPL PHYSIOL NUTR ME, V33, P1290, DOI 10.1139/H08-123
   van Dam RM, 2006, NUTR METAB CARDIOVAS, V16, P69, DOI 10.1016/j.numecd.2005.10.003
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
   Van Dam RM, 2004, DIABETES CARE, V27, P2990, DOI 10.2337/diacare.27.12.2990
   van Dijk AE, 2009, DIABETES CARE, V32, P1023, DOI 10.2337/dc09-0207
   Williams CJ, 2008, DIABETES CARE, V31, P504, DOI 10.2337/dc07-1952
   Zampelas A, 2004, AM J CLIN NUTR, V80, P862, DOI 10.1093/ajcn/80.4.862
NR 29
TC 133
Z9 143
U1 0
U2 49
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2891
EI 
J9 NUTR J
JI Nutr. J.
PD SEP 13
PY 2011
VL 10
IS 
BP 
EP 
DI 10.1186/1475-2891-10-93
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 826TJ
UT WOS:000295377300002
PM 21914162
DA 2025-04-28
ER

PT J
AU Sung, JH
   Chon, JW
   Lee, MA
   Park, JK
   Woo, JT
   Park, YK
AF Sung, Ju-Hyun
   Chon, Jeong-Woo
   Lee, Mi-Ae
   Park, Jin-Kyung
   Woo, Jeong-Taek
   Park, Yoo Kyoung
TI The anti-obesity effect of Lethariella cladonioides in 3T3-L1 cells and obese mice
SO NUTRITION RESEARCH AND PRACTICE
LA English
DT Article
DE Lethariella cladonioides; obesity; 3T3-L1 cells; obese mice
ID high-fat diet; body-weight regulation; green tea; in-vitro; caffeine; rats; antioxidant; extract; protein; differentiation
AB The aim of this study was to investigate whether a water extract of L. cladonioides (LC) has an anti-obesity effect in 3T3-L1 cells and obese mice. Treatment of differentiated 3T3-L1 adipocytes with LC caused a significant increase in glycerol release and reduced the protein expression of the adipogenic transcription factors, PPAR gamma and C/EBPa. In an animal model, obese mice were artificially induced by a high fat diet for 10 weeks. Experimental groups were treated with LC (100 mg/kg/day) by gavage for the next 10 weeks. At the end of experiment, the body weight of the LC group mice was reduced by 14.2% compared to the high fat diet (HFD) group. The treatment also decreased liver (31.0%), epididymal (18.0%) and retroperitoneal (19.3%) adipose tissue, and kidney (6.7%) weights, respectively, compared with those of the RFD group. LC prevented diet-induced increases in the serum level of TC (22.6%), TG (11.6%), and glucose (35.0%), respectively, compared with the HFD group. However, the HDL-C level was higher in the LC group (26.1%) than the HFD group. The results of this study thus suggest that LC suppressed lipid accumulation and expression of adipogenic transcription factors, and increased the amount of glycerol release. LC also indicated an anti-obese and anti-hyperlipidemic effect.
C1 [Sung, Ju-Hyun; Chon, Jeong-Woo; Lee, Mi-Ae; Park, Jin-Kyung; Park, Yoo Kyoung] Kyung Hee Univ, Grad Sch EW Med Sci, Dept Med Nutr, Yongin 446701, Gyeonggi, South Korea.
   [Woo, Jeong-Taek] Kyung Hee Univ, Sch Med, Dept Endocrinol & Metab, Seoul 130701, South Korea.
   [Park, Yoo Kyoung] Kyung Hee Univ, Res Inst Med Nutr, Seoul 130701, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University
RP Park, YK (corresponding author), Kyung Hee Univ, Grad Sch EW Med Sci, Dept Med Nutr, 1 Seocheon Dong, Yongin 446701, Gyeonggi, South Korea.
EM ypark@khu.ac.kr
FU Kyung Hee University [KHU-20071517]
CR Basu A, 2010, J AM COLL NUTR, V29, P31, DOI 10.1080/07315724.2010.10719814
   Chen N, 2009, NUTR RES, V29, P784, DOI 10.1016/j.nutres.2009.10.003
   Chumark P, 2008, J ETHNOPHARMACOL, V116, P439, DOI 10.1016/j.jep.2007.12.010
   Chun MR, 2010, J KOREAN MED SCI, V25, P1053, DOI 10.3346/jkms.2010.25.7.1053
   Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276
   Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5
   Farmer SR, 2005, INT J OBESITY, V29, PS13, DOI 10.1038/sj.ijo.0802907
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   FRAYN KN, 1980, J LIPID RES, V21, P139
   Hauck M, 2009, ANN BOT-LONDON, V103, P13, DOI 10.1093/aob/mcn202
   Hursel R, 2010, INT J OBESITY, V34, P659, DOI 10.1038/ijo.2009.299
   Jiang B, 2001, FITOTERAPIA, V72, P832, DOI 10.1016/S0367-326X(01)00287-8
   JUNG RT, 1981, CLIN SCI, V60, P527, DOI 10.1042/cs0600527
   Kersten S, 2001, EMBO REP, V2, P282, DOI 10.1093/embo-reports/kve071
   Kinoshita K, 2010, J NAT MED-TOKYO, V64, P85, DOI 10.1007/s11418-009-0364-2
   Lee WJ, 2005, INT J BIOCHEM CELL B, V37, P2254, DOI 10.1016/j.biocel.2005.06.019
   Meier U, 2004, CLIN CHEM, V50, P1511, DOI 10.1373/clinchem.2004.032482
   Mori S, 2009, INT J BIOL SCI, V5, P311
   MOUSSALLI C, 1986, DIABETES, V35, P759, DOI 10.2337/diabetes.35.7.759
   Murosaki S, 2007, J NUTR, V137, P2252, DOI 10.1093/jn/137.10.2252
   Naik GH, 2003, PHYTOCHEMISTRY, V63, P97, DOI 10.1016/S0031-9422(02)00754-9
   Niu DL, 2011, LICHENOLOGIST, V43, P213, DOI 10.1017/S0024282911000119
   OBENNAYER W, 2001, BIBL LICHENOL, V78, P321
   Park YS, 2007, WORLD J GASTROENTERO, V13, P3493, DOI 10.3748/wjg.v13.i25.3493
   Pittler MH, 2005, OBES REV, V6, P93, DOI 10.1111/j.1467-789X.2005.00169.x
   Poulos SP, 2010, EXP BIOL MED, V235, P1185, DOI 10.1258/ebm.2010.010063
   Qureshi K, 2007, WORLD J GASTROENTERO, V13, P3540, DOI 10.3748/wjg.v13.i26.3540
   RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069
   Saito M, 2005, FOOD CHEM TOXICOL, V43, P411, DOI 10.1016/j.fct.2004.11.008
   Shehzad A, 2011, EUR J NUTR, V50, P151, DOI 10.1007/s00394-011-0188-1
   Shi YG, 2004, NAT REV DRUG DISCOV, V3, P695, DOI 10.1038/nrd1469
   Slanc P, 2009, PHYTOTHER RES, V23, P874, DOI 10.1002/ptr.2718
   Tzanavari T, 2010, CURR DIR AUTOIMMUN, V11, P145, DOI 10.1159/000289203
   Wei AH, 2012, J SCI FOOD AGR, V92, P373, DOI 10.1002/jsfa.4601
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   Yun JW, 2008, EXP ANIM TOKYO, V57, P461, DOI 10.1538/expanim.57.461
   Zheng GD, 2004, IN VIVO, V18, P55
NR 37
TC 14
Z9 17
U1 0
U2 17
PU KOREAN NUTRITION SOC
PI SEOUL
PA 804 KST CTR, 635-4 YEOGSAM-SONG KANGNAM-KU, SEOUL, 135-703, SOUTH KOREA
SN 1976-1457
EI 2005-6168
J9 NUTR RES PRACT
JI Nutr. Res. Pract.
PD DEC 15
PY 2011
VL 5
IS 6
BP 503
EP 510
DI 10.4162/nrp.2011.5.6.503
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 874DQ
UT WOS:000298936000002
PM 22259674
DA 2025-04-28
ER

PT J
AU Egawa, T
   Tsuda, S
   Ma, X
   Hamada, T
   Hayashi, T
AF Egawa, Tatsuro
   Tsuda, Satoshi
   Ma, Xiao
   Hamada, Taku
   Hayashi, Tatsuya
TI Caffeine modulates phosphorylation of insulin receptor substrate-1 and impairs insulin signal transduction in rat skeletal muscle
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE serine phosphorylation; Akt; 5 '-AMP-activated protein kinase; p70 S6 kinase; inhibitor-kappa B kinase
ID phosphatidylinositol 3-kinase activity; 5'-amp-activated protein-kinase; stimulated glucose-transport; kappa-b kinase; serine phosphorylation; activation; obesity; irs-1; translocation; theophylline
AB Egawa T, Tsuda S, Ma X, Hamada T, Hayashi T. Caffeine modulates phosphorylation of insulin receptor substrate-1 and impairs insulin signal transduction in rat skeletal muscle. J Appl Physiol 111: 1629-1636, 2011. First published September 22, 2011; doi:10.1152/japplphysiol.00249.2011.-Caffeine decreases insulin sensitivity and insulin-stimulated glucose transport in skeletal muscle; however, the precise mechanism responsible for this deleterious effect is not understood fully. We investigated the effects of incubation with caffeine on insulin signaling in rat epitrochlearis muscle. Caffeine (>= 1 mM, >= 15 min) suppressed insulin-stimulated insulin receptor substrate (IRS)-1 Tyr(612) phosphorylation in a dose- and time-dependent manner. These responses were associated with inhibition of the insulin-stimulated phosphorylation of phosphatidylinositol 3-kinase (PI3K) Tyr(458), Akt Ser(473), and glycogen synthase kinase-3 beta Ser(9) and with inhibition of insulin-stimulated 3-O-methyl-D-glucose (3MG) transport but not with inhibition of the phosphorylation of insulin receptor-beta Tyr(1158/62/63). Furthermore, caffeine enhanced phosphorylation of IRS-1 Ser(307) and an IRS-1 Ser(307) kinase, inhibitor-kappa B kinase (IKK)-alpha/beta Ser(176/180). Blockade of IKK/IRS-1 Ser(307) by caffeic acid ameliorated the caffeine-induced downregulation of IRS-1 Tyr(612) phosphorylation and 3MG transport. Caffeine also increased the phosphorylation of IRS-1 Ser(789) and an IRS-1 Ser(789) kinase, 5'-AMP-activated protein kinase (AMPK). However, inhibition of IRS-1 Ser(789) and AMPK phosphorylation by dantrolene did not rescue the caffeine-induced downregulation of IRS-1 Tyr(612) phosphorylation or 3MG transport. In addition, caffeine suppressed the phosphorylation of insulin-stimulated IRS-1 Ser(636/639) and upstream kinases, including the mammalian target of rapamycin and p70S6 kinase. Intravenous injection of caffeine at a physiological dose (5 mg/kg) in rats inhibited the phosphorylation of insulin-stimulated IRS-1 Tyr(612) and Akt Ser(473) in epitrochlearis muscle. Our results indicate that caffeine inhibits insulin signaling partly through the IKK/IRS-1 Ser(307) pathway, via a Ca2+- and AMPK-independent mechanism in skeletal muscle.
C1 [Hayashi, Tatsuya] Kyoto Univ, Grad Sch Human & Environm Studies, Lab Sports & Exercise Med, Sakyo Ku, Kyoto 6068501, Japan.
   [Hamada, Taku] Osaka Univ Hlth & Sport Sci, Dept Hlth & Sports Management, Osaka, Japan.
C3 Kyoto University
RP Hayashi, T (corresponding author), Kyoto Univ, Grad Sch Human & Environm Studies, Lab Sports & Exercise Med, Sakyo Ku, Yoshida Nihonmatsu Cho, Kyoto 6068501, Japan.
EM tatsuya@kuhp.kyoto-u.ac.jp
FU All Japan Coffee Association; Nestle Nutrition Council of Japan; Japan Vascular Disease Research Foundation; Japan Society for the Promotion of Science [22500616, 20500576]; Grants-in-Aid for Scientific Research [22500616, 23617009, 20500576, 10J00163] Funding Source: KAKEN
CR Abbott MJ, 2009, AM J PHYSIOL-REG I, V297, PR1724, DOI 10.1152/ajpregu.00179.2009
   Abdul-Ghani MA, 2010, J BIOMED BIOTECHNOL, V0, P0, DOI DOI 10.1155/2010/476279
   ABRAMOFF MD, 2004, BIOPHOTONICS INT, V11, P36, DOI 10.1201/9781420005615.AX4
   Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200
   Battram DS, 2005, J PHYSIOL-LONDON, V569, P347, DOI 10.1113/jphysiol.2005.097444
   Boura-Halfon S, 2009, AM J PHYSIOL-ENDOC M, V296, PE581, DOI 10.1152/ajpendo.90437.2008
   Corbould A, 2006, DIABETES, V55, P751, DOI 10.2337/diabetes.55.03.06.db05-0453
   DAlessandris C, 2007, DIABETOLOGIA, V50, P840, DOI 10.1007/s00125-006-0522-y
   de Alvaro C, 2004, J BIOL CHEM, V279, P17070, DOI 10.1074/jbc.M312021200
   DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667
   Egawa T, 2011, ACTA PHYSIOL, V201, P227, DOI 10.1111/j.1748-1716.2010.02169.x
   Egawa T, 2009, METABOLISM, V58, P1609, DOI 10.1016/j.metabol.2009.05.013
   Esposito DL, 2001, ENDOCRINOLOGY, V142, P2833, DOI 10.1210/en.142.7.2833
   Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200
   FREDHOLM BB, 1980, TRENDS PHARMACOL SCI, V1, P129
   Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200
   Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349
   Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019
   Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069
   Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369
   Hiratani K, 2005, BIOCHEM BIOPH RES CO, V335, P836, DOI 10.1016/j.bbrc.2005.07.152
   Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137
   Horike N, 2003, J BIOL CHEM, V278, P18440, DOI 10.1074/jbc.M211770200
   Iwanaka N, 2010, J APPL PHYSIOL, V108, P274, DOI 10.1152/japplphysiol.00420.2009
   Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200
   Jensen TE, 2007, AM J PHYSIOL-ENDOC M, V293, PE286, DOI 10.1152/ajpendo.00693.2006
   Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364
   Kolnes AJ, 2010, ACTA PHYSIOL, V200, P65, DOI 10.1111/j.1748-1716.2010.02103.x
   Lau C, 2008, J IMMUNOL, V180, P870, DOI 10.4049/jimmunol.180.2.870
   Lee S, 2005, DIABETES CARE, V28, P566, DOI 10.2337/diacare.28.3.566
   LELO A, 1986, CLIN PHARMACOL THER, V39, P54, DOI 10.1038/clpt.1986.10
   Moon MK, 2009, BIOL PHARM BULL, V32, P1371, DOI 10.1248/bpb.32.1371
   Morino K, 2005, J CLIN INVEST, V115, P3587, DOI 10.1172/JCI25151
   Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200
   Shoelson SE, 2003, INT J OBESITY, V27, PS49, DOI 10.1038/sj.ijo.0802501
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837
   Tanti JF, 2009, CURR OPIN PHARMACOL, V9, P753, DOI 10.1016/j.coph.2009.07.004
   Thong FSL, 2002, DIABETES, V51, P583, DOI 10.2337/diabetes.51.3.583
   Toyoda T, 2004, AM J PHYSIOL-ENDOC M, V287, PE166, DOI 10.1152/ajpendo.00487.2003
   Tremblay F, 2005, DIABETES, V54, P2674, DOI 10.2337/diabetes.54.9.2674
   Tzatsos A, 2007, J BIOL CHEM, V282, P18069, DOI 10.1074/jbc.M610101200
   Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866
   YOUN JH, 1991, AM J PHYSIOL, V260, PC555, DOI 10.1152/ajpcell.1991.260.3.C555
   YOUNG DA, 1986, J BIOL CHEM, V261, P6049
   Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200
NR 45
TC 29
Z9 35
U1 0
U2 9
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750-7587
EI 1522-1601
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD DEC 15
PY 2011
VL 111
IS 6
BP 1629
EP 1636
DI 10.1152/japplphysiol.00249.2011
PG 8
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA 865YF
UT WOS:000298346100017
PM 21940847
DA 2025-04-28
ER

PT J
AU Hursel, R
   Viechtbauer, W
   Dulloo, AG
   Tremblay, A
   Tappy, L
   Rumpler, W
   Westerterp-Plantenga, MS
AF Hursel, R.
   Viechtbauer, W.
   Dulloo, A. G.
   Tremblay, A.
   Tappy, L.
   Rumpler, W.
   Westerterp-Plantenga, M. S.
TI The effects of catechin rich teas and caffeine on energy expenditure and fat oxidation: a meta-analysis
SO OBESITY REVIEWS
LA English
DT Article
DE Caffeine; catechins; green tea; oolong tea
ID sympathetic-nervous-system; body-weight loss; green tea; epigallocatechin gallate; obese women; black tea; intestinal-absorption; o-methyltransferase; in-vitro; thermogenesis
AB Different outcomes of the effect of catechin-caffeine mixtures and caffeine-only supplementation on energy expenditure and fat oxidation have been reported in short-term studies. Therefore, a meta-analysis was conducted to elucidate whether catechin-caffeine mixtures and caffeine-only supplementation indeed increase thermogenesis and fat oxidation. First, English-language studies measuring daily energy expenditure and fat oxidation by means of respiration chambers after catechin-caffeine mixtures and caffeine-only supplementation were identified through PubMed. Six articles encompassing a total of 18 different conditions fitted the inclusion criteria. Second, results were aggregated using random/mixed-effects models and expressed in terms of the mean difference in 24 h energy expenditure and fat oxidation between the treatment and placebo conditions. Finally, the influence of moderators such as BMI and dosage on the results was examined as well. The catechin-caffeine mixtures and caffeine-only supplementation increased energy expenditure significantly over 24 h (428.0 kJ (4.7%); P < 0.001 and 429.1 kJ (4.8%); P < 0.001, respectively). However, 24 h fat oxidation was only increased by catechin-caffeine mixtures (12.2 g (16.0%); P < 0.02 and 9.5 g (12.4%); P = 0.11, respectively). A dose-response effect on 24 h energy expenditure and fat oxidation occurred with a mean increase of 0.53 kJ mg(-1) (P < 0.01) and 0.02 g mg(-1) (P < 0.05) for catechin-caffeine mixtures and 0.44 kJ mg(-1) (P < 0.001) and 0.01 g mg(-1) (P < 0.05) for caffeine-only. In conclusion, catechin-caffeine mixtures or a caffeine-only supplementation stimulates daily energy expenditure dose-dependently by 0.4-0.5 kJ mg(-1) administered. Compared with placebo, daily fat-oxidation was only significantly increased after catechin-caffeine mixtures ingestion.
C1 [Hursel, R.; Westerterp-Plantenga, M. S.] Maastricht Univ, Dept Human Biol, Nutr & Toxicol Res Inst Maastricht NUTRIM, NL-6200 MD Maastricht, Netherlands.
   [Viechtbauer, W.] Maastricht Univ, Dept Methodol & Stat, NL-6200 MD Maastricht, Netherlands.
   [Dulloo, A. G.] Univ Fribourg, Dept Med Physiol, CH-1700 Fribourg, Switzerland.
   [Tremblay, A.] Univ Laval, Div Kinesiol, Quebec City, PQ, Canada.
   [Tappy, L.] Univ Lausanne, Dept Physiol, Lausanne, Switzerland.
   [Rumpler, W.] Beltsville Human Nutr Res Ctr, Beltsville, MD USA.
C3 Maastricht University; Maastricht University; University of Fribourg; Laval University; University of Lausanne
RP Hursel, R (corresponding author), Maastricht Univ, Dept Human Biol, Nutr & Toxicol Res Inst Maastricht NUTRIM, POB 616, NL-6200 MD Maastricht, Netherlands.
EM rick.hursel@hb.unimaas.nl
CR Acheson KJ, 2004, AM J CLIN NUTR, V79, P40
   Auvichayapat P, 2008, PHYSIOL BEHAV, V93, P486, DOI 10.1016/j.physbeh.2007.10.009
   Belza A, 2009, EUR J CLIN NUTR, V63, P57, DOI 10.1038/sj.ejcn.1602901
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   Boschmann M, 2007, J AM COLL NUTR, V26, P389S, DOI 10.1080/07315724.2007.10719627
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   BRAY GA, 1991, J NUTR, V121, P1146, DOI 10.1093/jn/121.8.1146
   Davy KP, 2009, NEUROSCI BIOBEHAV R, V33, P116, DOI 10.1016/j.neubiorev.2008.05.024
   Diepvens K, 2005, BRIT J NUTR, V94, P1026, DOI 10.1079/BJN20051580
   Diepvens K, 2007, AM J PHYSIOL-REG I, V292, PR77, DOI 10.1152/ajpregu.00832.2005
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Gregersen NT, 2009, BRIT J NUTR, V102, P1187, DOI 10.1017/S0007114509371779
   Hase T, 2001, JOURNAL OF OLEO SCIENCE, V50, P599, DOI 10.5650/jos.50.599
   Hodgson JM, 2006, BRIT J NUTR, V95, P14, DOI 10.1079/BJN20051621
   Hsu CH, 2008, CLIN NUTR, V27, P363, DOI 10.1016/j.clnu.2008.03.007
   Hursel R, 2010, INT J OBESITY, V34, P659, DOI 10.1038/ijo.2009.299
   Hursel R, 2009, INT J OBESITY, V33, P956, DOI 10.1038/ijo.2009.135
   Juhel C, 2000, J NUTR BIOCHEM, V11, P45, DOI 10.1016/S0955-2863(99)00070-4
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Koo SI, 2007, J NUTR BIOCHEM, V18, P179, DOI 10.1016/j.jnutbio.2006.12.005
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   Krul C, 2001, MUTAT RES-FUND MOL M, V474, P71, DOI 10.1016/S0027-5107(00)00158-5
   LANDSBERG L, 1986, Q J MED, V61, P1081
   Langley-Evans SC, 2000, INT J FOOD SCI NUTR, V51, P181, DOI 10.1080/09637480050029683
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Nagao T, 2007, OBESITY, V15, P1473, DOI 10.1038/oby.2007.176
   Palmatier MA, 1999, BIOL PSYCHIAT, V46, P557, DOI 10.1016/S0006-3223(99)00098-0
   Raederstorff DG, 2003, J NUTR BIOCHEM, V14, P326, DOI 10.1016/S0955-2863(03)00054-8
   Rudelle S, 2007, OBESITY, V15, P349, DOI 10.1038/oby.2007.529
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   SCHUTZ Y, 1992, AM J CLIN NUTR, V55, P670, DOI 10.1093/ajcn/55.3.670
   SCHUTZ Y, 1989, AM J CLIN NUTR, V50, P307, DOI 10.1093/ajcn/50.2.307
   Serafini M, 1996, EUR J CLIN NUTR, V50, P28
   Shishikura Y, 2006, J AGR FOOD CHEM, V54, P1906, DOI 10.1021/jf051988p
   Shixian Q, 2006, J MED FOOD, V9, P451, DOI 10.1089/jmf.2006.9.451
   TSUCHIDA T, 2002, PROGR MED, V22, P2189
   Viechtbauer W, 2005, J EDUC BEHAV STAT, V30, P261, DOI 10.3102/10769986030003261
   Wang H, 2009, OBESITY SILVER SPRIN, V0, P0
   Wang S, 2006, J NUTR, V136, P2791, DOI 10.1093/jn/136.11.2791
   Westerterp KR, 2008, AM J CLIN NUTR, V87, P132, DOI 10.1093/ajcn/87.1.132
   Westerterp-Plantenga M, 2006, PHYSIOL BEHAV, V89, P85, DOI 10.1016/j.physbeh.2006.01.027
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   Yang FJ, 2001, MOL PHARMACOL, V60, P528
NR 46
TC 130
Z9 138
U1 2
U2 85
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1467-7881
EI 
J9 OBES REV
JI Obes. Rev.
PD JUL 15
PY 2011
VL 12
IS 7
BP E573
EP E581
DI 10.1111/j.1467-789X.2011.00862.x
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 795OA
UT WOS:000292982300002
PM 21366839
DA 2025-04-28
ER

PT J
AU Keast, RSJ
   Sayompark, D
   Sacks, G
   Swinburn, BA
   Riddell, LJ
AF Keast, R. S. J.
   Sayompark, D.
   Sacks, G.
   Swinburn, B. A.
   Riddell, L. J.
TI The influence of caffeine on energy content of sugar-sweetened beverages: 'the caffeine-calorie effect'
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE obesity; threshold; flavour; soft drinks
ID body-weight; childhood obesity; food-intake; consumption; children; carbohydrate; individuals; adolescents; prevention; density
AB Background/Objectives: Caffeine is a mildly addictive psychoactive chemical and controversial additive to sugar-sweetened beverages (SSBs). The objective of this study is to assess if removal of caffeine from SSBs allows co-removal of sucrose (energy) without affecting flavour of SSBs, and if removal of caffeine could potentially affect population weight gain. Subjects/Methods: The research comprised of three studies; study 1 used three-alternate forced choice and paired comparison tests to establish detection thresholds for caffeine in water and sucrose solution (subjects, n = 63), and to determine if caffeine suppressed sweetness. Study 2 (subjects, n = 30) examined the proportion of sucrose that could be co-removed with caffeine from SSBs without affecting the flavour of the SSBs. Study 3 applied validated coefficients to estimate the impact on the weight of the United States population if there was no caffeine in SSBs. Results: Detection threshold for caffeine in water was higher (1.09 +/- 0.08 mM) than the detection threshold for caffeine in sucrose solution (0.49 +/- 0.04 mM), and a paired comparison test revealed caffeine significantly reduced the sweetness of sucrose (P<0.001). Removing caffeine from SSBs allowed co-removal of 10.3% sucrose without affecting flavour of the SSBs, equating to 116 kJ per 500 ml serving. The effect of this on body weight in adults and children would be 0.600 and 0.142 kg, which are equivalent to 2.08 and 1.10 years of observed existing trends in weight gain, respectively. Conclusion: These data suggest the extra energy in SSBs as a result of caffeine's effect on sweetness may be associated with adult and child weight gain. European Journal of Clinical Nutrition (2011) 65, 1338-1344; doi:10.1038/ejcn.2011.123; published online 20 July 2011
C1 [Keast, R. S. J.; Sayompark, D.; Sacks, G.; Swinburn, B. A.; Riddell, L. J.] Deakin Univ, Sch Exercise & Nutr Sci, Burwood, Vic 3125, Australia.
   [Sayompark, D.] Rajamangala Univ Technol Tawan Ok, Fac Sci & Technol, Chon Buri, Thailand.
C3 Deakin University; Rajamangala University of Technology Tawan-ok
RP Keast, RSJ (corresponding author), Deakin Univ, Sch Exercise & Nutr Sci, 221 Burwood Highway, Burwood, Vic 3125, Australia.
EM russell.keast@deakin.edu.au
FU Diabetes Australia Research Trust; Faculty of Health, Medicine, Nursing and Behavioural Sciences, Deakin University, Australia
CR Bartoshuk LM, 2000, CHEM SENSES, V25, P447, DOI 10.1093/chemse/25.4.447
   Bleich SN, 2009, AM J CLIN NUTR, V89, P372, DOI 10.3945/ajcn.2008.26883
   CDC, 2004, MEAN BOD WEIGHT HEIG, V0, P0
   Datamonitor, 2007, CARB SOFT DRINKS US, V0, P0
   Delwiche JF, 2001, PERCEPT PSYCHOPHYS, V63, P761, DOI 10.3758/BF03194436
   DiMeglio DP, 2000, INT J OBESITY, V24, P794, DOI 10.1038/sj.ijo.0801229
   Ebbeling CB, 2006, PEDIATRICS, V117, P673, DOI 10.1542/peds.2005-0983
   Egger G, 2003, OBES REV, V4, P115, DOI 10.1046/j.1467-789X.2003.00100.x
   Garrett BE, 1998, PSYCHOPHARMACOLOGY, V139, P195, DOI 10.1007/s002130050704
   GREEN BG, 1988, PHYSIOL BEHAV, V43, P515, DOI 10.1016/0031-9384(88)90127-8
   Griffiths RR, 2000, ARCH FAM MED, V9, P727, DOI 10.1001/archfami.9.8.727
   GRIFFITHS RR, 1988, J PHARMACOL EXP THER, V246, P21
   Harrington S, 2008, J SCH NURS, V24, P3, DOI 10.1622/1059-8405(2008)024[0003:TROSBC]2.0.CO;2
   Hayes JE, 2007, CHEM SENSES, V32, P225, DOI 10.1093/chemse/bjl050
   HUGHES JR, 1993, DRUG ALCOHOL DEPEN, V32, P239, DOI 10.1016/0376-8716(93)90088-8
   James J, 2005, INT J OBESITY, V29, PS54, DOI 10.1038/sj.ijo.0803062
   Keast RSJ, 2007, APPETITE, V49, P255, DOI 10.1016/j.appet.2006.11.003
   Keast RSJ, 2007, CHEM SENSES, V32, P245, DOI 10.1093/chemse/bjl052
   Krachler B, 2006, NUTR J, V5, P0, DOI 10.1186/1475-2891-5-34
   Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1
   MCBRIDE RL, 1983, PERCEPT PSYCHOPHYS, V34, P77, DOI 10.3758/BF03205899
   McGartland C, 2003, J BONE MINER RES, V18, P1563, DOI 10.1359/jbmr.2003.18.9.1563
   Meilgaard MC, 1999, SENSORY EVALUATION TECHNIQUES, V0, P0
   Reid M, 2007, BRIT J NUTR, V97, P193, DOI 10.1017/S0007114507252705
   Rolls BJ, 2010, P NUTR SOC, V69, P70, DOI 10.1017/S0029665109991674
   Rolls BJ, 2009, PHYSIOL BEHAV, V97, P609, DOI 10.1016/j.physbeh.2009.03.011
   Schuh KJ, 1997, PSYCHOPHARMACOLOGY, V130, P320, DOI 10.1007/s002130050246
   Striegel-Moore RH, 2006, J PEDIATR-US, V148, P183, DOI 10.1016/j.jpeds.2005.11.025
   SUN M, 1980, SCIENCE, V209, P1500
   Swinburn BA, 2006, AM J CLIN NUTR, V83, P859, DOI 10.1093/ajcn/83.4.859
   Swinburn BA, 2004, PUBLIC HEALTH NUTR, V7, P123, DOI 10.1079/PHN2003585
   Swinburn B, 2010, AM J CLIN NUTR, V91, P817, DOI 10.3945/ajcn.2009.29041
   Swinburn BA, 2009, AM J CLIN NUTR, V89, P1723, DOI 10.3945/ajcn.2008.27061
   Temple JL, 2009, NEUROSCI BIOBEHAV R, V33, P793, DOI 10.1016/j.neubiorev.2009.01.001
   Tijms H, 2004, UNDERSTANDING PROBAB, V0, P0
   Troiano RP, 2000, AM J CLIN NUTR, V72, P1343S, DOI 10.1093/ajcn/72.5.1343s
   USCensus Bureau, 2009, CENS POP HOUS, V0, P0
   USDepartment of Agriculture, 2008, NUTR INT FOOD MEAN A, V0, P0
   US Census Bureau, 2008, AG GROUPS SEX 2000, V0, P0
   Wang YC, 2008, PEDIATRICS, V121, PE1604, DOI 10.1542/peds.2007-2834
   Wang YC, 2009, ARCH PEDIAT ADOL MED, V163, P336, DOI 10.1001/archpediatrics.2009.23
   Yeomans MR, 2000, APPETITE, V35, P131, DOI 10.1006/appe.2000.0339
NR 42
TC 21
Z9 22
U1 0
U2 29
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0954-3007
EI 1476-5640
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD DEC 15
PY 2011
VL 65
IS 12
BP 1338
EP 1344
DI 10.1038/ejcn.2011.123
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 863NE
UT WOS:000298170300011
PM 21772315
DA 2025-04-28
ER

PT J
AU Murase, T
   Misawa, K
   Minegishi, Y
   Aoki, M
   Ominami, H
   Suzuki, Y
   Shibuya, Y
   Hase, T
AF Murase, Takatoshi
   Misawa, Koichi
   Minegishi, Yoshihiko
   Aoki, Masafumi
   Ominami, Hideo
   Suzuki, Yasuto
   Shibuya, Yusuke
   Hase, Tadashi
TI Coffee polyphenols suppress diet-induced body fat accumulation by downregulating SREBP-1c and related molecules in C57BL/6J mice
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE obesity; metabolic syndrome; energy metabolism; caffeoyl quinic acid; acetyl-coenzyme A carboxylase; sterol regulatory element-binding protein-1c
ID antisense oligonucleotide inhibitors; spontaneously hypertensive-rats; stearoyl-coa desaturase-1; type-2 diabetes-mellitus; activated protein-kinase; metabolic syndrome; insulin-resistance; hepatic steatosis; lipid-metabolism; induced obesity
AB Murase T, Misawa K, Minegishi Y, Aoki M, Ominami H, Suzuki Y, Shibuya Y, Hase T. Coffee polyphenols suppress diet-induced body fat accumulation by downregulating SREBP-1c and related molecules in C57BL/6J mice. Am J Physiol Endocrinol Metab 300: E122-E133, 2011. First published October 13, 2010; doi:10.1152/ajpendo.00441.2010.-The prevalence of obesity is increasing globally, and obesity is a major risk factor for type 2 diabetes and cardiovascular disease. We investigated the effects of coffee polyphenols (CPP), which are abundant in coffee and consumed worldwide, on diet-induced body fat accumulation. C57BL/6J mice were fed either a control diet, a high-fat diet, or a high-fat diet supplemented with 0.5 to 1.0% CPP for 2-15 wk. Supplementation with CPP significantly reduced body weight gain, abdominal and liver fat accumulation, and infiltration of macrophages into adipose tissues. Energy expenditure evaluated by indirect calorimetry was significantly increased in CPP-fed mice. The mRNA levels of sterol regulatory element-binding protein (SREBP)-1c, acetyl-CoA carboxylase-1 and -2, stearoyl-CoA desaturase-1, and pyruvate dehydrogenase kinase-4 in the liver were significantly lower in CPP-fed mice than in high-fat control mice. Similarly, CPP suppressed the expression of these molecules in Hepa 1-6 cells, concomitant with an increase in microRNA-122. Structure-activity relationship studies of nine quinic acid derivatives isolated from CPP in Hepa 1-6 cells suggested that mono-or di-caffeoyl quinic acids (CQA) are active substances in the beneficial effects of CPP. Furthermore, CPP and 5-CQA decreased the nuclear active form of SREBP-1, acetyl-CoA carboxylase activity, and cellular malonyl-CoA levels. These findings indicate that CPP enhances energy metabolism and reduces lipogenesis by downregulating SREBP-1c and related molecules, which leads to the suppression of body fat accumulation.
C1 [Murase, Takatoshi; Misawa, Koichi; Minegishi, Yoshihiko; Aoki, Masafumi; Ominami, Hideo; Suzuki, Yasuto; Shibuya, Yusuke; Hase, Tadashi] Kao Corp, Biol Sci Labs, Ichikai, Tochigi 3213497, Japan.
C3 KAO Corporation
RP Murase, T (corresponding author), Kao Corp, Biol Sci Labs, 2606 Akabane, Ichikai, Tochigi 3213497, Japan.
EM murase.takatoshi@kao.co.jp
CR Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100
   Cheung O, 2008, J HEPATOL, V48, PS47, DOI 10.1016/S0168-8278(08)60107-5
   Choi CS, 2007, P NATL ACAD SCI USA, V104, P16480, DOI 10.1073/pnas.0706794104
   Clifford MN, 1999, J SCI FOOD AGR, V79, P362, DOI 10.1002/(SICI)1097-0010(19990301)79:3<362::AID-JSFA256>3.0.CO;2-D
   Cool B, 2006, CELL METAB, V3, P403, DOI 10.1016/j.cmet.2006.05.005
   DEMOZ A, 1995, J CHROMATOGR B, V667, P148, DOI 10.1016/0378-4347(94)00595-V
   Dobrzyn A, 2004, TRENDS CARDIOVAS MED, V14, P77, DOI 10.1016/j.tcm.2003.12.005
   Dórea JG, 2005, BRIT J NUTR, V93, P773, DOI 10.1079/BJN20051370
   Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005
   Ferré P, 2007, HORM RES, V68, P72, DOI 10.1159/000100426
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Girard M, 2008, J HEPATOL, V48, P648, DOI 10.1016/j.jhep.2008.01.019
   Harwood HJ, 2005, EXPERT OPIN THER TAR, V9, P267, DOI 10.1517/14728222.9.2.267
   Higdon JV, 2006, CRIT REV FOOD SCI, V46, P101, DOI 10.1080/10408390500400009
   Hwahng SH, 2009, HEPATOLOGY, V49, P1913, DOI 10.1002/hep.22887
   Iliopoulos D, 2010, J LIPID RES, V51, P1513, DOI 10.1194/jlr.M004812
   Inoue M, 2005, JNCI-J NATL CANCER I, V97, P293, DOI 10.1093/jnci/dji040
   JEEJEEBHOY KN, 1970, CLIN BIOCHEM, V3, P157, DOI 10.1016/S0009--912(0()70)80021--2
   Jiang GQ, 2005, J CLIN INVEST, V115, P1030, DOI 10.1172/JCI200523962
   Kim MS, 2004, NAT MED, V10, P727, DOI 10.1038/nm1061
   Kusunoki J, 2006, ENDOCRINE, V29, P91, DOI 10.1385/ENDO:29:1:91
   Li AC, 2004, J LIPID RES, V45, P2161, DOI 10.1194/jlr.R400010-JLR200
   Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044
   Mao J, 2006, P NATL ACAD SCI USA, V103, P8552, DOI 10.1073/pnas.0603115103
   McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x
   Monteiro M, 2007, J NUTR, V137, P2196, DOI 10.1093/jn/137.10.2196
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Murase T, 2005, AM J PHYSIOL-REG I, V288, PR708, DOI 10.1152/ajpregu.00693.2004
   Murase T, 2008, AM J PHYSIOL-REG I, V295, PR281, DOI 10.1152/ajpregu.00880.2007
   Murase T, 2010, AM J PHYSIOL-ENDOC M, V299, PE266, DOI 10.1152/ajpendo.00774.2009
   Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699
   Odegaard JI, 2008, NAT CLIN PRACT ENDOC, V4, P619, DOI 10.1038/ncpendmet0976
   Rector RS, 2008, AM J PHYSIOL-GASTR L, V294, PG619, DOI 10.1152/ajpgi.00428.2007
   Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900
   Ross GW, 2000, JAMA-J AM MED ASSOC, V283, P2674, DOI 10.1001/jama.283.20.2674
   Ruhl CE, 2005, GASTROENTEROLOGY, V129, P1928, DOI 10.1053/j.gastro.2005.08.056
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   Savage DB, 2006, J CLIN INVEST, V116, P817, DOI 10.1172/JCI27300
   Shimano H, 2009, FEBS J, V276, P616, DOI 10.1111/j.1742-4658.2008.06806.x
   Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, PE855, DOI 10.1152/ajpendo.00526.2002
   SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X
   Suzuki A, 2006, J HYPERTENS, V24, P1065, DOI 10.1097/01.hjh.0000226196.67052.c0
   Suzuki A, 2007, AM J HYPERTENS, V20, P508, DOI 10.1016/j.amjhyper.2006.11.008
   Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743
   Tanabe T, 1981, METHODS ENZYMOL, V71 Pt C, P5
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
NR 47
TC 176
Z9 188
U1 1
U2 39
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
EI 
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD JAN 15
PY 2011
VL 300
IS 1
BP E122
EP E133
DI 10.1152/ajpendo.00441.2010
PG 12
WC Endocrinology & Metabolism; Physiology
SC Endocrinology & Metabolism; Physiology
GA 700CU
UT WOS:000285711200015
PM 20943752
DA 2025-04-28
ER

PT J
AU Truthmann, J
   Mensink, GBM
   Richter, A
AF Truthmann, Julia
   Mensink, Gert B. M.
   Richter, Almut
TI Relative validation of the KiGGS Food Frequency Questionnaire among adolescents in Germany
SO NUTRITION JOURNAL
LA English
DT Article
DE adolescents; dietary surveys; nutrition assessment; Germany; population characteristics; epidemiology
ID dietary assessment; health interview; validity; reproducibility; children; reliability; agreement; design; quality; energy
AB Background: The aim of this study was to determine the relative validity of the self-administered Food Frequency Questionnaire (FFQ) "What do you eat?", which was used in the German National Health Interview and Examination Survey for Children and Adolescents (KiGGS 2003-2006). Methods: The validation was conducted in the EsKiMo Nutrition Module, a subsample of KiGGS. The study population included 1,213 adolescents aged between 12 and 17. A modified diet history interview DISHES (Dietary Interview Software for Health Examination Studies) was used as the reference method. In order to compare the food groups, the data assessed with both instruments were aggregated to 40 similar food groups. The statistical analysis included calculating and comparing Spearman's correlation coefficients, calculating the mean difference between both methods, and ranking participants (quartiles) according to food group consumption, including weighted kappa coefficients. Correlations were also evaluated for relative body weight and socioeconomic status subgroups. Results: In the total study population the Spearman correlation coefficients ranged from 0.22 for pasta/rice to 0.69 for margarine; most values were 0.50 and higher. The mean difference ranged between 1.4% for milk and 100.3% for pasta/rice. The 2.5 percentiles and 97.5 percentiles indicated a wide range of differences. Classifications in the same and adjacent quartile varied between 70.1% for pasta/rice and 90.8% for coffee. For most groups, Cohen's weighted kappa showed values between 0.21 and 0.60. Only for white bread and pasta/rice were values less than 0.20. Most of the 40 food groups showed acceptable to good correlations in all investigated subgroups concerning age, sex, body weight and socio-economic status. Conclusions: The KiGGS FFQ showed fair to moderate ranking validity except for pasta/rice and white bread. However, the ability to assess absolute intakes is limited. The correlation coefficients for most food items were similar for normal weight and overweight as well as for different socio-economic status groups. Overall, the results of the relative validity were comparable to FFQs from the current literature.
C1 [Mensink, Gert B. M.; Richter, Almut] Robert Koch Inst, Dept Epidemiol & Hlth Reporting, D-13302 Berlin, Germany.
   [Truthmann, Julia] Tech Univ Munich, Sch Management Mkt & Consumer Res, D-85350 Freising Weihenstephan, Germany.
C3 Robert Koch Institute; Technical University of Munich
RP Richter, A (corresponding author), Robert Koch Inst, Dept Epidemiol & Hlth Reporting, Post Box 65 02 61, D-13302 Berlin, Germany.
EM RichterA@rki.de
FU German Research Foundation; German Ministry of Health; Ministry of Education and Research; Robert Koch Institute; German Federal Ministry of Food, Agriculture and Consumer Protection
CR Ambrosini GL, 2009, EUR J CLIN NUTR, V63, P1251, DOI 10.1038/ejcn.2009.44
   Ambrosini GL, 2001, PUBLIC HEALTH NUTR, V4, P255, DOI 10.1079/PHN200062
   Araujo MC, 2010, J AM DIET ASSOC, V110, P1170, DOI 10.1016/j.jada.2010.05.008
   Bandini LG, 1997, AM J CLIN NUTR, V65, P1138
   BEATON GH, 1994, AM J CLIN NUTR, V59, P253S, DOI 10.1093/ajcn/59.1.253S
   BELLACH B, 1993, EUR J CLIN NUTR, V47, P0
   Bland JM, 2003, ULTRASOUND OBST GYN, V22, P85, DOI 10.1002/uog.122
   Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1177/096228029900800204
   Boschi V, 2003, ANN NUTR METAB, V47, P284, DOI 10.1159/000072401
   Cade J, 2002, PUBLIC HEALTH NUTR, V5, P567, DOI 10.1079/PHN2001318
   Cade JE, 2004, NUTR RES REV, V17, P5, DOI 10.1079/NRR200370
   Cullen KW, 2004, J AM DIET ASSOC, V104, P1415, DOI 10.1016/j.jada.2004.06.022
   Fink A, 2007, HDB EPIDEMIOLOGY, V0, P0
   Haftenberger M, 2010, NUTR J, V9, P0, DOI 10.1186/1475-2891-9-36
   Hartmann BM, 2006, ERNAHRUNGS UMSCHAU, V53, P124
   Hong TK, 2010, PUBLIC HEALTH NUTR, V13, P368, DOI 10.1017/S136898000999125X
   Kamtsiuris P, 2007, BUNDESGESUNDHEITSBLA, V50, P547, DOI 10.1007/s00103-007-0215-9
   Kesse-Guyot E, 2011, ANN NUTR METAB, V57, P153, DOI 10.1159/000321680
   Krems C, 2006, ERNAHRUNGS-UMSCHAU, V53, P44
   Kristal AR, 2005, CANCER EPIDEM BIOMAR, V14, P2826, DOI 10.1158/1055-9965.EPI-12-ED1
   Kromeyer-Hauschild K, 2001, MONATSSCHR KINDERH, V149, P807, DOI 10.1007/s001120170107
   Kurth BM, 2007, BUNDESGESUNDHEITSBLA, V50, P533, DOI 10.1007/s00103-007-0214-x
   Kurth BM, 2008, BMC PUBLIC HEALTH, V8, P0, DOI 10.1186/1471-2458-8-196
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lange M, 2007, BUNDESGESUNDHEITSBLA, V50, P578, DOI 10.1007/s00103-007-0219-5
   Livingstone MBE, 2004, BRIT J NUTR, V92, PS213, DOI 10.1079/BJN20041169
   Livingstone MBE, 2000, P NUTR SOC, V59, P279, DOI 10.1017/S0029665100000318
   Marks GC, 2006, J NUTR, V136, P459, DOI 10.1093/jn/136.2.459
   Matthys C, 2007, J AM DIET ASSOC, V107, P605, DOI 10.1016/j.jada.2007.01.005
   Mensink GBM, 2007, BUNDESGESUNDHEITSBLA, V50, P902, DOI 10.1007/s00103-007-0254-2
   Mensink G B M, 2004, BUNDESGESUNDHEITSBLATT GESUNDHEITSFORSCHUNG GESUNDHEITSSCHUTZ, V47, P219, DOI 10.1007/s00103-003-0794-z
   Mensink GBM, 2001, EUR J CLIN NUTR, V55, P409, DOI 10.1038/sj.ejcn.1601174
   Moore GF, 2007, EUR J CLIN NUTR, V61, P420, DOI 10.1038/sj.ejcn.1602531
   Papadopoulou SK, 2008, INT J FOOD SCI NUTR, V59, P148, DOI 10.1080/09637480701530004
   Price GM, 1997, BRIT J NUTR, V77, P833, DOI 10.1079/BJN19970083
   Rockett HRH, 2005, J AM DIET ASSOC, V105, P1867, DOI 10.1016/j.jada.2005.10.007
   Rockett HRH, 2003, CURR OPIN CLIN NUTR, V6, P557, DOI 10.1097/00075197-200309000-00009
   Serra-Majem L, 2009, BRIT J NUTR, V102, PS3, DOI 10.1017/S0007114509993114
   Shu XO, 2004, EUR J CLIN NUTR, V58, P17, DOI 10.1038/sj.ejcn.1601738
   Slater B, 2003, EUR J CLIN NUTR, V57, P629, DOI 10.1038/sj.ejcn.1601588
   Stallone DD, 1997, EUR J CLIN NUTR, V51, P815, DOI 10.1038/sj.ejcn.1600491
   Van Kappel A, 1994, EPIC-SOFT PICTURE BOOK FOR ESTIMATION OF FOOD PORTION SIZES, V0, P0
   Villegas R, 2007, BRIT J NUTR, V97, P993, DOI 10.1017/S0007114507669189
   WARDLE J, 1990, J PSYCHOSOM RES, V34, P377, DOI 10.1016/0022-3999(90)90061-8
   Watson JF, 2009, INT J BEHAV NUTR PHY, V6, P0, DOI 10.1186/1479-5868-6-62
   WHO, 2003, WHO TECHN REP SER, V0, P0
   Willet W, 1998, NUTR EPIDEMIOLOGY, V0, PP47, DOI 10.1093/ACPROF:OSO/9780195122978.003.06
   Willett W, 1998, NUTRITIONAL EPIDEMIOLOGY, V2nd, P74, DOI 10.1093/acprof:oso/9780195122978.001.0001
   Winkler J, 1999, GESUNDHEITSWESEN, V61, P178
NR 50
TC 57
Z9 57
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1475-2891
J9 NUTR J
JI Nutr. J.
PD DEC 7
PY 2011
VL 10
IS 
BP 
EP 
DI 10.1186/1475-2891-10-133
PG 12
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 878NQ
UT WOS:000299264200001
PM 22152115
DA 2025-04-28
ER

PT J
AU Lonac, MC
   Richards, JC
   Schweder, MM
   Johnson, TK
   Bell, C
AF Lonac, Mark C.
   Richards, Jennifer C.
   Schweder, Melani M.
   Johnson, Tyler K.
   Bell, Christopher
TI Influence of Short-Term Consumption of the Caffeine-Free, Epigallocatechin-3-Gallate Supplement, Teavigo, on Resting Metabolism and the Thermic Effect of Feeding
SO OBESITY
LA English
DT Article
ID catechol-o-methyltransferase; tonic sympathetic support; green tea catechins; fat oxidation; body-weight; energy-expenditure; adipose-tissue; obese subjects; abdominal fat; ascorbic-acid
AB Green tea is purported to promote weight loss. Resting metabolic rate (RMR) and the thermic effect of feeding (TEF) are significant components of total daily energy expenditure and are partially determined by the sympathetic nervous system via catecholamine-mediated stimulation of beta-adrenergic receptors. Epigallocatechin-3-gallate (EGCG: the most bioactive catechin in green tea) inhibits catechol-O-methyltransferase, an enzyme contributing to the degradation of catecholamines. Accordingly, we hypothesized that short-term consumption of a commercially available EGCG supplement (Teavigo) augments RMR and TEF. On two separate occasions, seven placebo or seven EGCG capsules (135 mg/capsule) were administered to 16 adults (9 males, 7 females, age 25 +/- 2 years, BMI 24.6 +/- 1.2 kg/m(2) (mean +/- s.e.)). Capsules (three/day) were consumed over 48 h; the final capsule was consumed 2 h prior to visiting the laboratory. Energy expenditure (ventilated hood technique) was determined at rest and for 5 h following ingestion of a liquid meal (caloric content: 40% RMR). Contrary to our hypothesis, RMR was not greater (P = 0.10) following consumption of EGCG (6,740 +/- 373 kJ/day) compared with placebo (6,971 +/- 352). Similarly, the area under the TEF response curve (Delta energy expenditure) was also unaffected by EGCG (246,808 +/- 23,748 vs. 243,270 +/- 22,177 kJ; P = 0.88). EGCG had no effect on respiratory exchange ratio at rest (P = 0.29) or throughout the TEF measurement (P = 0.56). In summary, together RMR and TEF may account for up to 85% of total daily energy expenditure; we report that short-term consumption of a commercially available EGCG supplement did not increase RMR or TEF.
C1 [Lonac, Mark C.; Richards, Jennifer C.; Schweder, Melani M.; Johnson, Tyler K.; Bell, Christopher] Colorado State Univ, Dept Hlth & Exercise Sci, Ft Collins, CO 80523 USA.
C3 Colorado State University System; Colorado State University Fort Collins
RP Bell, C (corresponding author), Colorado State Univ, Dept Hlth & Exercise Sci, Ft Collins, CO 80523 USA.
EM cbell@cahs.colostate.edu
FU National Institute on Aging [NIA AG022053]; American Diabetes Association [ADA 1-09-RA-09]; Colorado Agricultural Experiment Station at Colorado State University
CR Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160
   Bell C, 2005, J APPL PHYSIOL, V98, P845, DOI 10.1152/japplphysiol.00790.2004
   Bell C, 2004, J CLIN ENDOCR METAB, V89, P3573, DOI 10.1210/jc.2003-032146
   Bell C, 2001, J CLIN ENDOCR METAB, V86, P4440, DOI 10.1210/jc.86.9.4440
   BORCHARDT RT, 1975, J MED CHEM, V18, P120, DOI 10.1021/jm00235a030
   BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012
   Boschmann M, 2007, J AM COLL NUTR, V26, P389S, DOI 10.1080/07315724.2007.10719627
   Bose M, 2008, J NUTR, V138, P1677, DOI 10.1093/jn/138.9.1677
   Chantre P, 2002, PHYTOMEDICINE, V9, P3, DOI 10.1078/0944-7113-00078
   Chesley A, 1998, AM J PHYSIOL-REG I, V275, PR596, DOI 10.1152/ajpregu.1998.275.2.R596
   Chow HHS, 2003, CLIN CANCER RES, V9, P3312
   Diepvens K, 2007, AM J PHYSIOL-REG I, V292, PR77, DOI 10.1152/ajpregu.00832.2005
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Franklin BA, 2000, ACSMS GUIDELINES FOR EXERCISE TRAINING AND PRESCRIPTION, V7th, P0
   Granata GP, 2002, NUTR REV, V60, P223, DOI 10.1301/002966402320289359
   Gregersen NT, 2009, BRIT J NUTR, V102, P1187, DOI 10.1017/S0007114509371779
   Hill AM, 2007, J AM COLL NUTR, V26, P396S, DOI 10.1080/07315724.2007.10719628
   Hursel R, 2010, INT J OBESITY, V34, P659, DOI 10.1038/ijo.2009.299
   Hursel R, 2009, INT J OBESITY, V33, P956, DOI 10.1038/ijo.2009.135
   Jones PP, 2004, J CLIN ENDOCR METAB, V89, P5138, DOI 10.1210/jc.2004-0101
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Lee MS, 2009, PHYTOTHER RES, V23, P1088, DOI 10.1002/ptr.2737
   Lee MS, 2009, ANN NUTR METAB, V54, P151, DOI 10.1159/000214834
   Lee MS, 2009, BIOSCI BIOTECH BIOCH, V73, P434, DOI 10.1271/bbb.80563
   Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025
   Maki KC, 2009, J NUTR, V139, P264, DOI 10.3945/jn.108.098293
   Monroe MB, 2001, AM J PHYSIOL-ENDOC M, V280, PE740, DOI 10.1152/ajpendo.2001.280.5.E740
   Nagao T, 2007, OBESITY, V15, P1473, DOI 10.1038/oby.2007.176
   Newsom SA, 2008, OBESITY, V16, P1749, DOI 10.1038/oby.2008.304
   Phung OJ, 2010, AM J CLIN NUTR, V91, P73, DOI 10.3945/ajcn.2009.28157
   RAVUSSIN E, 1992, AM J CLIN NUTR, V55, P242
   RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802
   Reed GW, 1996, AM J CLIN NUTR, V63, P164, DOI 10.1093/ajcn/63.2.164
   Richards JC, 2010, MED SCI SPORT EXER, V42, P739, DOI 10.1249/MSS.0b013e3181bcab6c
   SCHWARTZ RS, 1988, AM J PHYSIOL, V254, PR90, DOI 10.1152/ajpregu.1988.254.1.R90
   SCHWARTZ RS, 1990, METABOLISM, V39, P733, DOI 10.1016/0026-0495(90)90109-P
   Seeram NP, 2006, J AGR FOOD CHEM, V54, P1599, DOI 10.1021/jf052857r
   Shixian Q, 2006, J MED FOOD, V9, P451, DOI 10.1089/jmf.2006.9.451
   Stob NR, 2007, J APPL PHYSIOL, V103, P616, DOI 10.1152/japplphysiol.01434.2006
   Straznicky NE, 2009, DIABETES, V58, P1126, DOI 10.2337/db08-1595
   Straznicky NE, 2009, AM J CLIN NUTR, V89, P27, DOI 10.3945/ajcn.2008.26299
   Tanaka H, 2001, J AM COLL CARDIOL, V37, P153, DOI 10.1016/S0735-1097(00)01054-8
   TAPPY L, 1986, AM J PHYSIOL, V250, PE718, DOI 10.1152/ajpendo.1986.250.6.E718
   Tappy L, 1996, REPROD NUTR DEV, V36, P391, DOI 10.1051/rnd:19960405
   Thielecke F, 2010, EUR J CLIN NUTR, V64, P704, DOI 10.1038/ejcn.2010.47
   Thielecke F, 2009, PHYTOCHEMISTRY, V70, P11, DOI 10.1016/j.phytochem.2008.11.011
   Ullmann U, 2003, J INT MED RES, V31, P88, DOI 10.1177/147323000303100205
   Venables MC, 2008, AM J CLIN NUTR, V87, P778, DOI 10.1093/ajcn/87.3.778
   Wang HQ, 2010, OBESITY, V18, P773, DOI 10.1038/oby.2009.256
   Westerterp-Plantenga MS, 2010, PHYSIOL BEHAV, V100, P42, DOI 10.1016/j.physbeh.2010.02.005
   Wolfram S, 2005, ANN NUTR METAB, V49, P54, DOI 10.1159/000084178
   Wolfram S, 2007, J AM COLL NUTR, V26, P373S, DOI 10.1080/07315724.2007.10719626
   Zhu BT, 2008, XENOBIOTICA, V38, P130, DOI 10.1080/00498250701744641
NR 56
TC 35
Z9 40
U1 2
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD FEB 15
PY 2011
VL 19
IS 2
BP 298
EP 304
DI 10.1038/oby.2010.181
PG 7
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 712FW
UT WOS:000286651400011
PM 20725062
DA 2025-04-28
ER

PT J
AU Imatoh, T
   Tanihara, S
   Miyazaki, M
   Momose, Y
   Uryu, Y
   Une, H
AF Imatoh, T.
   Tanihara, S.
   Miyazaki, M.
   Momose, Y.
   Uryu, Y.
   Une, H.
TI Coffee consumption but not green tea consumption is associated with adiponectin levels in Japanese males
SO EUROPEAN JOURNAL OF NUTRITION
LA English
DT Article
DE Adiponectin; Epidemiological study; Coffee; Green tea
ID type-2 diabetes-mellitus; decaffeinated coffee; insulin-resistance; risk; women; caffeine; obesity; components; reduce; men
AB Coffee is among the most widely consumed beverages in the world. Numerous epidemiological studies have reported a significant inverse association between coffee consumption and risk of type 2 diabetes mellitus, but the underlying mechanisms are still not fully understood. Therefore, we conducted an epidemiological study to clarify the relationship between coffee consumption and adiponectin levels in Japanese males. We also evaluated whether green tea consumption affected adiponectin levels. We carried out a cross-sectional study. The subjects were 665 male employees in Japan. Coffee consumption was assessed, using a self-administered questionnaire, as the number of times per week and cups per day respondents drank, and subjects were grouped into four levels (non, 1-5 times/week, 1-2 cups/day and a parts per thousand yen3 cups/day). The means of adiponectin levels were positively associated with coffee consumption. A dose-response relationship was found between coffee consumption and circulating adiponectin levels. The relationship remained significant after adjustment for potential confounding factors (P for trend < 0.05). However, green tea consumption was not significantly associated with adiponectin levels (P for trend = 0.90). We not only revealed that habitual coffee consumption is associated with higher adiponectin levels in Japanese males but also found a dose-dependent association between coffee consumption and adiponectin levels. Therefore, our study suggested that coffee components might play an important role in the elevation of adiponectin level.
C1 [Imatoh, T.; Tanihara, S.; Momose, Y.; Uryu, Y.; Une, H.] Fukuoka Univ, Dept Hyg & Prevent Med, Sch Med, Jonan Ku, Fukuoka 8140180, Japan.
   [Miyazaki, M.] Saitama City Inst Hlth Sci & Res, Chuou Ku, Saitama 3380013, Japan.
C3 Fukuoka University
RP Imatoh, T (corresponding author), Fukuoka Univ, Dept Hyg & Prevent Med, Sch Med, Jonan Ku, 7-45-1 Nanakuma, Fukuoka 8140180, Japan.
EM imatoh@cis.fukuoka-u.ac.jp
FU Japan Society for the Promotion of Science [20590619, 21790564]; Grants-in-Aid for Scientific Research [20590619, 21790564] Funding Source: KAKEN
CR Arsenault BJ, 2009, EUR J CLIN NUTR, V63, P1419, DOI 10.1038/ejcn.2009.112
   Balk L, 2009, EUR J EPIDEMIOL, V24, P203, DOI 10.1007/s10654-009-9323-1
   Bravi F, 2007, HEPATOLOGY, V46, P430, DOI 10.1002/hep.21708
   Greenberg JA, 2005, INT J OBESITY, V29, P1121, DOI 10.1038/sj.ijo.0802999
   Greenberg JA, 2007, AM J CLIN NUTR, V85, P392, DOI 10.1093/ajcn/85.2.392
   Hamer M, 2008, BRIT J NUTR, V100, P1046, DOI 10.1017/S0007114508944135
   Hsu CH, 2008, CLIN NUTR, V27, P363, DOI 10.1016/j.clnu.2008.03.007
   Huxley R, 2009, ARCH INTERN MED, V169, P2053, DOI 10.1001/archinternmed.2009.439
   Kagami K, 2008, J PHARM PHARMACOL, V60, P1161, DOI 10.1211/jpp.60.9.0007
   Kato M, 2009, ENDOCR J, V56, P459, DOI 10.1507/endocrj.K09E-003
   Kempf K, 2010, AM J CLIN NUTR, V91, P950, DOI 10.3945/ajcn.2009.28548
   Klatsky AL, 2006, ARCH INTERN MED, V166, P1190, DOI 10.1001/archinte.166.11.1190
   Kotani K, 2008, CLIN CHEM LAB MED, V46, P1434, DOI 10.1515/CCLM.2008.286
   Lee JE, 2007, INT J CANCER, V121, P2246, DOI 10.1002/ijc.22909
   Matsuzawa Y, 2005, ATHEROSCLEROSIS SUPP, V6, P7, DOI 10.1016/j.atherosclerosissup.2005.02.003
   Nagao T, 2009, OBESITY, V17, P310, DOI 10.1038/oby.2008.505
   Oba S, 2010, BRIT J NUTR, V103, P453, DOI 10.1017/S0007114509991966
   Odegaard AO, 2008, AM J CLIN NUTR, V88, P979, DOI 10.1093/ajcn/88.4.979
   Pimentel GD, 2009, DIABETOL METAB SYNDR, V1, P0, DOI 10.1186/1758-5996-1-6
   Potenza MA, 2007, AM J PHYSIOL-ENDOC M, V292, PE1378, DOI 10.1152/ajpendo.00698.2006
   Richard D, 2009, PHARMACOL RES, V59, P351, DOI 10.1016/j.phrs.2009.01.015
   Ruhl CE, 2005, GASTROENTEROLOGY, V128, P24, DOI 10.1053/j.gastro.2004.09.075
   Ryu OH, 2006, DIABETES RES CLIN PR, V71, P356, DOI 10.1016/j.diabres.2005.08.001
   Schaefer B, 2004, ANN INTERN MED, V141, P321, DOI 10.7326/0003-4819-141-4-200408170-00016
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   van Dam RM, 2008, APPL PHYSIOL NUTR ME, V33, P1269, DOI 10.1139/H08-120
   van Dieren S, 2009, DIABETOLOGIA, V52, P2561, DOI 10.1007/s00125-009-1516-3
   van Dijk AE, 2009, DIABETES CARE, V32, P1023, DOI 10.2337/dc09-0207
   Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930
   Williams CJ, 2008, DIABETES CARE, V31, P504, DOI 10.2337/dc07-1952
NR 31
TC 43
Z9 48
U1 0
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1436-6207
EI 1436-6215
J9 EUR J NUTR
JI Eur. J. Nutr.
PD JUN 15
PY 2011
VL 50
IS 4
BP 279
EP 284
DI 10.1007/s00394-010-0136-5
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 769SK
UT WOS:000291038400007
PM 20953616
DA 2025-04-28
ER

PT J
AU Sakane, N
AF Sakane, Naoki
TI Merits and Demerits of Food With Hearth Claims for the Prevention of Metabolic Syndrome
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE metabolic syndrome; obesity; mazindol; orlistat; health food
ID weight-loss; body-weight; antiobesity; medications; management; reduction; mazindol; obesity; disease; women
AB The merits and demerits of food with health claims for the prevention of metabolic syndrome (MS) are reviewed. One major underlying cause of MS is obesity. Diet and lifestyle changes remain the cornerstones of therapy for obesity, but resulting weight loss is often small and long-term success is extremely uncommon and disappointing. Many anti-obesity drugs have been associated with unintended therapeutic outcomes. Currently, only one drug (mazindol) is approved in Japan for short-term treatment of individuals with a BMI over 35 kg/m(2). Treatment with orlistat with dietary modification, caffeine, or protein supplementation; consuming a low-fat diet; adherence to physical activity routines; prolonged contact with participants; problem-solving therapy; and the alternative treatment of acupressure are efficacious in reducing weight regain after weight loss treatment. Because obesity is highly stigmatized, any effective treatment should be made available to improve quality of life and self-image. Therefore, it is necessary to provide information to consumers through the media concerning 1) basic knowledge about health foods and laws concerning them, 2) scientifically based information on safety/effectiveness of health foods and food elements, and 3) reports on health disturbances associated with health foods around the world.
C1 Natl Hosp Org, Kyoto Med Ctr, Clin Res Inst Endocrine & Metab Dis, Div Prevent Med, Kyoto 6128555, Japan.
RP Sakane, N (corresponding author), Natl Hosp Org, Kyoto Med Ctr, Clin Res Inst Endocrine & Metab Dis, Div Prevent Med, Kyoto 6128555, Japan.
EM nsakane@kyotolan.hosp.go.jp
CR Allison DB, 2001, CRIT REV FOOD SCI, V41, P1, DOI 10.1080/20014091091661
   Bray GA, 1997, OBES RES, V5, P634, DOI 10.1002/j.1550-8528.1997.tb00586.x
   Bray GA, 2008, OBESITY, V16, P509, DOI 10.1038/oby.2007.100
   Bray GA, 2008, ENDOCRIN METAB CLIN, V37, P923, DOI 10.1016/j.ecl.2008.08.004
   Cresswell J, 1999, COMMUNITY NURSE, V5, P30
   De Flines J, 2010, ACTA GASTRO-ENT BELG, V73, P261
   Ferrer-Lorente R, 2007, J PHARMACOL SCI, V104, P176, DOI 10.1254/jphs.FP0061441
   Greenway FL, 2010, CURR DIABETES REP, V10, P108, DOI 10.1007/s11892-010-0096-4
   Hioki C, 2004, CLIN EXP PHARMACOL P, V31, P614, DOI 10.1111/j.1440-1681.2004.04056.x
   Kushner RF, 2008, EXPERT OPIN PHARMACO, V9, P1339, DOI 10.1517/14656566.9.8.1339
   Lee HK, 2009, CURR TOP MED CHEM, V9, P482, DOI 10.2174/156802609788897844
   Low S, 2009, ANN ACAD MED SINGAP, V38, P57
   Nakashima N, 2007, STUD HEALTH TECHNOL, V129, P1174
   Pittler MH, 2005, OBES REV, V6, P93, DOI 10.1111/j.1467-789X.2005.00169.x
   Pittler MH, 2005, INT J OBESITY, V29, P1030, DOI 10.1038/sj.ijo.0803008
   Saito M, 2007, YAKUGAKU ZASSHI, V127, P407, DOI 10.1248/yakushi.127.407
   Sattar N, 2008, LANCET, V371, P1927, DOI 10.1016/S0140-6736(08)60602-9
   Schwartz SM, 2008, OBESITY, V16, P623, DOI 10.1038/oby.2007.96
   Tsai AG, 2009, J GEN INTERN MED, V24, P1073, DOI 10.1007/s11606-009-1042-5
   Turk MW, 2009, J CARDIOVASC NURS, V24, P58, DOI 10.1097/01.JCN.0000317471.58048.32
   Yamada K, 2008, J NUTR, V138, P1192S, DOI 10.1093/jn/138.6.1192S
   Yoshida T, 1996, CLIN EXP PHARMACOL P, V23, P476, DOI 10.1111/j.1440-1681.1996.tb02764.x
   YOSHIDA T, 1995, INT J OBESITY, V19, P717
   YOSHIDA T, 1994, INT J CLIN PHARM RES, V14, P125
   Yoshiike N, 2002, OBES REV, V3, P183, DOI 10.1046/j.1467-789X.2002.00070.x
NR 25
TC 5
Z9 6
U1 0
U2 3
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPAN
SN 1347-8613
EI 
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD APR 15
PY 2011
VL 115
IS 4
BP 476
EP 480
DI 10.1254/jphs.10R36FM
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 755IM
UT WOS:000289922700010
PM 21436603
DA 2025-04-28
ER

PT J
AU Olthof, MR
   van Dijk, AE
   Deacon, CF
   Heine, RJ
   van Dam, RM
AF Olthof, Margreet R.
   van Dijk, Aimee E.
   Deacon, Carolyn F.
   Heine, Robert J.
   van Dam, Rob M.
TI Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on incretin hormones
SO NUTRITION & METABOLISM
LA English
DT Article
ID glucose-tolerance; consumption; secretion; plasma; risk
AB Coffee consumption is associated with a lower risk of type 2 diabetes. We tested the hypothesis that this is mediated by incretin hormones by measuring the acute effects of decaffeinated coffee and coffee components on GLP-1 and GIP concentrations. A randomized cross-over trial of the effects of 12 g decaffeinated coffee, 1 g chlorogenic acid, 500 mg trigonelline, and placebo on total and intact GLP-1 and GIP concentrations during an oral glucose tolerance test took place in fifteen overweight men. No treatment significantly affected the overall GLP-1 or GIP secretion pattern following an OGTT relative to placebo. Decaffeinated coffee slightly increased total GLP-1 concentration 30 minutes after ingestion (before the OGTT) relative to placebo (2.7 pmol/L, p = 0.03), but this change did not correspond with changes in glucose or insulin secretion. These findings do not support the hypothesis that coffee acutely improves glucose tolerance through effects on the secretion of incretin hormones. Chronic effects of coffee and its major components still need to be investigated.
C1 [Olthof, Margreet R.; van Dijk, Aimee E.] Vrije Univ Amsterdam, Dept Hlth Sci, Amsterdam, Netherlands.
   [Olthof, Margreet R.; van Dijk, Aimee E.] Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands.
   [Deacon, Carolyn F.] Univ Copenhagen, Panum Inst, Dept Biomed Sci, DK-1168 Copenhagen, Denmark.
   [Heine, Robert J.] Vrije Univ Amsterdam, Med Ctr, Dept Endocrinol, Ctr Diabet, Amsterdam, Netherlands.
   [van Dam, Rob M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Epidemiol & Publ Hlth, Singapore 117595, Singapore.
   [van Dam, Rob M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore.
C3 Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; University of Copenhagen; Vrije Universiteit Amsterdam; National University of Singapore; National University of Singapore
RP Olthof, MR (corresponding author), Vrije Univ Amsterdam, Dept Hlth Sci, Amsterdam, Netherlands.
EM margreet.olthof@falw.vu.nl
FU Dutch Diabetes Research Foundation [2006.11.020]
CR Bassoli BK, 2008, CELL BIOCHEM FUNCT, V26, P320, DOI 10.1002/cbf.1444
   Clifford MN, 1999, J SCI FOOD AGR, V79, P362, DOI 10.1002/(SICI)1097-0010(19990301)79:3<362::AID-JSFA256>3.0.CO;2-D
   de Sotillo DVR, 2002, J NUTR BIOCHEM, V13, P717, DOI 10.1016/S0955-2863(02)00231-0
   Greenberg JA, 2010, DIABETES CARE, V33, P278, DOI 10.2337/dc09-1539
   Johnston KL, 2003, AM J CLIN NUTR, V78, P728, DOI 10.1093/ajcn/78.4.728
   McCarty MF, 2005, MED HYPOTHESES, V64, P848, DOI 10.1016/j.mehy.2004.03.037
   Minamisawa M, 2004, ANAL SCI, V20, P325, DOI 10.2116/analsci.20.325
   MISHKINSKY J, 1967, LANCET, V2, P1311
   van Dam RM, 2006, DIABETES CARE, V29, P398, DOI 10.2337/diacare.29.02.06.dc05-1512
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
   van Dijk AE, 2009, DIABETES CARE, V32, P1023, DOI 10.2337/dc09-0207
   Vilsboll T, 2003, J CLIN ENDOCR METAB, V88, P2706, DOI 10.1210/jc.2002-021873
   Vollmer K, 2008, DIABETES, V57, P678, DOI 10.2337/db07-1124
NR 13
TC 57
Z9 60
U1 0
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1743-7075
J9 NUTR METAB
JI Nutr. Metab.
PD FEB 7
PY 2011
VL 8
IS 
BP 
EP 
DI 10.1186/1743-7075-8-10
PG 4
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 724WE
UT WOS:000287606200001
PM 21299855
DA 2025-04-28
ER

PT J
AU Tsutsumi, H
   Kinoshita, Y
   Sato, T
   Ishizu, T
AF Tsutsumi, Hiroyuki
   Kinoshita, Yoshifumi
   Sato, Takashi
   Ishizu, Takashi
TI Configurational Studies of Complexes of Various Tea Catechins and Caffeine in Crystal State
SO CHEMICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE (+)-catechin; (-)-epicatechin; (-)-catechin-3-O-gallate; caffeine; intermolecular interaction; X-ray crystallographic analysis
ID antibacterial activity; gallocatechin gallate; polyphenols; inhibition; obesity
AB Crystals of the complexes of (+)-catechin (CA) of non-galloylated catechin and (-)-catechin-3-O-gallate (Cg) of galloylated catechin with caffeine were prepared, and their stereochemical structures and intermolecular interactions were determined by X-ray crystallographic analysis. CA formed a 1:1 complex with caffeine by intermolecular hydrogen bonds, whereas Cg formed a 1: 2 complex with caffeine, which was formed by face-to-face and offset pi-pi interactions and intermolecular hydrogen bonds. A solution of two kinds of non-galloylated catechin, CA and (-)-epicatechin (EC), and caffeine (molar ratio 1 :1 : 2) in water afforded a 1 :1 : 2 complex, the crystal structure of which had two layers, one layer in which CA and caffeine formed alternate lines and an other layer in which EC and caffeine formed alternate lines. The 1 :1 : 2 complex was formed by offset pi-pi and CH-pi interactions and intermolecular hydrogen bonds.
C1 [Tsutsumi, Hiroyuki; Kinoshita, Yoshifumi; Sato, Takashi; Ishizu, Takashi] Fukuyama Univ, Fac Pharm & Pharmaceut Sci, Hiroshima 7290292, Japan.
C3 Fukuyama University
RP Ishizu, T (corresponding author), Fukuyama Univ, Fac Pharm & Pharmaceut Sci, 1 Sanzo Gakuen Cho, Hiroshima 7290292, Japan.
EM ishizu@fupharm.fukuyama-u.ac.jp
CR Unknown -, 1997, SHELX97, V0, P0
   Beurskens PT, 1999, THE DIRDIF99 PROGRAM SYSTEM, V0, P0
   Bose M, 2008, J NUTR, V138, P1677, DOI 10.1093/jn/138.9.1677
   BURLA MC, 2005, SIR2004, V0, P0
   CAI Y, 1990, J CHEM SOC PERK T 2, V0, PP2197, DOI 10.1039/p29900002197
   CARRUTHERS JR, 1999, CRYSTALS ISSUE 11, V0, P0
   Frei B, 2003, J NUTR, V133, P3275S, DOI 10.1093/jn/133.10.3275S
   FUKAI K, 1991, AGR BIOL CHEM TOKYO, V55, P1895, DOI 10.1080/00021369.1991.10870886
   GAFFNEY SH, 1986, J CHEM SOC CHEM COMM, V0, PP107, DOI 10.1039/c39860000107
   HARA Y, 1989, J JPN SOC FOOD SCI, V36, P951
   Hayashi N, 2004, BIOSCI BIOTECH BIOCH, V68, P2512, DOI 10.1271/bbb.68.2512
   Hayashi N, 2008, J ORG CHEM, V73, P4848, DOI 10.1021/jo800406e
   HORMAN I, 1972, J FOOD SCI, V37, P925, DOI 10.1111/j.1365-2621.1972.tb03705.x
   Isemura M, 2000, BIOFACTORS, V13, P81, DOI 10.1002/biof.5520130114
   Ishizu T, 2010, CHEM LETT, V39, P607, DOI 10.1246/cl.2010.607
   Ishizu T, 2009, CHEM LETT, V38, P230, DOI 10.1246/cl.2009.230
   Ishizu T, 2009, TETRAHEDRON LETT, V50, P4121, DOI 10.1016/j.tetlet.2009.04.113
   Leone M, 2003, CANCER RES, V63, P8118
   MARTIN R, 1987, PHYTOCHEMISTRY, V26, P273, DOI 10.1016/S0031-9422(00)81527-7
   MARUYAMA N, 1991, PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON TEA SCIENCE, V0, P145
   MIURA S, 1994, BIOL PHARM BULL, V17, P1567
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Okabe S, 1997, JPN J CANCER RES, V88, P639, DOI 10.1111/j.1349-7006.1997.tb00431.x
   Qiong Guo, 1999, BIOCHIMICA ET BIOPHYSICA ACTA, V1427, P13
   *RIG RIG AM AM, 2000, CRYSTALSTRUCTURE 3 8, V0, P0
   Shiota S, 1999, BIOL PHARM BULL, V22, P1388, DOI 10.1248/bpb.22.1388
   Tezuka M, 1997, JPN J TOX ENV HEALTH, V43, P311
   Tsutsumi H, 2010, CHEM PHARM BULL, V58, P572, DOI 10.1248/cpb.58.572
NR 28
TC 15
Z9 15
U1 2
U2 21
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0009-2363
EI 
J9 CHEM PHARM BULL
JI Chem. Pharm. Bull.
PD AUG 15
PY 2011
VL 59
IS 8
BP 1008
EP 1015
DI 10.1248/cpb.59.1008
PG 8
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 815HJ
UT WOS:000294516400014
PM 21804246
DA 2025-04-28
ER

PT J
AU Machado, LMM
   da Costa, THM
   da Silva, EF
   Dórea, JG
AF Machado, Liliane M. M.
   da Costa, Teresa H. M.
   da Silva, Eduardo F.
   Dorea, Jose G.
TI Association of Moderate Coffee Intake with Self-Reported Diabetes among Urban Brazilians
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE coffee intake; diabetes mellitus; chlorogenic acids; caffeine; body mass index
ID impaired glucose-tolerance; consumption; risk; validity; weight; adults; tea
AB Coffee has been associated with reductions in the risk of non-communicable chronic diseases (NCCD), including diabetes mellitus. Because differences in food habits are recognizable modifying factors in the epidemiology of diabetes, we studied the association of coffee consumption with type-2 diabetes in a sample of the adult population of the Federal District, Brazil. This cross-sectional study was conducted by telephone interview (n = 1,440). A multivariate analysis was run controlling for socio-behavioural variables, obesity and family antecedents of NCCD. A hierarchical linear regression model and a Poisson regression were used to verify association of type-2 diabetes and coffee intake. The independent variables which remained in the final model, following the hierarchical inclusion levels, were: first level-age and marital status; second level-diabetes and dyslipidaemias in antecedents; third level-cigarette smoking, supplement intake, body mass index; and fourth level-coffee intake (<= 100 mL/d, 101 to 400 mL/day, and >400 mL/day). After adjusting hierarchically for the confounding variables, consumers of 100 to 400 mL of coffee/day had a 2.7% higher (p = 0.04) prevalence of not having diabetes than those who drank less than 100 mL of coffee/day. Compared to coffee intake of <= 100 mL/day, adults consuming >400 mL of coffee/day showed no statistically significant difference in the prevalence of diabetes. Thus, moderate coffee intake is favourably associated with self-reported type-2 diabetes in the studied population. This is the first study to show a relationship between coffee drinking and diabetes in a Brazilian population.
C1 [Machado, Liliane M. M.; da Costa, Teresa H. M.; Dorea, Jose G.] Univ Brasilia, Fac Ciencias Saude, Nucleo Nutr, Lab Bioquim Nutr, BR-70910900 Brasilia, DF, Brazil.
   [da Silva, Eduardo F.] Univ Brasilia, Dept Estat, Inst Ciencias Exatas, BR-70910900 Brasilia, DF, Brazil.
C3 Universidade de Brasilia; Universidade de Brasilia
RP da Costa, THM (corresponding author), Univ Brasilia, Fac Ciencias Saude, Nucleo Nutr, Lab Bioquim Nutr, Campus Univ Darcy Ribeiro Asa Norte, BR-70910900 Brasilia, DF, Brazil.
EM liliane.machado25@gmail.com; thmdacosta@gmail.com; edufrei@unb.br; dorea@rudah.com.br
FU CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Coordination for Improved Capacity of Post-Graduate Level Staff); CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-National Council for Scientific and Technological Development) [402834/2005-4]
CR Agardh EE, 2004, J INTERN MED, V255, P645, DOI 10.1111/j.1365-2796.2004.01331.x
   American Heart Association (AHA), 2010, DRINK SUG SWEET BEV, V0, P0
   Unknown -, 2005, BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM, V0, P0
   Unknown -, 2005, PREVENTING CHRONIC DISEASES: A VITAL INVESTMENT, V0, P0
   Unknown -, 2000, DIETARY REFERENCE INTAKES FOR VITAMIN C, V0, P0
   Ärnlöv J, 2004, JAMA-J AM MED ASSOC, V291, P1199, DOI 10.1001/jama.291.10.1199-b
   Barros Aluisio J D, 2003, BMC MED RES METHODOL, V3, P21, DOI 10.1186/1471-2288-3-21
   Battram DS, 2006, J NUTR, V136, P1276, DOI 10.1093/jn/136.5.1276
   Bidel S, 2008, COFFEE RISK TYPE 2 D, V0, P0
   Czerny M, 1999, J AGR FOOD CHEM, V47, P695, DOI 10.1021/jf980759i
   de Moraes SA, 2010, CAD SAUDE PUBLICA, V26, P929, DOI 10.1590/S0102-311X2010000500015
   del Castillo MD, 2002, J AGR FOOD CHEM, V50, P3698, DOI 10.1021/jf011702q
   Dórea JG, 2005, BRIT J NUTR, V93, P773, DOI 10.1079/BJN20051370
   Farah A, 2006, J AGR FOOD CHEM, V54, P374, DOI 10.1021/jf0518305
   Ferruzzi MG, 2010, PHYSIOL BEHAV, V100, P33, DOI 10.1016/j.physbeh.2010.01.035
   Færch K, 2005, J NUTR, V135, P1177, DOI 10.1093/jn/135.5.1177
   Peixoto MDG, 2006, REV SAUDE PUBL, V40, P1065, DOI 10.1590/S0034-89102006000700015
   Isogawa A, 2003, LANCET, V361, P703, DOI 10.1016/S0140-6736(03)12586-X
   Loopstra-Masters RC, 2011, DIABETOLOGIA, V54, P320, DOI 10.1007/s00125-010-1957-8
   Louie JCY, 2008, ASIA PAC J CLIN NUTR, V17, P657
   Moisey LL, 2008, AM J CLIN NUTR, V87, P1254, DOI 10.1093/ajcn/87.5.1254
   Mougios V, 2003, J APPL PHYSIOL, V94, P476, DOI 10.1152/japplphysiol.00624.2002
   Nelson DE, 2001, SOZ PRAVENTIV MED, V46, P0
   Nettleton JA, 2008, DIABETES CARE, V31, P1777, DOI 10.2337/dc08-0760
   Nicoli MC, 1997, FOOD SCI TECHNOL-LEB, V30, P292, DOI 10.1006/fstl.1996.0181
   Odegaard AO, 2008, AM J CLIN NUTR, V88, P979, DOI 10.1093/ajcn/88.4.979
   Panagiotakos Demosthenes B, 2007, REV DIABET STUD, V4, P105, DOI 10.1900/RDS.2007.4.105
   Pereira MA, 2006, ARCH INTERN MED, V166, P1311, DOI 10.1001/archinte.166.12.1311
   Petrocelli JV, 2003, MEAS EVAL COUNS DEV, V36, P9, DOI 10.1080/07481756.2003.12069076
   Rosengren A, 2004, J INTERN MED, V255, P89, DOI 10.1046/j.1365-2796.2003.01260.x
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   SALVAGGIO A, 1991, AM J EPIDEMIOL, V134, P149, DOI 10.1093/oxfordjournals.aje.a116067
   Sartorelli DS, 2010, AM J CLIN NUTR, V91, P1002, DOI 10.3945/ajcn.2009.28741
   SCHMIDT MI, 1993, REV SAUDE PUBL, V27, P271, DOI 10.1590/S0034-89101993000400007
   Sistema IBGE de recuperacao automatica (SIDRA), 2000, BANC DAD AGR DAD CEN, V0, P0
   Soriguer F, 2004, ANN INTERN MED, V141, P321, DOI 10.7326/0003-4819-141-4-200408170-00017
   Trugo L C, 2003, ENCYCLOPEDIA OF FOOD SCIENCES AND NUTRITION, V3, P1498
   Van Dam RM, 2003, ANN NUTR METAB, V47, P319
   van Dam RM, 2004, DIABETOLOGIA, V47, P2152, DOI 10.1007/s00125-004-1573-6
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   VelasquezMelendez G, 1997, REV SAUDE PUBL, V31, P157, DOI 10.1590/S0034-89101997000200009
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Yamaji T, 2004, DIABETOLOGIA, V47, P2145, DOI 10.1007/s00125-004-1590-5
NR 44
TC 6
Z9 7
U1 0
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD AUG 15
PY 2011
VL 8
IS 8
BP 3216
EP 3231
DI 10.3390/ijerph8083216
PG 16
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health
GA 811WP
UT WOS:000294248600011
PM 21909302
DA 2025-04-28
ER

PT J
AU Szeitz-Szabó, M
   Bíró, L
   Bíró, G
   Sali, J
AF Szeitz-Szabo, M.
   Biro, L.
   Biro, Gy
   Sali, J.
TI DIETARY SURVEY IN HUNGARY, 2009. PART I. MACRONUTRIENTS, ALCOHOL, CAFFEINE, FIBRE
SO ACTA ALIMENTARIA
LA English
DT Article
DE nutrition survey; food consumption; nutrient intake; energy intake; fatty acid pattern; cholesterol intake; risk assessment
AB In 2009 Hungarian Food Safety Office (HFSO) performed a countrywide representative dietary survey to obtain food consumption data for quantitative food safety risk assessment utilizable in the field of public health nutrition as well. The consumption of foodstuffs, daily energy-and nutrient intakes, nutritional habits and dietary supplement usage of Hungarian population was assessed. The complex system has included three-day dietary record and a food consumption frequency questionnaire. Some anthropometric parameters were also self-recorded. According to the body mass index, a considerable proportion of both the 31-60 years old males (69%) and females (46%) were overweight or obese. The energy intake of the Hungarian adult population is slightly exceeds the recommendation. The intake of proteins is satisfactory in general. The average intake of total fats is very high (36.1-38.9 energy percent), and the fatty acid composition - mostly the ratio of n-6/n-3 fatty acids - is unfavourable, but the fatty acid pattern regarding saturated-(SFA), mono-(MUFA) and polyunsaturated (PUFA) fatty acid ratio shows favourable tendency. The proportion of complex carbohydrates within the intake of energy providing macronutrients is far lower than the optimal level, but it is a positive finding that added sugar intake is below the outmost recommendation. The average daily cholesterol intake is high (males: 469 mg, females: 335 mg), whilst the dietary fibre intake is lower than the recommended. The article provides data on alcohol, caffeine and fibre consumption, too.
C1 [Szeitz-Szabo, M.; Biro, Gy; Sali, J.] Hungarian Food Safety Off, H-1097 Budapest, Hungary.
   [Biro, L.] NutriComp Nutr & Hlth Co, H-1091 Budapest, Hungary.
RP Szeitz-Szabó, M (corresponding author), Hungarian Food Safety Off, Gyali Ut 2-6, H-1097 Budapest, Hungary.
EM szabo.maria@mebih.gov.hu
CR Unknown -, 1985, TECHN REP SER, V0, P0
   Antal M, 2005, UJ TAPANYAGTABLAZAT, V0, P19
   Biro G, 1996, EUR J CLIN NUTR, V50, P201
   BIRO GY, 1992, AZ ELSO MAGYARORSZAG, V1, P0
   Biro L, 2005, EGESZSEGTUDOMANY, V49, P145
   BIRO L, 1999, DIABETOLOGIA HUNGARI, V7, P243
   GOLDBERG GR, 1991, EUR J CLIN NUTR, V45, P569
   Lajos Biro, 2007, ORVOSI HETILAP, V148, P703, DOI 10.1556/OH.2007.28017
   Rodler Imre, 2005, ORV HETIL, V146, P1781
   Schofield W N, 1985, HUM NUTR CLIN NUTR, V39 Suppl 1, P5
   *WHO, 2004, EUR SER WHO REG PUBL, V96, P0
   WHO, 2003, DIET NUTR PREV CHRON, V0, P0
   Zajkas Gabor, 2007, ORVOSI HETILAP, V148, P1593, DOI 10.1556/OH.2007.28182
NR 14
TC 30
Z9 31
U1 0
U2 4
PU AKADEMIAI KIADO RT
PI BUDAPEST
PA PRIELLE K U 19, PO BOX 245,, H-1117 BUDAPEST, HUNGARY
SN 0139-3006
EI 1588-2535
J9 ACTA ALIMENT HUNG
JI Acta Aliment.
PD MAR 15
PY 2011
VL 40
IS 1
BP 142
EP 152
DI 10.1556/AAlim.40.2011.1.16
PG 11
WC Food Science & Technology; Nutrition & Dietetics
SC Food Science & Technology; Nutrition & Dietetics
GA 736LG
UT WOS:000288495600017
DA 2025-04-28
ER

PT J
AU Kubot, K
   Sumi, S
   Tojo, H
   Sumi-Inoue, Y
   I-Chin, H
   Oi, Y
   Fujita, H
   Urata, H
AF Kubot, Kazumitsu
   Sumi, Shunichiro
   Tojo, Hideaki
   Sumi-Inoue, Yukiko
   I-chin, Hou
   Oi, Yasuyuki
   Fujita, Hiroyuki
   Urata, Hidenori
TI Improvements of mean body mass index and body weight in preobese and overweight Japanese adults with black Chinese tea (Pu-Erh) water extract
SO NUTRITION RESEARCH
LA English
DT Article
DE Black Chinese tea; Obesity; Visceral fat area; Pu-Erh; Metabolic syndrome; Food for Specified Health Uses: Human
ID double-blind; gallic acid; fat; obesity; accumulation; cholesterol; borderline; catechins; caffeine; healthy
AB Water-soluble black Chinese (Pu-Erh) tea extract (BTE), which contains high gallic acid content, has been demonstrated to elicit antiobese effects in animals. Because gallic acid is related with the reduction of visceral fat and cholesterol contents and improvement of obesity in animals, we investigated the effects of BTE intake on 36 preobese Japanese adults (body mass index [BMI], >25-<30 kg/m(2)) in a 12-week double-blind, randomized, placebo-controlled group comparison study using powdered barley tea with or without (placebo) BTE. A follow-up 4-week period after BTE intake termination was monitored to observe the withdrawal effect. All subjects ingested barley tea with or without BTE (333 mg) before each of the 3 daily meals. In the BTE-treated group, the mean pretreament values of body weight and BMI significantly decreased after intake and after BTE withdrawal. However, the corresponding values scored significant differences only from 8 weeks after intake (vs the placebo-treated group). The mean values of the waist circumference indicated a similar tendency. Furthermore, coronal navel section (same anatomical position) images of computed tomography of all BTE- and non BTE-treated subjects revealed that the visceral fat areas (cm(2)) were significantly (P < .05) less in the former 12 weeks after BTE ingestion. Measured biochemical parameters did not indicate significant differences, and BTE-treated subjects did not complain of any adverse effects (abdominal distension, etc). Ingestion of BTE exhibited significant effects in reducing the mean waist circumference, BMI, and visceral fat values and might be useful for weight control and prevention of obesity development (or metabolic syndrome) in humans. Crown Copyright (C) 2011 Published by Elsevier Inc. All rights reserved.
C1 [I-chin, Hou; Oi, Yasuyuki; Fujita, Hiroyuki] Nippon Supplement Inc, Dept Res & Dev, Kita Ku, Osaka 5300013, Japan.
   [Kubot, Kazumitsu; Sumi, Shunichiro; Tojo, Hideaki; Sumi-Inoue, Yukiko; Urata, Hidenori] Fukuoka Univ, Chikushi Hosp, Dept Cardiovasc Dis, Fukuoka 8188502, Japan.
C3 Fukuoka University
RP Fujita, H (corresponding author), Nippon Supplement Inc, Dept Res & Dev, Kita Ku, 19-19 Chayamachi, Osaka 5300013, Japan.
EM fujita@nippon-sapuri.co.jp
FU R&D division of Nippon Supplement, Inc.
CR Unknown -, 2017, ANNEX 3-03, V0, P4
   Billington CJ, 2000, ARCH INTERN MED, V160, P898, DOI 10.1001/archinte.160.7.898
   Boschmann M, 2007, J AM COLL NUTR, V26, P389S, DOI 10.1080/07315724.2007.10719627
   Chacko Sabu M, 2010, CHIN MED, V5, P13, DOI 10.1186/1749-8546-5-13
   Field AE, 2001, ARCH INTERN MED, V161, P1581, DOI 10.1001/archinte.161.13.1581
   Fujita H, 2000, J FOOD SCI, V65, P564, DOI 10.1111/j.1365-2621.2000.tb16049.x
   Fujita H, 2001, J NUTR, V131, P2105, DOI 10.1093/jn/131.8.2105
   Fujita H, 2008, PHYTOTHER RES, V22, P1275, DOI 10.1002/ptr.2477
   Fujita H, 2008, ANN NUTR METAB, V53, P33, DOI 10.1159/000153006
   Fujita H, 2008, NUTR RES, V28, P450, DOI 10.1016/j.nutres.2008.04.005
   GARY DM, 2006, OBESITY, V139, P1219
   Heckman MA, 2010, J FOOD SCI, V75, PR77, DOI 10.1111/j.1750-3841.2010.01561.x
   Hosokawa M, 2010, ARCH BIOCHEM BIOPHYS, V504, P17, DOI 10.1016/j.abb.2010.05.031
   Hsu CL, 2007, BRIT J NUTR, V98, P727, DOI 10.1017/S000711450774686X
   IKEDA I, 1992, BIOCHIM BIOPHYS ACTA, V1127, P141, DOI 10.1016/0005-2760(92)90269-2
   Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245
   KEY TJ, 2002, LANCET, V288, P1723
   Kobayashi M, 2007, DIABETES, V56, P239, DOI 10.2337/db06-0353
   Kuo KL, 2005, J AGR FOOD CHEM, V53, P480, DOI 10.1021/jf049375k
   Lin JK, 1998, J AGR FOOD CHEM, V46, P3635, DOI 10.1021/jf980223x
   Lin JK, 2006, MOL NUTR FOOD RES, V50, P211, DOI 10.1002/mnfr.200500138
   Lin YS, 2003, J AGR FOOD CHEM, V51, P1864, DOI 10.1021/jf021066b
   MARIEPIERRE SO, 2008, J CLIN NUTR, V87, P621
   Matsuzawa Y, 2002, CIRC J, V66, P987, DOI 10.1253/circj.66.987
   Nagao T, 2000, J NUTR, V130, P792, DOI 10.1093/jn/130.4.792
   Najm W, 2010, PRIMARY CARE, V37, P237, DOI 10.1016/j.pop.2010.02.008
   TORIS T, 2007, NIPPON NOUGEIKAGAK S, V0, P261
   TSUCHIDA T, 2002, PROGR MED, V22, P2189
   Tsuji H, 2001, J NUTR, V131, P2853, DOI 10.1093/jn/131.11.2853
   Way TD, 2009, J AGR FOOD CHEM, V57, P5257, DOI 10.1021/jf900730e
   Yang TTC, 1997, PHARMACOL RES, V35, P505, DOI 10.1006/phrs.1997.0176
   Yoo HJ, 2010, J KOREAN MED SCI, V25, P49, DOI 10.3346/jkms.2010.25.1.49
NR 32
TC 61
Z9 72
U1 1
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
EI 
J9 NUTR RES
JI Nutr. Res.
PD JUN 15
PY 2011
VL 31
IS 6
BP 421
EP 428
DI 10.1016/j.nutres.2011.05.004
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 795AQ
UT WOS:000292944300002
PM 21745623
DA 2025-04-28
ER

PT J
AU Cherniack, EP
AF Cherniack, E. Paul
TI Polyphenols: Planting the seeds of treatment for the metabolic syndrome
SO NUTRITION
LA English
DT Review
DE Polyphenol; Metabolic syndrome
ID green tea polyphenol; pulp preparation rich; mediated oxidative stress; insoluble dietary fiber; reduces blood-pressure; insulin-resistance; cardiovascular-disease; endothelial function; proinflammatory cytokines; adipocyte differentiation
AB Greater understanding about the pathogenesis of metabolic syndrome and potential causes suggests that plant polyphenols might be useful as a treatment. Dietary excess energy can be stored in adipocytes, leading to the release of proinflammatory cytokines and adipose-related hormones that cause vascular injury. Plant polyphenols, organic compounds found in numerous plant species and their fruits, are being actively studied as potential treatments for components of the metabolic syndrome. Individual polyphenols that have been examined include resveratrol, quercetin, epigallocathechin-3-gallate, and curcumin. Resveratrol lowers weight, blood pressure, glucose, and insulin resistance in rodents, and a human trial is currently underway. Quercetin decreases lipid and glucose levels in obese rats, and in a human investigation of subjects with the metabolic syndrome has lowered blood pressure without significant alteration of lipids. Epigallocathechin-3-gallate-induced weight loss has attenuated glucose levels and insulin resistance in rodents and improved hemoglobin A(1c) and lipid in human studies. Plant extracts also can be used. Grape seed and chokeberry extracts have decreased blood pressure and lipid levels in small human trials. Other human investigations have shown the beneficial effects of cocoa, coffee, carob, and Momordica charantia. Thus far, most studies have involved a small number of subjects and have been of short duration. Future studies should be designed to account for a disease process in which the pathogenic factors may take place for years before disease manifestations take place, the possibly limited bioavailability of polyphenols, and the potential need to provide combinations or modifications of polyphenols. Published by Elsevier Inc.
C1 [Cherniack, E. Paul] Univ Miami, Miller Sch Med, Dept Med, Geriatr Inst,Div Gerontol & Geriatr Med, Miami, FL 33136 USA.
   [Cherniack, E. Paul] Bruce W Carter Vet Affairs Med Ctr, Miami, FL USA.
C3 University of Miami
RP Cherniack, EP (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Geriatr Inst,Div Gerontol & Geriatr Med, Miami, FL 33136 USA.
EM evan.cherniack@va.gov
CR Ahn J, 2008, J HEPATOL, V49, P1019, DOI 10.1016/j.jhep.2008.08.012
   Alexopoulos N, 2008, EUR J CARDIOV PREV R, V15, P300, DOI 10.1097/HJR.0b013e3282f4832f
   Altschuler JA, 2007, DIABETES CARE, V30, P813, DOI 10.2337/dc06-1871
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Anderson RA, 2008, P NUTR SOC, V67, P48, DOI 10.1017/S0029665108006010
   Baiges I, 2010, MOL CELL PROTEOMICS, V9, P1499, DOI 10.1074/mcp.M000055-MCP201
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Baur JA, 2010, MECH AGEING DEV, V131, P261, DOI 10.1016/j.mad.2010.02.007
   Beher D, 2009, CHEM BIOL DRUG DES, V74, P619, DOI 10.1111/j.1747-0285.2009.00901.x
   Berrougui H, 2009, ATHEROSCLEROSIS, V207, P420, DOI 10.1016/j.atherosclerosis.2009.05.017
   Bonita JS, 2007, PHARMACOL RES, V55, P187, DOI 10.1016/j.phrs.2007.01.006
   Boots AW, 2008, NUTRITION, V24, P703, DOI 10.1016/j.nut.2008.03.023
   Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200
   Bose M, 2008, J NUTR, V138, P1677, DOI 10.1093/jn/138.9.1677
   Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753-4887.1998.tb01670.x
   Broncel M, 2010, MED SCI MONITOR, V16, P0
   Brown AL, 2009, BRIT J NUTR, V101, P886, DOI 10.1017/S0007114508047727
   Campia U, 2008, J AM COLL CARDIOL, V51, P2150, DOI 10.1016/j.jacc.2008.02.058
   Chen N, 2009, NUTR RES, V29, P784, DOI 10.1016/j.nutres.2009.10.003
   Chou E, 2002, CIRCULATION, V105, P373, DOI 10.1161/hc0302.102143
   Cottart CH, 2010, MOL NUTR FOOD RES, V54, P7, DOI 10.1002/mnfr.200900437
   Dans AML, 2007, J CLIN EPIDEMIOL, V60, P554, DOI 10.1016/j.jclinepi.2006.07.009
   Desch S, 2010, AM J HYPERTENS, V23, P97, DOI 10.1038/ajh.2009.213
   Djousse L, 2010, ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, V10, P124
   Driessen MT, 2009, EUR J CLIN NUTR, V63, P536, DOI 10.1038/ejcn.2008.6
   Egert S, 2010, J NUTR, V140, P278, DOI 10.3945/jn.109.117655
   Egert S, 2009, BRIT J NUTR, V102, P1065, DOI 10.1017/S0007114509359127
   Ejaz A, 2009, J NUTR, V139, P919, DOI 10.3945/jn.108.100966
   Fischer-Posovszky P, 2010, AM J CLIN NUTR, V92, P5, DOI 10.3945/ajcn.2009.28435
   Floyd ZE, 2008, METABOLISM, V57, PS32, DOI 10.1016/j.metabol.2008.04.006
   Ford ES, 2005, DIABETES CARE, V28, P2745, DOI 10.2337/diacare.28.11.2745
   Fukino Y, 2008, EUR J CLIN NUTR, V62, P953, DOI 10.1038/sj.ejcn.1602806
   Fukushima Y, 2009, J AGR FOOD CHEM, V57, P11100, DOI 10.1021/jf901278u
   Gonzales AM, 2008, NUTR METAB, V5, P0, DOI 10.1186/1743-7075-5-17
   Graham TE, 2006, NEW ENGL J MED, V354, P2552, DOI 10.1056/NEJMoa054862
   Gruendel S, 2006, J NUTR, V136, P1533, DOI 10.1093/jn/136.6.1533
   Gruendel S, 2007, BRIT J NUTR, V98, P1170, DOI 10.1017/S0007114507777127
   Gruendel S, 2007, BRIT J NUTR, V98, P101, DOI 10.1017/S0007114507701642
   Guarente L, 2006, NATURE, V444, P868, DOI 10.1038/nature05486
   Hanhineva K, 2010, INT J MOL SCI, V11, P1365, DOI 10.3390/ijms11041365
   Heiss C, 2010, J AM COLL CARDIOL, V56, P218, DOI 10.1016/j.jacc.2010.03.039
   Hininger-Favier I, 2009, J AM COLL NUTR, V28, P355, DOI 10.1080/07315724.2009.10718097
   Hino A, 2007, DIABETES RES CLIN PR, V76, P383, DOI 10.1016/j.diabres.2006.09.033
   Huang KC, 2008, OBESITY, V16, P684, DOI 10.1038/oby.2007.112
   Jia L, 2010, AM J CLIN NUTR, V92, P218, DOI 10.3945/ajcn.2009.28202
   Khan A, 2003, DIABETES CARE, V26, P3215, DOI 10.2337/diacare.26.12.3215
   Kim HY, 2010, BRIT J NUTR, V103, P502, DOI 10.1017/S0007114509991978
   Kim NH, 2008, PFLUG ARCH EUR J PHY, V457, P293, DOI 10.1007/s00424-008-0537-y
   Knutson MD, 2008, NUTR REV, V66, P591, DOI 10.1111/j.1753-4887.2008.00109.x
   Kovacs P, 2007, DIABETES, V56, P3095, DOI 10.2337/db06-1647
   Lee DH, 2007, PANCREAS, V35, P53, DOI 10.1097/01.mpa.0000278676.58491.ef
   Li CH, 2006, J BIOL CHEM, V281, P10214, DOI 10.1074/jbc.M512792200
   Li HL, 2006, FREE RADICAL BIO MED, V40, P1756, DOI 10.1016/j.freeradbiomed.2006.01.005
   Li RW, 2006, J ETHNOPHARMACOL, V104, P24, DOI 10.1016/j.jep.2005.08.045
   Lin J, 2005, OBES RES, V13, P982, DOI 10.1038/oby.2005.115
   Maki KC, 2009, J NUTR, V139, P264, DOI 10.3945/jn.108.098293
   Marshall Stephen, 2006, SCI STKE, V2006, P0
   Martínez-Flórez S, 2005, J NUTR, V135, P1359, DOI 10.1093/jn/135.6.1359
   Morishita R, 1998, J ATHEROSCLER THROMB, V4, P128
   Muthusamy VS, 2010, BRIT J NUTR, V0, P1
   Nerurkar PV, 2010, BMC COMPLEM ALTERN M, V10, P0, DOI 10.1186/1472-6882-10-34
   Palsamy P, 2008, BIOMED PHARMACOTHER, V62, P598, DOI 10.1016/j.biopha.2008.06.037
   Palsamy P, 2010, CHEM-BIOL INTERACT, V186, P200, DOI 10.1016/j.cbi.2010.03.028
   Palsamy P, 2010, J CELL PHYSIOL, V224, P423, DOI 10.1002/jcp.22138
   Peng N, 2009, J AGR FOOD CHEM, V57, P7268, DOI 10.1021/jf901169y
   Pérez YY, 2007, AM J CHINESE MED, V35, P1037, DOI 10.1142/S0192415X07005491
   Pinent M, 2005, INT J OBESITY, V29, P934, DOI 10.1038/sj.ijo.0802988
   Potenza MA, 2007, AM J PHYSIOL-ENDOC M, V292, PE1378, DOI 10.1152/ajpendo.00698.2006
   Poudyal H, 2010, J NUTR, V140, P946, DOI 10.3945/jn.109.117812
   Ramadan G, 2009, BRIT J NUTR, V102, P1611, DOI 10.1017/S000711450999208X
   Rivera L, 2008, OBESITY, V16, P2081, DOI 10.1038/oby.2008.315
   Rivera L, 2009, BIOCHEM PHARMACOL, V77, P1053, DOI 10.1016/j.bcp.2008.11.027
   Robich MP, 2010, SURGERY, V148, P453, DOI 10.1016/j.surg.2010.04.013
   Rocha KKR, 2009, FOOD CHEM TOXICOL, V47, P1362, DOI 10.1016/j.fct.2009.03.010
   Ruiz PA, 2007, J NUTR, V137, P1208, DOI 10.1093/jn/137.5.1208
   Scalbert Augustin, 2000, JOURNAL OF NUTRITION, V130, P0
   Silha JV, 2005, INT J OBESITY, V29, P1308, DOI 10.1038/sj.ijo.0802987
   Sivaprakasapillai B, 2009, METABOLISM, V58, P1743, DOI 10.1016/j.metabol.2009.05.030
   Skoczynska A, 2007, PHARMACOL REP, V59, P177
   Solà R, 2010, ATHEROSCLEROSIS, V211, P630, DOI 10.1016/j.atherosclerosis.2010.03.010
   Szkudelska K, 2009, J STEROID BIOCHEM, V113, P17, DOI 10.1016/j.jsbmb.2008.11.001
   Tongia Abhishek, 2004, INDIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, V48, P241
   Vachharajani V, 2009, IUBMB LIFE, V61, P424, DOI 10.1002/iub.169
   Valcheva-Kuzmanova S, 2007, PLANT FOOD HUM NUTR, V62, P19, DOI 10.1007/s11130-006-0036-2
   Vanschoonbeek K, 2006, J NUTR, V136, P977, DOI 10.1093/jn/136.4.977
   Yang JY, 2008, LIFE SCI, V82, P1032, DOI 10.1016/j.lfs.2008.03.003
   Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711
   Yin Jun, 2008, ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, V8, P99, DOI 10.2174/187153008784534330
   Yu SW, 2008, MOL CANCER THER, V7, P2609, DOI 10.1158/1535-7163.MCT-07-2400
   Zern TL, 2005, J NUTR, V135, P1911, DOI 10.1093/jn/135.8.1911
   Ziegenfuss TN, 2006, J INT SOC SPORT NUTR, V3, P0, DOI 10.1186/1550-2783-3-2-45
NR 97
TC 93
Z9 110
U1 2
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0899-9007
EI 1873-1244
J9 NUTRITION
JI Nutrition
PD JUN 15
PY 2011
VL 27
IS 6
BP 617
EP 623
DI 10.1016/j.nut.2010.10.013
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA V44LJ
UT WOS:000209750200001
PM 21367579
DA 2025-04-28
ER

PT J
AU Tsutsumi, H
   Sato, T
   Ishizu, T
AF Tsutsumi, Hiroyuki
   Sato, Takashi
   Ishizu, Takashi
TI Stereochemical Structure and Intermolecular Interaction of Complexes of (-)-Gallocatechin-3-O-gallate and Caffeine
SO CHEMICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE (-)-gallocatechin-3-O-gallate caffeine; X ray crystallographic analysis; intermolecular interaction
ID tea catechins; antioxidant activity; polyphenols; gallate; obesity; liver; rats; fat
AB A suspension containing an equimolecular amount of (-)-gallocatechin-3-O-gallate (GCg) and caffeine in water was heated at 90 degrees C for 30 min to give a 1 2 complex of GCg and caffeine X-Ray crystallographic analysis of crystal of the 1 2 complex showed that pi-pi interactions formed between the A, B' rings of GCg and the two six-membered rings of caffeine Whereas, the same suspension was heated at 90 degrees C for 30 s to give a sticky substance, which contained GCg, caffeine, and water at a molar ratio of 1 1 22 based on measurement of the integral volume of H-1-NMR signals The sticky substance crystallized slowly to give a 2 2 complex of GCg and caffeine X-Ray crystallographic analysis of crystal of the 2 2 complex showed that the A and C rings of GCg moieties faced each other, and face-to-face pi-pi interactions formed between the B ring of GCg and caffeine, the B' ring of GCg and caffeine
C1 [Tsutsumi, Hiroyuki; Sato, Takashi; Ishizu, Takashi] Fukuyama Univ, Fac Pharm & Pharmaceut Sci, Hiroshima 7290292, Japan.
C3 Fukuyama University
RP Ishizu, T (corresponding author), Fukuyama Univ, Fac Pharm & Pharmaceut Sci, 1 Sanzo Gakuen Cho, Hiroshima 7290292, Japan.
CR Unknown -, 1997, SHELX97, V0, P0
   Beurskens PT, 1999, DIRD1F 99 PROGR SYST, V0, P0
   Bose M, 2008, J NUTR, V138, P1677, DOI 10.1093/jn/138.9.1677
   BURLA MC, 2003, SIR2002, V0, P0
   BURLA MC, 2005, SIR2004, V0, P0
   CAI Y, 1990, J CHEM SOC PERK T 2, V0, PP2197, DOI 10.1039/p29900002197
   Frei B, 2003, J NUTR, V133, P3275S, DOI 10.1093/jn/133.10.3275S
   FUKAI K, 1991, AGR BIOL CHEM TOKYO, V55, P1895, DOI 10.1080/00021369.1991.10870886
   Gaffney SH, 1986, CHEM COMMUN, V2, P107
   Guo Q, 1999, BBA-GEN SUBJECTS, V1427, P13, DOI 10.1016/S0304-4165(98)00168-8
   Hayashi N, 2004, BIOSCI BIOTECH BIOCH, V68, P2512, DOI 10.1271/bbb.68.2512
   HORMAN I, 1972, J FOOD SCI, V37, P925, DOI 10.1111/j.1365-2621.1972.tb03705.x
   Ikeda I, 2005, J NUTR, V135, P155, DOI 10.1093/jn/135.2.155
   Isemura M, 2000, BIOFACTORS, V13, P81, DOI 10.1002/biof.5520130114
   Ishizu T, 2009, TETRAHEDRON LETT, V50, P4121, DOI 10.1016/j.tetlet.2009.04.113
   Lee SM, 2008, LIPIDS, V43, P419, DOI 10.1007/s11745-008-3167-4
   Leone M, 2003, CANCER RES, V63, P8118
   MARTIN R, 1987, PHYTOCHEMISTRY, V26, P273, DOI 10.1016/S0031-9422(00)81527-7
   Martin R, 1986, CHEM COMMUN, V2, P105
   MARUYAMA N, 1991, PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON TEA SCIENCE, V0, P145
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Shiota S, 1999, BIOL PHARM BULL, V22, P1388, DOI 10.1248/bpb.22.1388
   Tsutsumi H, 2010, CHEM PHARM BULL, V58, P230
NR 25
TC 7
Z9 7
U1 0
U2 19
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0009-2363
EI 
J9 CHEM PHARM BULL
JI Chem. Pharm. Bull.
PD JAN 15
PY 2011
VL 59
IS 1
BP 100
EP 105
DI 10.1248/cpb.59.100
PG 6
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 699XS
UT WOS:000285696800015
PM 21212555
DA 2025-04-28
ER

PT J
AU Wang, Y
   Nakagawa, Y
   Liu, L
   Wang, W
   Ren, X
   Anghel, A
   Lutfy, K
   Friedman, TC
   Liu, Y
AF Wang, Y.
   Nakagawa, Y.
   Liu, L.
   Wang, W.
   Ren, X.
   Anghel, A.
   Lutfy, K.
   Friedman, T. C.
   Liu, Y.
TI Tissue-specific dysregulation of hexose-6-phosphate dehydrogenase and glucose-6-phosphate transporter production in db/db mice as a model of type 2 diabetes
SO DIABETOLOGIA
LA English
DT Article
DE 11 beta-HSD1; G6PT; G6PT inhibitor; H6PDH; H6PDH siRNA; Insulin resistance; NADPH; Type 2 diabetes
ID beta-hydroxysteroid dehydrogenase; 11-beta-hydroxysteroid dehydrogenase; glucocorticoid-receptor; endoplasmic-reticulum; insulin-resistance; adipose-tissue; obesity; hepatocytes; expression; hyperglycemia
AB Tissue-specific amplification of glucocorticoid action through 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) affects the development of the metabolic syndrome. Hexose-6-phosphate dehydrogenase (H6PDH) mediates intracellular NADPH availability for 11 beta-HSD1 and depends on the glucose-6-phosphate transporter (G6PT). Little is known about the tissue-specific alterations of H6PDH and G6PT and their contributions to local glucocorticoid action in db/db mice. We characterised the role of H6PDH and G6PT in pre-receptor metabolism of glucocorticoids by examining the production of the hepatic 11 beta-HSD1-H6PDH-G6PT system in db/db mice. We observed that increased production of hepatic H6PDH in db/db mice was paralleled by upregulation of hepatic G6PT production and responded to elevated circulating levels of corticosterone. Treatment of db/db mice with the glucocorticoid antagonist RU486 markedly reduced production of both H6PDH and 11 beta-HSD1 and improved hyperglycaemia and insulin resistance. The reduction of H6PDH and 11 beta-HSD1 production by RU486 was accompanied by RU486-induced suppression of hepatic G6pt (also known as Slc37a4) mRNA. Incubation of mouse primary hepatocytes with corticosterone enhanced G6PT and H6PDH production with corresponding activation of 11 beta-HSD1 and PEPCK: effects that were blocked by RU486. Knockdown of H6pd by small interfering RNA showed effects comparable with those of RU486 for attenuating the corticosterone-induced H6PDH production and 11-HSD1 reductase activity in these intact cells. Addition of the G6PT inhibitor chlorogenic acid to primary hepatocytes suppressed H6PDH production. These findings suggest that increased hepatic H6PDH and G6PT production contribute to 11 beta-HSD1 upregulation of local glucocorticoid action that may be related to the development of type 2 diabetes.
C1 [Wang, Y.; Wang, W.; Ren, X.; Anghel, A.; Lutfy, K.; Friedman, T. C.; Liu, Y.] Univ Calif Los Angeles, Sch Med, Charles Drew Univ Med & Sci, Div Endocrinol Metab & Mol Med, Los Angeles, CA 90059 USA.
   [Nakagawa, Y.] Hamamatsu Univ Sch Med, Dept Pediat, Hamamatsu, Shizuoka 4313192, Japan.
   [Liu, L.] Shanghai Jiao Tong Univ, Dept Endocrinol & Metab, Affiliated Peoples Hosp 6, Shanghai Diabet Inst, Shanghai 200030, Peoples R China.
C3 University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Charles R. Drew University of Medicine & Science; Hamamatsu University School of Medicine; Shanghai Jiao Tong University
RP Liu, Y (corresponding author), Univ Calif Los Angeles, Sch Med, Charles Drew Univ Med & Sci, Div Endocrinol Metab & Mol Med, 1731 E 120th St, Los Angeles, CA 90059 USA.
EM dryanjunliu@hotmail.com
FU NIH [KO1 DK073272, SC1DK087655, R01 DA14659, K21 DA00276];  [S21MD000103-NIH/NCMHD]
CR Alberts P, 2002, DIABETOLOGIA, V45, P1528, DOI 10.1007/s00125-002-0959-6
   Andrews RC, 2003, J CLIN ENDOCR METAB, V88, P285, DOI 10.1210/jc.2002-021194
   Atanasov AG, 2004, FEBS LETT, V571, P129, DOI 10.1016/j.febslet.2004.06.065
   Balachandran A, 2008, ENDOCRINOLOGY, V149, P4069, DOI 10.1210/en.2008-0088
   Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245
   Bánhegyi G, 2004, J BIOL CHEM, V279, P27017, DOI 10.1074/jbc.M404159200
   Belkaid A, 2006, CANCER CELL INT, V6, P0, DOI 10.1186/1475-2867-6-7
   Björntorp P, 2000, NUTRITION, V16, P924, DOI 10.1016/S0899-9007(00)00422-6
   Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8
   Chou Janice Yang, 2002, CURRENT MOLECULAR MEDICINE (HILVERSUM), V2, P121, DOI 10.2174/1566524024605798
   Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214
   Friedman JE, 1997, J BIOL CHEM, V272, P31475, DOI 10.1074/jbc.272.50.31475
   Havel PJ, 1996, AM J PHYSIOL-REG I, V271, PR710, DOI 10.1152/ajpregu.1996.271.3.R710
   Hewitt KN, 2005, ENDOCRINOLOGY, V146, P2539, DOI 10.1210/en.2005-0117
   Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532
   Hiraiwa H, 2001, DNA CELL BIOL, V20, P447, DOI 10.1089/104454901316976073
   Hsu CL, 2006, J AGR FOOD CHEM, V54, P4191, DOI 10.1021/jf0609882
   JAMIESON PM, 1995, ENDOCRINOLOGY, V136, P4754, DOI 10.1210/en.136.11.4754
   Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842
   Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924
   Lavery GG, 2006, J BIOL CHEM, V281, P6546, DOI 10.1074/jbc.M512635200
   Liu YJ, 2008, J MOL ENDOCRINOL, V41, P53, DOI 10.1677/JME-08-0004
   Liu YJ, 2006, ENDOCRINOLOGY, V147, P5061, DOI 10.1210/en.2006-0243
   Liu YJ, 2005, DIABETES, V54, P32, DOI 10.2337/diabetes.54.1.32
   Liu YJ, 2003, DIABETES, V52, P1409, DOI 10.2337/diabetes.52.6.1409
   Marcolongo P, 2008, BIOCHEM PHARMACOL, V76, P382, DOI 10.1016/j.bcp.2008.05.027
   Marcolongo P, 2007, ENDOCRINOLOGY, V148, P2487, DOI 10.1210/en.2006-1472
   Mason PJ, 1999, BLOOD CELL MOL DIS, V25, P30, DOI 10.1006/bcmd.1999.0224
   Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285
   McCormick KL, 2006, J BIOL CHEM, V281, P341, DOI 10.1074/jbc.M506026200
   Mziaut H, 1999, J BIOL CHEM, V274, P14122, DOI 10.1074/jbc.274.20.14122
   Nakano S, 2007, AM J PHYSIOL-ENDOC M, V292, PE1213, DOI 10.1152/ajpendo.00340.2006
   Nammi S, 2007, AM J PHYSIOL-REG I, V292, PR1101, DOI 10.1152/ajpregu.00255.2006
   Napolitano A, 1998, J STEROID BIOCHEM, V64, P251, DOI 10.1016/S0960-0760(97)00200-8
   NIEMAN LK, 1985, J CLIN ENDOCR METAB, V61, P536, DOI 10.1210/jcem-61-3-536
   Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762
   Opherk C, 2004, MOL ENDOCRINOL, V18, P1346, DOI 10.1210/me.2003-0283
   OZOLS J, 1993, P NATL ACAD SCI USA, V90, P5302, DOI 10.1073/pnas.90.11.5302
   Paterson JM, 2004, P NATL ACAD SCI USA, V101, P7088, DOI 10.1073/pnas.0305524101
   Piccirella S, 2006, J BIOL CHEM, V281, P4671, DOI 10.1074/jbc.M509406200
   Rajan V, 1996, J NEUROSCI, V16, P65
   RIZZA RA, 1982, J CLIN ENDOCR METAB, V54, P131, DOI 10.1210/jcem-54-1-131
   Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371
   SHIMOMURA Y, 1987, HORM METAB RES, V19, P295, DOI 10.1055/s-2007-1011804
   Stewart PM, 1999, J CLIN ENDOCR METAB, V84, P1022, DOI 10.1210/jc.84.3.1022
   Taylor AI, 2009, HORM METAB RES, V41, P899, DOI 10.1055/s-0029-1234071
   Tiosano D, 2003, J CLIN ENDOCR METAB, V88, P379, DOI 10.1210/jc.2002-020511
   Üçkaya G, 2008, DIABETES RES CLIN PR, V82, PS135, DOI 10.1016/j.diabres.2008.09.022
   Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513
   Walker EA, 2007, J BIOL CHEM, V282, P27030, DOI 10.1074/jbc.M704144200
   Wang SJY, 2006, DIABETOLOGIA, V49, P1333, DOI 10.1007/s00125-006-0239-y
NR 51
TC 22
Z9 23
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD FEB 15
PY 2011
VL 54
IS 2
BP 440
EP 450
DI 10.1007/s00125-010-1956-9
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 703SO
UT WOS:000286001800030
PM 21052977
DA 2025-04-28
ER

PT J
AU Nicotra, G
AF Nicotra, Giovanna
TI Obesity and natural dietary supplements
SO AGRO FOOD INDUSTRY HI-TECH
LA English
DT Review
DE Obesity; overweight; dietary supplements; BMI; energy expenditure; thermogenesis; Griffonia; Guarana; Common Bean; Green Tea
ID phaseolus-vulgaris; weight-loss; efficacy; caffeine; ephedrine; placebo
C1 EPO Srl Ist Farmochim Fitoterap, I-20141 Milan, Italy.
RP Nicotra, G (corresponding author), EPO Srl Ist Farmochim Fitoterap, Via Stadera 19, I-20141 Milan, Italy.
CR ASTRUP A, 1992, INT J OBESITY, V16, P269
   Barrett ML, 2011, NUTR J, V10, P0, DOI 10.1186/1475-2891-10-24
   Berube-Parent S, 1900, V94, V0, P432
   Boozer CN, 1900, V26, V0, P593
   Capasso F, 2006, FITOTERAPIA, V0, P455
   Carai MAM, 2009, DIABETES METAB SYNDR, V2, P145, DOI 10.2147/DMSO.S4236
   Celleno Leonardo, 2007, INT J MED SCI, V4, P45
   Chevalier A, 1996, ENCY MED PLANTS, V0, P243
   Diepvens K, 2007, AM J PHYSIOL-REG I, V292, PR77, DOI 10.1152/ajpregu.00832.2005
   Duke JA, 1983, HANDBOOK OF ENERGY CROPS, V0, P0
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Li MF, 2011, WORLD J DIABETES, V2, P19, DOI 10.4239/wjd.v2.i2.19
   Opala T, 2006, EUR J MED RES, V11, P343
   Rondanelli M, 2009, INT J OBESITY, V33, P1174, DOI 10.1038/ijo.2009.155
   Singh DK, 2009, J NUTR BIOCHEM, V20, P816, DOI 10.1016/j.jnutbio.2008.07.011
   Thielecke F, 2009, PHYTOCHEMISTRY, V70, P11, DOI 10.1016/j.phytochem.2008.11.011
   World Health Organization (WHO), 2011, FACT SHEET 311, V0, P0
NR 19
TC 0
Z9 0
U1 0
U2 15
PU TEKNOSCIENZE PUBL
PI MILANO
PA VIALE BRIANZA 22, 20127 MILANO, ITALY
SN 1722-6996
EI 2035-4606
J9 AGRO FOOD IND HI TEC
JI Agro Food Ind. Hi-Tech
PD NOV-DEC 15
PY 2011
VL 22
IS 6
BP 26
EP 29
DI 
PG 4
WC Biotechnology & Applied Microbiology; Food Science & Technology
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 872TW
UT WOS:000298833600006
DA 2025-04-28
ER

PT J
AU Gyntelberg, F
   Hein, HO
   Suadicani, P
AF Gyntelberg, Finn
   Hein, Hans Ole
   Suadicani, Poul
TI Determinants of Obesity Among Men with the Lewis Double-Negative Blood Group: A Genetic Marker of Obesity-The Copenhagen Male Study
SO METABOLIC SYNDROME AND RELATED DISORDERS
LA English
DT Article
ID coffee consumption; glucose-tolerance; risk
AB Objective: Middle-aged and elderly men with the Lewis blood group phenotype Le(a-b-), have a two-fold higher prevalence of obesity than others. We investigated if the association could be ascribed to differences in lifestyle, or if obesity determinants had a different impact in this group. Method: This was a cross-sectional study of 3,290 men aged 53-74 years with a mean of 63 years drawn from the Copenhagen Male Study. The main outcome measure was prevalence of obesity [body mass index (BMI) >= 30 (kg/m(2))]. Results: Among men with the Le(a-b-) phenotype (n = 315), the prevalence of obesity was 15.6%; it was 8.1% among men with other phenotypes (n = 2,975, p<0.001). Obesity-related life style habits did not differ between Le(a-b-) and other men. In multiple logistic regression analyses, the role of obesity covariates was conspicuously different between men with the Le(a-b-) phenotype and men with other Lewis phenotypes. However, among Le(a-b-) men, a much stronger inverse association was found between high coffee consumption (>7 cups/day vs. less) and obesity, and between lacking fat avoidance and obesity; the odds ratio [95% confidence interval (CI)] for high coffee consumption was 0.2(0.1-0.7) and for avoidance of fatty foods 2.0(1.04-3.7). The association of obesity with leisure time physical activity, smoking, alcohol use, use of sugar in hot beverages, and tea consumption, did not differ between Le(a-b-) men and others. Conclusions: Our findings suggests a gene-environment interaction between lifestyle and obesity. Because some ethnic groups have up to 40% with the Le(a-b-) phenotype, the above observations may be of significant public health interest.
C1 [Gyntelberg, Finn; Hein, Hans Ole; Suadicani, Poul] Univ Copenhagen, Bispebjerg Hosp, Epidemiol Res Unit, Dept Occupat & Environm Med, DK-2400 Copenhagen NV, Denmark.
   [Hein, Hans Ole] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark.
C3 University of Copenhagen; Bispebjerg Hospital; Copenhagen University Hospital; University of Copenhagen; Copenhagen University Hospital
RP Gyntelberg, F (corresponding author), Univ Copenhagen, Bispebjerg Hosp, Epidemiol Res Unit, Dept Occupat & Environm Med, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.
EM fgyn0001@bbhregionh.dk
CR Agardh EE, 2004, J INTERN MED, V255, P645, DOI 10.1111/j.1365-2796.2004.01331.x
   Unknown -, 1998, OB PREV MAN GLOB EP, V0, P0
   GYNTELBERG F, 1973, DAN MED BULL, V20, P1
   GYNTELBERG F, 1975, DAN MED BULL, V22, P81
   HEIN HO, 1992, J INTERN MED, V232, P481, DOI 10.1111/j.1365-2796.1992.tb00620.x
   Hein HO, 2005, INT J OBESITY, V29, P540, DOI 10.1038/sj.ijo.0802923
   Hosmer D, 1989, APPL LOGISTIC REGRES, V0, P0
   KLEINBAUM DG, 1982, EPIDEMIOLOGICAL RES, V0, PCH19
   Mourant AE, 1976, DISTRIBUTION HUMAN B, V0, P0
   NORUSIS M, 1997, SPSS WINDOWS PROFESS, V0, P0
   NORUSIS MJ, 1997, SPSS WINDOWS BASE SY, V0, P0
   Omvik Per, 1996, BLOOD PRESSURE, V5, P71, DOI 10.3109/08037059609062111
   Petrie HJ, 2004, AM J CLIN NUTR, V80, P22
   Suadicani P, 2005, EUR J CARDIOV PREV R, V12, P236, DOI 10.1097/00149831-200506000-00009
   SUADICANI P, 1994, INT J EPIDEMIOL, V23, P293, DOI 10.1093/ije/23.2.293
   Tuomilehto J, 2004, JAMA-J AM MED ASSOC, V291, P1213, DOI 10.1001/jama.291.10.1213
NR 16
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-4196
EI 1557-8518
J9 METAB SYNDR RELAT D
JI Metab. Syndr. Relat. Disord.
PD APR 15
PY 2011
VL 9
IS 2
BP 99
EP 103
DI 10.1089/met.2010.0044
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 741EY
UT WOS:000288847200004
PM 21117959
DA 2025-04-28
ER

PT J
AU Giri, A
   Sturgeon, SR
   Luisi, N
   Bertone-Johnson, E
   Balasubramanian, R
   Reeves, KW
AF Giri, Ayush
   Sturgeon, Susan R.
   Luisi, Nicole
   Bertone-Johnson, Elizabeth
   Balasubramanian, Raji
   Reeves, Katherine W.
TI Caffeinated Coffee, Decaffeinated Coffee and Endometrial Cancer Risk: A Prospective Cohort Study among US Postmenopausal Women
SO NUTRIENTS
LA English
DT Article
DE coffee; endometrial cancer; estrogen; insulin; body mass index
ID hormone-binding globulin; chlorogenic acid; dietary factors; consumption; insulin; premenopausal; polymorphisms; epidemiology; secretion; obesity
AB There is plausible biological evidence as well as epidemiologic evidence to suggest coffee consumption may lower endometrial cancer risk. We evaluated the associations between self-reported total coffee, caffeinated coffee and decaffeinated coffee, and endometrial cancer risk using the Women's Health Initiative Observational Study Research Materials obtained from the National Heart, Lung, and Blood Institute Biological Specimen and Data Repository Coordinating Center. Our primary analyses included 45,696 women and 427 incident endometrial cancer cases, diagnosed over a total of 342,927 person-years of follow-up. We used Cox-proportional hazard models to evaluate coffee consumption and endometrial cancer risk. Overall, we did not find an association between coffee consumption and endometrial cancer risk. Compared to non-daily drinkers (none or <1 cup/day), the multivariable adjusted hazard ratios for women who drank >= 4 cups/day were 0.86 (95% confidence interval (CI) 0.63, 1.18) for total coffee, 0.89 (95% CI 0.63, 1.27) for caffeinated coffee, and 0.51 (95% CI 0.25, 1.03) for decaf coffee. In subgroup analyses by body mass index (BMI) there were no associations among normal-weight and overweight women for total coffee and caffeinated coffee. However among obese women, compared to the referent group (none or <1 cup/day), the hazard ratios for women who drank >= 2 cups/day were: 0.72 (95% CI 0.50, 1.04) for total coffee and 0.66 (95% CI 0.45, 0.97) for caffeinated coffee. Hazard ratios for women who drank >= 2 cups/day for decaffeinated coffee drinkers were 0.67 (0.43-1.06), 0.93 (0.55-1.58) and 0.80 (0.49-1.30) for normal, overweight and obese women, respectively. Our study suggests that caffeinated coffee consumption may be associated with lower endometrial cancer risk among obese postmenopausal women, but the association with decaffeinated coffee remains unclear.
C1 [Giri, Ayush; Sturgeon, Susan R.; Luisi, Nicole; Bertone-Johnson, Elizabeth; Balasubramanian, Raji; Reeves, Katherine W.] Univ Massachusetts Amherst, Dept Publ Hlth, Sch Publ Hlth & Hlth Sci, Div Biostat & Epidemiol, Amherst, MA 01003 USA.
C3 Massachusetts Department of Public Health; University of Massachusetts System; University of Massachusetts Amherst
RP Reeves, KW (corresponding author), Univ Massachusetts Amherst, Dept Publ Hlth, Sch Publ Hlth & Hlth Sci, Div Biostat & Epidemiol, 715 N Pleasant St, Amherst, MA 01003 USA.
EM agiri@schoolph.umass.edu; ssturgeon@schoolph.umass.edu; nluisi@schoolph.umass.edu; ebertone@schoolph.umass.edu; rbalasub@schoolph.umass.edu; kwreeves@schoolph.umass.edu
CR Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61
   Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874
   Ärnlöv J, 2004, JAMA-J AM MED ASSOC, V291, P1199, DOI 10.1001/jama.291.10.1199-b
   Bandera EV, 2009, CANCER CAUSE CONTROL, V20, P1117, DOI 10.1007/s10552-009-9336-9
   Clifford MN, 2000, J SCI FOOD AGR, V80, P1118, DOI 10.1002/(SICI)1097-0010(20000515)80:7<1118::AID-JSFA570>3.0.CO;2-9
   Curb JD, 2003, ANN EPIDEMIOL, V13, PS122, DOI 10.1016/S1047-2797(03)00048-6
   ELWOOD JM, 1977, JNCI-J NATL CANCER I, V59, P1055, DOI 10.1093/jnci/59.4.1055
   Ferrini RL, 1996, AM J EPIDEMIOL, V144, P642, DOI 10.1093/oxfordjournals.aje.a008975
   Friberg E, 2007, DIABETOLOGIA, V50, P1365, DOI 10.1007/s00125-007-0681-5
   Friberg E, 2009, INT J CANCER, V125, P2413, DOI 10.1002/ijc.24543
   Goto A, 2011, DIABETES, V60, P269, DOI 10.2337/db10-1193
   GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O
   Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502
   Horn-Ross PL, 2003, J NATL CANCER I, V95, P1158, DOI 10.1093/jnci/djg015
   Johnston KL, 2003, AM J CLIN NUTR, V78, P728, DOI 10.1093/ajcn/78.4.728
   Kaaks R, 2002, CANCER EPIDEM BIOMAR, V11, P1531
   Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842
   Kalandidi A, 1996, ONCOLOGY, V53, P354
   KAZER RR, 1995, INT J CANCER, V62, P403, DOI 10.1002/ijc.2910620408
   Kotsopoulos J, 2009, CANCER-AM CANCER SOC, V115, P2765, DOI 10.1002/cncr.24328
   LEVI F, 1993, CANCER, V71, P3575, DOI 10.1002/1097-0142(19930601)71:11<3575::AID-CNCR2820711119>3.0.CO;2-0
   LONDON S, 1991, AM J CLIN NUTR, V53, P166, DOI 10.1093/ajcn/53.1.166
   Lukanova A, 2004, INT J CANCER, V108, P425, DOI 10.1002/ijc.11529
   McCann SE, 2009, INT J CANCER, V124, P1650, DOI 10.1002/ijc.24125
   Mikhailova ON, 2006, PHARMACOGENOMICS J, V6, P189, DOI 10.1038/sj.tpj.6500365
   Nagamani M, 1998, AM J OBSTET GYNECOL, V179, P6, DOI 10.1016/S0002-9378(98)70244-3
   Nagata C, 1998, NUTR CANCER, V30, P21, DOI 10.1080/01635589809514635
   NESTLER JE, 1991, J CLIN ENDOCR METAB, V72, P83, DOI 10.1210/jcem-72-1-83
   PARAZZINI F, 1991, AM J OBSTET GYNECOL, V164, P522, DOI 10.1016/S0002-9378(11)80012-8
   Purdie DM, 2001, BEST PRACT RES CL OB, V15, P341, DOI 10.1053/beog.2000.0180
   Sachse C, 2003, BRIT J CLIN PHARMACO, V55, P68, DOI 10.1046/j.1365-2125.2003.01733.x
   Shimazu T, 2008, INT J CANCER, V123, P2406, DOI 10.1002/ijc.23760
   STENSVOLD I, 1994, CANCER CAUSE CONTROL, V5, P401, DOI 10.1007/BF01694753
   Svilaas A, 2004, J NUTR, V134, P562, DOI 10.1093/jn/134.3.562
   Williams CJ, 2008, DIABETES CARE, V31, P504, DOI 10.2337/dc07-1952
   World Cancer Research Fund, 2007, FOOD NUTR PHYS ACT P, V0, P0
   Wu TY, 2005, DIABETES CARE, V28, P1390, DOI 10.2337/diacare.28.6.1390
   Yu XF, 2011, BMC CANCER, V11, P0, DOI 10.1186/1471-2407-11-96
   Zeleniuch-Jacquotte A, 2001, BRIT J CANCER, V84, P975, DOI 10.1054/bjoc.2001.1704
NR 39
TC 30
Z9 33
U1 0
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD NOV 15
PY 2011
VL 3
IS 11
BP 937
EP 950
DI 10.3390/nu3110937
PG 14
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 864OH
UT WOS:000298249000003
PM 22254087
DA 2025-04-28
ER

PT J
AU Inoue, N
   Nagao, K
   Nomura, S
   Shirouchi, B
   Inafuku, M
   Hirabaru, H
   Nakahara, N
   Nishizono, S
   Tanaka, T
   Yanagita, T
AF Inoue, Nao
   Nagao, Koji
   Nomura, Saori
   Shirouchi, Bungo
   Inafuku, Masashi
   Hirabaru, Hideaki
   Nakahara, Noriaki
   Nishizono, Shoko
   Tanaka, Takashi
   Yanagita, Teruyoshi
TI Effect of Vaccinium ashei reade Leaf Extracts on Lipid Metabolism in Obese OLETF Rats
SO BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE blueberry leaf; flavonol glycoside; proanthocyanidin; lipid metabolism; Otsuka Long-Evans Tokushima Fatty rat
ID c-reactive protein; blueberry; leaves; proanthocyanidins; consumption; oxidation; capacity; diseases; tannins; enzyme
AB The effects of a hot water extract and fractional extracts from rabbiteye blueberry (Vaccinium ashei reade) leaves (BBL) on lipid metabolism were studied in obese Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Feeding the hot water extract and fractional extracts from BBL alleviated hepatic triglyceride accumulation in the rats. Additionally, feeding with the flavonol glycoside (FG) and proanthocyanidin (PA) fractions lowered serum cholesterol levels in the obese rats. The results from measurements of the hepatic enzyme activity indicate that the hypolipidemic effects of the hot water extract and the PA fraction might be attributable to enhanced lipolysis in the liver. The reduced serum levels of C-reactive protein, an inflammatory cytokine, by the chlorogenic acid + rutin fraction and FG fraction might be associated with alleviating the metabolic abnormalities in obese rats. These results indicate that the BBL extracts, and especially FG and PA, exerted hypolipidemic effects on obese OLETF rats and suggest that an infusion of BBL can be useful as a dietary hypolipidemic component.
C1 [Inoue, Nao; Nagao, Koji; Nomura, Saori; Shirouchi, Bungo; Inafuku, Masashi; Yanagita, Teruyoshi] Saga Univ, Dept Appl Biochem & Food Sci, Saga 8408502, Japan.
   [Inoue, Nao] Tohoku Univ, Grad Sch Agr Sci, Sendai, Miyagi 9818555, Japan.
   [Hirabaru, Hideaki; Nakahara, Noriaki] Unkai Shuzo Co Ltd, Res Inst, Miyazaki 8801303, Japan.
   [Nishizono, Shoko] Miyazaki Univ, Cooperat Res Ctr, Miyazaki 8801303, Japan.
   [Tanaka, Takashi] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528521, Japan.
C3 Saga University; Tohoku University; University of Miyazaki; Nagasaki University
RP Yanagita, T (corresponding author), Saga Univ, Dept Appl Biochem & Food Sci, Saga 8408502, Japan.
EM yanagitt@cc.saga-u.ac.jp
FU Japanese Ministry of Education, Culture, Sports, Science, and Technology; Grants-in-Aid for Scientific Research [23700899, 23580173] Funding Source: KAKEN
CR Bisoendial RJ, 2007, ATHEROSCLEROSIS, V195, PE10, DOI 10.1016/j.atherosclerosis.2007.04.053
   Bladé C, 2010, MOL NUTR FOOD RES, V54, P37, DOI 10.1002/mnfr.200900476
   Cignarella A, 1996, THROMB RES, V84, P311, DOI 10.1016/S0049-3848(96)00195-8
   Del Bas JM, 2008, MOL NUTR FOOD RES, V52, P1172, DOI 10.1002/mnfr.200800054
   Fernandez ML, 2006, NUTR METAB, V3, P0, DOI 10.1186/1743-7075-3-17
   FLETCHER MJ, 1968, CLIN CHIM ACTA, V22, P393, DOI 10.1016/0009-8981(68)90041-7
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Formiguera X, 2004, BEST PRACT RES CL GA, V18, P1125, DOI 10.1016/j.bpg.2004.06.030
   Fukuda N, 2011, J NUTR SCI VITAMINOL, V57, P144, DOI 10.3177/jnsv.57.144
   KAWANO K, 1992, DIABETES, V41, P1422, DOI 10.2337/diabetes.41.11.1422
   KELLEY DS, 1986, BIOCHEM J, V235, P87, DOI 10.1042/bj2350087
   KISSEBAH AH, 1994, PHYSIOL REV, V74, P761, DOI 10.1152/physrev.1994.74.4.761
   Li RW, 2006, J ETHNOPHARMACOL, V104, P24, DOI 10.1016/j.jep.2005.08.045
   Li XC, 2002, J NAT PROD, V65, P1909, DOI 10.1021/np020289t
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MARKWELL MAK, 1973, J BIOL CHEM, V248, P3433
   Martineau LC, 2006, PHYTOMEDICINE, V13, P612, DOI 10.1016/j.phymed.2006.08.005
   Matsuo Y, 2010, FOOD CHEM, V121, P1073, DOI 10.1016/j.foodchem.2010.01.052
   Mizrahi A, 2009, BRIT J NUTR, V102, P1075, DOI 10.1017/S0007114509359097
   Montonen J, 2005, EUR J CLIN NUTR, V59, P441, DOI 10.1038/sj.ejcn.1602094
   Moran TH, 1998, AM J PHYSIOL-REG I, V274, PR618, DOI 10.1152/ajpregu.1998.274.3.R618
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Murase T, 2005, AM J PHYSIOL-REG I, V288, PR708, DOI 10.1152/ajpregu.00693.2004
   Nagao K, 2008, BIOSCI BIOTECH BIOCH, V72, P1619, DOI 10.1271/bbb.80036
   Nagao K, 2008, PROG LIPID RES, V47, P127, DOI 10.1016/j.plipres.2007.12.002
   Nanri A, 2007, ASIAN PAC J CANCER P, V8, P167
   Neto CC, 2007, MOL NUTR FOOD RES, V51, P652, DOI 10.1002/mnfr.200600279
   OCHOA S, 1955, METHOD ENZYMOL, V1, P739, DOI 10.1016/0076-6879(55)01129-4
   Piljac-Zegarac J, 2009, J MED FOOD, V12, P608, DOI 10.1089/jmf.2008.0081
   Sakaida H, 2007, BIOSCI BIOTECH BIOCH, V71, P2335, DOI 10.1271/bbb.70277
   Serrano J, 2009, MOL NUTR FOOD RES, V53, PS310, DOI 10.1002/mnfr.200900039
   SPERRY WM, 1950, J BIOL CHEM, V187, P97
   Takeshita M, 2009, J BIOL CHEM, V284, P21165, DOI 10.1074/jbc.M109.004945
   TANAKA T, 1994, J CHEM SOC PERK T 1, V0, PP3013, DOI 10.1039/p19940003013
   Zafra-Stone S, 2007, MOL NUTR FOOD RES, V51, P675, DOI 10.1002/mnfr.200700002
NR 35
TC 21
Z9 22
U1 0
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0916-8451
EI 1347-6947
J9 BIOSCI BIOTECH BIOCH
JI Biosci. Biotechnol. Biochem.
PD DEC 15
PY 2011
VL 75
IS 12
BP 2304
EP 2308
DI 10.1271/bbb.110451
PG 5
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Chemistry, Applied; Food Science & Technology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Chemistry; Food Science & Technology
GA 871YX
UT WOS:000298774700007
PM 22146710
DA 2025-04-28
ER

PT J
AU Matsuda, Y
   Kobayashi, M
   Yamauchi, R
   Ojika, M
   Hiramitsu, M
   Inoue, T
   Katagiri, T
   Murai, A
   Horio, F
AF Matsuda, Yuji
   Kobayashi, Misato
   Yamauchi, Rie
   Ojika, Makoto
   Hiramitsu, Masanori
   Inoue, Takashi
   Katagiri, Takao
   Murai, Atsushi
   Horio, Fumihiko
TI Coffee and Caffeine Improve Insulin Sensitivity and Glucose Tolerance in C57BL/6J Mice Fed a High-Fat Diet
SO BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE coffee; caffeine; diet-induced impaired glucose tolerance; antidiabetic effect; insulin resistance
ID type-2 diabetes-mellitus; tumor-necrosis-factor; cytokine signaling-3; chlorogenic acid; liver-disease; resistance; consumption; obesity; risk; expression
AB We have previously demonstrated that coffee and caffeine ameliorated hyperglycemia in spontaneously diabetic KK-A(y) mice. This present study evaluates the antidiabetic effects of coffee and caffeine on high-fat-diet-induced impaired glucose tolerance in C57BL/6J mice. C57BL/6J mice fed a high-fat diet were given regular drinking water (control group), or a 2.5-fold-diluted coffee or caffeine solution (200 mg/L) for 17 weeks. The ingestion of Coffee or caffeine improved glucose tolerance, insulin sensitivity, and hyperinsulinemia when compared with mice in the control group. The adipose tissue mRNA levels of inflammatory adipocytokines (MCP-1 and IL-6) and the liver mRNA levels of genes related to fatty acid synthesis were lower in the coffee and caffeine groups than those in the control group. These results suggest that coffee and caffeine exerted an ameliorative effect on high-fat-diet-induced impaired glucose tolerance by improving insulin sensitivity. This effect might be attributable in part to the reduction of inflammatory adipocytokine expression.
C1 [Matsuda, Yuji; Kobayashi, Misato; Yamauchi, Rie; Ojika, Makoto; Murai, Atsushi; Horio, Fumihiko] Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan.
C3 Nagoya University
RP Horio, F (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan.
EM horiof@agr.nagoya-u.ac.jp
FU All Japan Coffee Association; Grants-in-Aid for Scientific Research [21380079] Funding Source: KAKEN
CR Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x
   Dray C, 2007, J PHYSIOL BIOCHEM, V63, P329, DOI 10.1007/BF03165764
   Egawa T, 2009, METABOLISM, V58, P1609, DOI 10.1016/j.metabol.2009.05.013
   Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/0264-6021:3490013
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Fukushima Y, 2009, J AGR FOOD CHEM, V57, P11100, DOI 10.1021/jf901278u
   Goto A, 2011, DIABETES, V60, P269, DOI 10.2337/db10-1193
   Hemmerle H, 1997, J MED CHEM, V40, P137, DOI 10.1021/jm9607360
   HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183
   Huang ZL, 2005, NAT NEUROSCI, V8, P858, DOI 10.1038/nn1491
   Huxley R, 2009, ARCH INTERN MED, V169, P2053, DOI 10.1001/archinternmed.2009.439
   Ide T, 2004, NAT CELL BIOL, V6, P351, DOI 10.1038/ncb1111
   Jung EH, 2007, J AGR FOOD CHEM, V55, P9800, DOI 10.1021/jf0714463
   Jung UJ, 2006, J PHARMACOL EXP THER, V318, P476, DOI 10.1124/jpet.106.105163
   Kagami K, 2008, J PHARM PHARMACOL, V60, P1161, DOI 10.1211/jpp.60.9.0007
   Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, P0
   Lorenzo M, 2008, J ANIM SCI, V86, P0
   Malecki MT, 2005, DIABETES RES CLIN PR, V68, PS10, DOI 10.1016/j.diabres.2005.03.003
   McCarty MF, 2005, MED HYPOTHESES, V64, P848, DOI 10.1016/j.mehy.2004.03.037
   MISHKINSKY J, 1967, LANCET, V2, P1311
   Murase T, 2011, AM J PHYSIOL-ENDOC M, V300, PE122, DOI 10.1152/ajpendo.00441.2010
   Parillo M, 2004, BRIT J NUTR, V92, P7, DOI 10.1079/BJN20041117
   Postic C, 2008, J CLIN INVEST, V118, P829, DOI 10.1172/JCI34275
   REBUFFESCRIVE M, 1993, METABOLISM, V42, P1405, DOI 10.1016/0026-0495(93)90190-Y
   Sacks DB, 1996, AM J CLIN PATHOL, V105, P149
   Samuel VT, 2007, J CLIN INVEST, V117, P739, DOI 10.1172/JCI30400
   Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200
   Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100
   Senn JJ, 2003, J BIOL CHEM, V278, P13740, DOI 10.1074/jbc.M210689200
   Shearer J, 2007, CAN J PHYSIOL PHARM, V85, P823, DOI 10.1139/Y07-070
   Shi H, 2004, J BIOL CHEM, V279, P34733, DOI 10.1074/jbc.M403886200
   Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832
   SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
   Yamauchi R, 2010, J AGR FOOD CHEM, V58, P5597, DOI 10.1021/jf904062c
   Yoshinari O, 2010, CURR MED CHEM, V17, P2196, DOI 10.2174/092986710791299902
NR 38
TC 44
Z9 48
U1 1
U2 39
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0916-8451
EI 1347-6947
J9 BIOSCI BIOTECH BIOCH
JI Biosci. Biotechnol. Biochem.
PD DEC 15
PY 2011
VL 75
IS 12
BP 2309
EP 2315
DI 10.1271/bbb.110452
PG 7
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Chemistry, Applied; Food Science & Technology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Chemistry; Food Science & Technology
GA 871YX
UT WOS:000298774700008
PM 22146708
DA 2025-04-28
ER

PT J
AU Hursel, R
   Westerterp-Plantenga, MS
AF Hursel, Rick
   Westerterp-Plantenga, Margriet S.
TI Consumption of Milk-Protein Combined with Green Tea Modulates Diet-Induced Thermogenesis
SO NUTRIENTS
LA English
DT Article
DE obesity; catechins; polyphenol-protein complexes; energy expenditure
ID black tea; antioxidant capacity; energy-expenditure; fat oxidation; body-weight; polyphenols; caffeine; flavonoids; extracts; humans
AB Green tea and protein separately are able to increase diet-induced thermogenesis. Although their effects on long-term weight-maintenance were present separately, they were not additive. Therefore, the effect of milk-protein (MP) in combination with green tea on diet-induced thermogenesis (DIT) was examined in 18 subjects (aged 18-60 years; BMI: 23.0 +/- 2.1 kg/m(2)). They participated in an experiment with a randomized, 6 arms, crossover design, where energy expenditure and respiratory quotient (RQ) were measured. Green tea (GT) vs. placebo (PL) capsules were either given in combination with water or with breakfasts containing milk protein in two different dosages: 15 g (15 MP) (energy% P/C/F: 15/47/38; 1.7 MJ/500 mL), and 3.5 g (3.5 MP) (energy% P/C/F: 41/59/0; 146.4 kJ/100 mL). After measuring resting energy expenditure (REE) for 30 min, diet-induced energy expenditure was measured for another 3.5 h after the intervention. There was an overall significant difference observed between conditions (p < 0.001). Post-hoc, areas under the curve (AUCs) for diet-induced energy expenditure were significantly different (P <= 0.001) for GT + water (41.11 [91.72] kJ.3.5 h) vs. PL + water (10.86 [28.13] kJ.3.5 h), GT + 3.5 MP (10.14 [54.59] kJ.3.5 h) and PL + 3.5 MP (12.03 [34.09] kJ.3.5 h), but not between GT + 3.5 MP, PL + 3.5 MP and PL + water, indicating that MP inhibited DIT following GT. DIT after GT + 15 MP (167.69 [141.56] kJ.3.5 h) and PL + 15 MP (168.99 [186.56] kJ.3.5 h) was significantly increased vs. PL + water (P < 0.001), but these were not different from each other indicating that 15 g MP stimulated DIT, but inhibited the GT effect on DIT. No significant differences in RQ were seen between conditions for baseline and post-treatment. In conclusion, consumption of milk-protein inhibits the effect of green tea on DIT.
C1 [Hursel, Rick; Westerterp-Plantenga, Margriet S.] Maastricht Univ, Dept Human Biol, Nutr & Toxicol Res Inst Maastricht NUTRIM, NL-6200 MD Maastricht, Netherlands.
C3 Maastricht University
RP Hursel, R (corresponding author), Maastricht Univ, Dept Human Biol, Nutr & Toxicol Res Inst Maastricht NUTRIM, POB 616, NL-6200 MD Maastricht, Netherlands.
EM rick.hursel@maastrichtuniversity.nl; m.westerterp@maastrichtuniversity.nl
FU FrieslandCampina
CR Arts MJTJ, 2002, J AGR FOOD CHEM, V50, P1184, DOI 10.1021/jf010855a
   Arts MJTJ, 2001, FOOD CHEM TOXICOL, V39, P787, DOI 10.1016/S0278-6915(01)00020-5
   Auvichayapat P, 2008, PHYSIOL BEHAV, V93, P486, DOI 10.1016/j.physbeh.2007.10.009
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   Boirie Y, 1997, P NATL ACAD SCI USA, V94, P14930, DOI 10.1073/pnas.94.26.14930
   BROWN PJ, 1963, J CHROMATOGR, V11, P504, DOI 10.1016/S0021-9673(01)80953-5
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Harris JA, 1918, P NATL ACAD SCI USA, V4, P370, DOI 10.1073/pnas.4.12.370
   HASLAM E, 1974, BIOCHEM J, V139, P285, DOI 10.1042/bj1390285
   Hollman PCH, 2001, FREE RADICAL RES, V34, P297, DOI 10.1080/10715760100300261
   Hursel R, 2010, BRIT J NUTR, V103, P775, DOI 10.1017/S0007114509992352
   Hursel R, 2009, AM J CLIN NUTR, V89, P822, DOI 10.3945/ajcn.2008.27043
   Jöbstl E, 2006, J AGR FOOD CHEM, V54, P4077, DOI 10.1021/jf053259f
   Krul C, 2001, MUTAT RES-FUND MOL M, V474, P71, DOI 10.1016/S0027-5107(00)00158-5
   Langley-Evans SC, 2000, INT J FOOD SCI NUTR, V51, P181, DOI 10.1080/09637480050029683
   Leenen R, 2000, EUR J CLIN NUTR, V54, P87, DOI 10.1038/sj.ejcn.1600900
   Lorenz M, 2007, EUR HEART J, V28, P219, DOI 10.1093/eurheartj/ehl442
   LUCK G, 1994, PHYTOCHEMISTRY, V37, P357, DOI 10.1016/0031-9422(94)85061-5
   MCCARTY MF, 1994, MED HYPOTHESES, V42, P215, DOI 10.1016/0306-9877(94)90120-1
   Palmatier MA, 1999, BIOL PSYCHIAT, V46, P557, DOI 10.1016/S0006-3223(99)00098-0
   Reddy VC, 2005, ANN NUTR METAB, V49, P189, DOI 10.1159/000087071
   Schoffelen PFM, 1997, J APPL PHYSIOL, V83, P2064, DOI 10.1152/jappl.1997.83.6.2064
   SEIDELL JC, 1995, OBES RES, V3, PS89, DOI 10.1002/j.1550-8528.1995.tb00451.x
   Serafini M, 1996, EUR J CLIN NUTR, V50, P28
   Siebert KJ, 1996, J AGR FOOD CHEM, V44, P80, DOI 10.1021/jf9502459
   STUNKARD AJ, 1985, J PSYCHOSOM RES, V29, P71, DOI 10.1016/0022-3999(85)90010-8
   van het Hof KH, 1998, EUR J CLIN NUTR, V52, P356, DOI 10.1038/sj.ejcn.1600568
   WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363
   WESTERTERP KR, 1995, BRIT J NUTR, V73, P337, DOI 10.1079/BJN19950037
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
NR 30
TC 10
Z9 11
U1 0
U2 15
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2072-6643
EI 
J9 NUTRIENTS
JI Nutrients
PD AUG 15
PY 2011
VL 3
IS 8
BP 725
EP 733
DI 10.3390/nu3080725
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 864NQ
UT WOS:000298247300001
PM 22254119
DA 2025-04-28
ER

PT J
AU Hirata, T
   Kobayashi, T
   Wada, A
   Ueda, T
   Fujikawa, T
   Miyashita, H
   Ikeda, T
   Tsukamoto, S
   Nohara, T
AF Hirata, T.
   Kobayashi, T.
   Wada, A.
   Ueda, T.
   Fujikawa, T.
   Miyashita, H.
   Ikeda, T.
   Tsukamoto, S.
   Nohara, T.
TI Anti-obesity compounds in green leaves of Eucommia ulmoides
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Eucommia ulmoides Oliv.; Anti-obesity; Iridoid; Asperuloside; Chronic high-dose administration
ID insulin-resistance; leaf extract; adiponectin; acid; rats
AB The anti-hypertensive effect of Eucommia leaves has been confirmed clinically,(1a,b) and the study of their anti-obesity properties has advanced. 2 However, the compounds involved in their anti-obesity effect have not been fully elucidated. In this Letter, we examined the anti-obesity effect of Eucommia green leaf extract (EGLE) divided into five fractions with high porous polystyrene gel and of the compounds isolated, geniposidic acid, asperuloside and chlorogenic acid, respectively. A metabolic syndrome-like clinical model in mice was generated by feeding a 40% high-fat diet to examine the anti-obesity effects of chronic administration of test substance. After 4 weeks, body weight, white adipose tissue weight, plasma triglyceride levels and total cholesterol levels in the model mice were significantly inhibited by the 30% MeOH fraction (containing much higher levels of asperuloside than the other fractions), and these effects were similar to those of EGLE. Chronic administration of isolated asperuloside in Eucommia leaves suppressed increases in model mouse body weight, white adipose tissue weight, plasma triglyceride levels and free fatty acids levels. These results suggest that asperuloside in Eucommia leaves has important anti-obesity effects. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Hirata, T.; Kobayashi, T.; Wada, A.; Ueda, T.] Kobayashi Pharmaceut Co Ltd, R&D Ctr, Osaka 5670057, Japan.
   [Fujikawa, T.] Suzuka Univ Med Sci, Dept Pharm, Lab Mol Prophylaxis & Pharmacol, Susuka, Mie 5138670, Japan.
   [Fujikawa, T.] Mie Univ, Grad Sch Med, Dept Biochem & Prote, Tsu, Mie 5148507, Japan.
   [Miyashita, H.; Nohara, T.] Sojo Univ, Fac Med & Pharmaceut Sci, Kumamoto 8620082, Japan.
   [Ikeda, T.; Tsukamoto, S.] Kumamoto Univ, Fac Med & Pharmaceut Sci, Kumamoto 8620973, Japan.
C3 Kobayashi Pharmaceutical Co Ltd; Mie University; Sojo University; Kumamoto University
RP Hirata, T (corresponding author), Kobayashi Pharmaceut Co Ltd, R&D Ctr, 1-30-3 Toyokawa, Osaka 5670057, Japan.
EM t.hirata@kobayashi.co.jp; tikeda@gpo.kumamoto-u.ac.jp
FU Grants-in-Aid for Scientific Research [22406001, 23590010, 22310138] Funding Source: KAKEN
CR Unknown -, 2007, INT S EUCOMMIA ULMOI, V0, P0, DOI DOI 10.3387/ISEU.1.63
   Cho AS, 2010, FOOD CHEM TOXICOL, V48, P937, DOI 10.1016/j.fct.2010.01.003
   Choi MS, 2008, AM J CHINESE MED, V36, P81, DOI 10.1142/S0192415X08005606
   Fujikawa T, 2010, BRIT J NUTR, V104, P1868, DOI 10.1017/S0007114510002965
   Jiangsu New Medical College, 1977, CHIN MAT MED DICT, V0, P1031
   Jin X, 2010, J ETHNOPHARMACOL, V128, P672, DOI 10.1016/j.jep.2010.02.019
   KAWASAKI K, 2000, J HEALTH SCI, V22, P29
   Li H, 2005, ULTRASON SONOCHEM, V12, P295, DOI 10.1016/j.ultsonch.2004.01.033
   Matsuzawa Y, 2005, ATHEROSCLEROSIS SUPP, V6, P7, DOI 10.1016/j.atherosclerosissup.2005.02.003
   METORI K, 1994, BIOL PHARM BULL, V17, P917
   Nakamura Takanori, 1997, NATURAL MEDICINES, V51, P275
   Nakazawa Yoshihisa, 1997, NATURAL MEDICINES, V51, P392
   Namba T, 1986, J TRAD MED, V3, P89
   NOMURA Y, 1986, J TRAD MED, V3, P328
   Takamura C, 2007, J NAT PROD, V70, P1312, DOI 10.1021/np0780046
   Takamura C, 2007, J NAT MED-TOKYO, V61, P220, DOI 10.1007/s11418-006-0027-5
   Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788
   Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
NR 19
TC 86
Z9 109
U1 5
U2 57
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAR 15
PY 2011
VL 21
IS 6
BP 1786
EP 1791
DI 10.1016/j.bmcl.2011.01.060
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 730DM
UT WOS:000288012800047
PM 21324693
DA 2025-04-28
ER

PT J
AU Kang, JS
   Lee, WK
   Yoon, WK
   Kim, N
   Park, SK
   Park, HK
   Ly, SY
   Han, SB
   Yun, J
   Lee, CW
   Lee, K
   Lee, KH
   Park, SK
   Kim, HM
AF Kang, Jong Soon
   Lee, Won Kyung
   Yoon, Won Kee
   Kim, Nayang
   Park, Sang-Ki
   Park, Hyoung Kook
   Ly, Sun Yung
   Han, Sang-Bae
   Yun, Jieun
   Lee, Chang Woo
   Lee, Kiho
   Lee, Ki Hoon
   Park, Song-Kyu
   Kim, Hwan Mook
TI A Combination of Grape Extract, Green Tea Extract and L-Carnitine Improves High-fat Diet-induced Obesity, Hyperlipidemia and Non-alcoholic Fatty Liver Disease in Mice
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE grape extract; green tea extract; L-carnitine; high-fat diet; hyperlipidemia; fatty liver disease
ID 3t3-l1 adipocytes; metabolic syndrome; gene-expression; resveratrol; catechins; caffeine; adipogenesis; polyphenols; inhibition; quercetin
AB To develop a therapeutic agent for obesity-related metabolic disorders, a mixture of dietary components was prepared, including grape extract, green tea extract and L-carnitine (RGTC), and its effects on obesity, hyperlipidemia and non-alcoholic fatty liver disease examined. The RGTC dramatically inhibited the high-fat diet (HFD)-induced increase in body weight and fat in C57BL/6 mice, whereas food consumption was not affected by RGTC treatment. The RGTC also concentration-dependently suppressed the HFD-induced increase in plasma lipids, such as low-density lipoprotein cholesterol and triglycerides. In addition, increases in liver weight and liver steatosis were returned to normal by RGTC treatment in HFD-fed C57BL/6 mice. The plasma levels of glutamic-oxaloacetic transaminase and glutamic-pyruvic transaminase were also significantly down-regulated by RGTC treatment. These results suggest that RGTC suppressed HFD-induced obesity, hyperlipidemia and non-alcoholic fatty liver disease, suggesting that RGTC supplementation might be a promising adjuvant therapy for the treatment of these metabolic disorders. Copyright (C) 2011 John Wiley & Sons, Ltd.
C1 [Park, Song-Kyu] Korea Univ, Coll Pharm, Jochiwon, Chungnam, South Korea.
   [Kang, Jong Soon; Yun, Jieun; Lee, Chang Woo; Lee, Kiho; Lee, Ki Hoon; Kim, Hwan Mook] Korea Res Inst Biosci & Biotechnol, Bioevaluat Ctr, Cheongwon, Chungbuk, South Korea.
   [Lee, Won Kyung; Kim, Nayang; Park, Sang-Ki; Park, Hyoung Kook] LG Household & Healthcare R&D Ctr, Taejon, South Korea.
   [Yoon, Won Kee] Korea Res Inst Biosci & Biotechnol, Biomed Mouse Resource Ctr, Cheongwon, Chungbuk, South Korea.
   [Ly, Sun Yung] Chungnam Natl Univ, Coll Human Ecol, Dept Food Nutr, Taejon, South Korea.
   [Han, Sang-Bae] Chungbuk Natl Univ, Coll Pharm, Cheongju, Chungbuk, South Korea.
C3 Korea University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University; Chungbuk National University
RP Park, SK (corresponding author), Korea Univ, Coll Pharm, Jochiwon, Chungnam, South Korea.
EM spark123@korea.ac.kr; hwanmook@kribb.re.kr
FU Cooperation of Industry, Research Institute and Government; Ministry for Health, Welfare and Family Affairs, Republic of Korea [A101836]; KRIBB
CR Amin KA, 2009, DIABETOL METAB SYNDR, V1, P0, DOI 10.1186/1758-5996-1-17
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Bertelli AAA, 2009, J CARDIOVASC PHARM, V54, P468, DOI 10.1097/FJC.0b013e3181bfaff3
   Bose M, 2008, J NUTR, V138, P1677, DOI 10.1093/jn/138.9.1677
   Brennan AM, 2006, NAT CLIN PRACT ENDOC, V2, P318, DOI 10.1038/ncpendmet0196
   Brisdelli F, 2009, CURR DRUG METAB, V10, P530, DOI 10.2174/138920009789375423
   Bruno RS, 2008, J NUTR, V138, P323, DOI 10.1093/jn/138.2.323
   Bujanda L, 2008, BMC GASTROENTEROL, V8, P0, DOI 10.1186/1471-230X-8-40
   Couillard C, 2000, INT J OBESITY, V24, P782, DOI 10.1038/sj.ijo.0801227
   Crespy V, 2004, J NUTR, V134, P3431S, DOI 10.1093/jn/134.12.3431S
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Ewald N, 2009, CURR OPIN LIPIDOL, V20, P497, DOI 10.1097/MOL.0b013e3283319a1d
   Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737
   Kohjima M, 2007, INT J MOL MED, V20, P351
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Lee MS, 2006, J MED FOOD, V9, P468, DOI 10.1089/jmf.2006.9.468
   LeRoith D, 2008, EXP CLIN ENDOCR DIAB, V116, PS4, DOI 10.1055/s-2008-1081488
   Maki KC, 2009, J NUTR, V139, P264, DOI 10.3945/jn.108.098293
   Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8
   Mitscher LA, 1997, MED RES REV, V17, P327, DOI 10.1002/(SICI)1098-1128(199707)17:4<327::AID-MED2>3.0.CO;2-Y
   Murosaki S, 2007, J NUTR, V137, P2252, DOI 10.1093/jn/137.10.2252
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Orgaard A, 2008, EXP BIOL MED, V233, P1066, DOI 10.3181/0712-MR-347
   Park HJ, 2008, J MED FOOD, V11, P773, DOI 10.1089/jmf.2008.0077
   Rayalam S, 2008, PHYTOTHER RES, V22, P1367, DOI 10.1002/ptr.2503
   Shang J, 2008, ACTA PHARMACOL SIN, V29, P698, DOI 10.1111/j.1745-7254.2008.00807.x
   Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9
   Staiger H, 2005, EXP CLIN ENDOCR DIAB, V113, P67, DOI 10.1055/s-2004-830555
   Thielecke F, 2009, PHYTOCHEMISTRY, V70, P11, DOI 10.1016/j.phytochem.2008.11.011
   Tian WX, 2006, CURR MED CHEM, V13, P967, DOI 10.2174/092986706776361012
   Wang HQ, 2010, OBESITY, V18, P773, DOI 10.1038/oby.2009.256
   Yang JY, 2008, LIFE SCI, V82, P1032, DOI 10.1016/j.lfs.2008.03.003
   Yang JY, 2006, J MED FOOD, V9, P459, DOI 10.1089/jmf.2006.9.459
   Zheng GD, 2004, IN VIVO, V18, P55
NR 35
TC 16
Z9 18
U1 0
U2 34
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD DEC 15
PY 2011
VL 25
IS 12
BP 1789
EP 1795
DI 10.1002/ptr.3476
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 864ZB
UT WOS:000298277900009
PM 21480410
DA 2025-04-28
ER

